An individual may have limited or impaired mobility such that typical urination processes are challenging or impossible. For example, the individual may have surgery or a disability that impairs mobility. In another example, the individual may have restricted travel conditions such as those experience by pilots, drivers, and workers in hazardous areas. Additionally, fluid collection from the individual may be needed for monitoring purposes or clinical testing.
Bed pans and urinary catheters, such as a Foley catheter, may be used to address some of these circumstances. However, bed pans and urinary catheters have several problems associated therewith. For example, bed pans may be prone to discomfort, spills, and other hygiene issues. Urinary catheters be may be uncomfortable, painful, and may cause urinary tract infections.
Thus, users and manufacturers of fluid collection assemblies continue to seek new and improved assemblies, systems, and methods to collect urine.
Embodiments are directed to fluid collection assemblies that include at least one of a protrusion or at least one expandable material, systems including the same, and method of using the same are disclosed herein. In an embodiment, a fluid collection assembly is disclosed. The fluid collection assembly includes a fluid impermeable barrier at least defining a chamber, at least one opening, and a fluid outlet. The fluid collection assembly also includes at least one porous material disposed in the chamber. The at least one porous material includes at least one of a protrusion extending outwardly from the at least one opening or at least one expandable material that expands when exposed to one or more bodily fluids.
In an embodiment, a fluid collection system is disclosed. The fluid collection system includes a fluid collection assembly. The fluid collection assembly includes a fluid impermeable barrier at least defining a chamber, at least one opening, and a fluid outlet. The fluid collection assembly also includes at least one porous material disposed in the chamber. The at least one porous material includes at least one of a protrusion extending outwardly from the at least one opening or at least one expandable material that expands when exposed to one or more bodily fluids. The fluid collection system also includes fluid storage container and a vacuum source. The chamber of the fluid collection assembly, the fluid storage container, and the vacuum source are in fluid communication with each other via one or more conduits.
In an embodiment, a method of forming a fluid collection assembly is disclosed. The method includes providing at least one porous material. The at least one porous material includes at least one of a protrusion extending outwardly from the at least one opening or at least one expandable material that expands when exposed to one or more bodily fluids. The method also includes disposing the at least one porous material in a chamber defined by a fluid impermeable barrier of the fluid collection, the fluid impermeable barrier defining a fluid outlet.
In an embodiment, a method of using a fluid collection assembly is disclosed. The method includes positioning at least one opening of the fluid collection assembly adjacent to a urethral opening of a patient. The fluid collection assembly includes a fluid impermeable barrier defining a chamber, at least one opening, and at least one fluid outlet. The fluid collection assembly also includes at least one porous material disposed in the chamber. The at least one porous material includes at least one of a protrusion extending outwardly from the at least one opening or at least one expandable material that expands when exposed to one or more bodily fluids. The method also includes receiving one or more bodily fluids from the urethral opening into the chamber.
Features from any of the disclosed embodiments may be used in combination with one another, without limitation. In addition, other features and advantages of the present disclosure will become apparent to those of ordinary skill in the art through consideration of the following detailed description and the accompanying drawings.
The drawings illustrate several embodiments of the present disclosure, wherein identical reference numerals refer to identical or similar elements or features in different views or embodiments shown in the drawings.
Embodiments are directed to fluid collection assemblies that include at least one of a protrusion or at least one expandable material, systems including the same, and method of using the same are disclosed herein. An example female fluid collection assembly includes a fluid impermeable barrier. The fluid impermeable barrier at least defines a chamber, at least one opening, and a fluid outlet. The female fluid collection assembly also includes at least one porous material disposed in the chamber. The porous material extends across the opening. In an embodiment, the porous material includes at least one expandable material that is configured to expand (e.g., increase in volume) when the expandable material exposed to one or more bodily fluids (e.g., urine). In an embodiment, the portion of the porous material that extends across the opening include a protrusion that extends outwardly from the opening.
During use, the female fluid collection assembly is disposed with the opening of the fluid collection assembly adjacent to a urethral opening of a female patient. The urethral opening may discharge one or more bodily fluids, such a urine, blood, or sweat. The bodily fluids may be received by the porous material and wicked away from the urethral opening and into the chamber. The bodily fluids may be removed from the chamber via a fluid outlet defined by the fluid impermeable barrier. For example, a suction force may be applied to a conduit that is at least partially disposed in the fluid outlet and the suction force may pull the bodily fluids into the conduit and out of the chamber.
Some of the bodily fluids that are discharged from the urethral opening may leak from the chamber. The leaked bodily fluids may cause patient (e.g., an individual using the fluid collection assembly) discomfort, embarrassment, and create unsanitary conditions that require cleaning. Poor fit between the female fluid collection assembly and the region about the urethral opening may cause the bodily fluids to leak from the female fluid collection assembly. For example, the poor fit may cause gaps to be present between the porous material that extends across the opening and the region about the urethral opening. These gaps may provide locations through which the bodily fluids may flow without being received by the porous material and/or locations at which bodily fluids may leave the porous material. The gaps may form between the porous material and the region about the urethral opening for a variety of reasons. For example, variations in the size, shape (e.g., curvature), and anatomy (e.g., labia folds) of the region about the urethral opening may cause gaps to form between the porous material and the region about the urethral opening.
In an embodiment, the female fluid collection assemblies disclosed herein include at least one porous material having at least one expandable material. The also expandable material is configured to increase in volume when the expandable material is exposed to the bodily fluids. The increase in volume of the expandable material may at least one of form a protrusion or cause the porous material to conform to the shape of the region about the urethral opening thereby minimizing or eliminating gaps. Further, conforming the porous material to the shape of the region about the urethral opening may also prevent or at least inhibit movement and shape changes of the female fluid collection assembly. When the expandable material forms a protrusion, the protrusion may be able to be positioned at least partially between the labia folds of the patient which minimizes or reduces gaps formed between the labia folds, between the labia folds and the porous material, and between the urethral opening and the porous material through which bodily fluids may leak. In an embodiment, instead of or in addition to the expandable material, the at least one porous material of the fluid collection assemblies disclosed herein includes a protrusion. The protrusion may minimize or prevent the formation of gaps between the porous material and the region about the urethral opening. For example, the protrusion may be able to be positioned at least partially between the labia folds of the patient which minimizes or reduces gaps formed between the labia folds, between the labia folds and the porous material, and between the urethral opening and the porous material through which bodily fluids may leak. Further, the labia folds may also hold the protrusion such that the position and/or shape of the fluid collection assembly does not move, thereby eliminating gaps caused by the fluid collection assembly moving or changing shape.
As will be discussed in more detail with regards to
The fluid impermeable barrier 102 at least partially defines a chamber 106 (e.g., interior region) and an opening 108. For example, the interior surface(s) 110 of the fluid impermeable barrier 102 at least partially define the chamber 106 within the fluid collection assembly 100. The fluid impermeable barrier 102 temporarily stores the bodily fluids in the chamber 106. The fluid impermeable barrier 102 may be formed of any suitable fluid impermeable material(s), such as a fluid impermeable polymer (e.g., silicone, polypropylene, polyethylene, polyethylene terephthalate, a polycarbonate, neoprene, etc.), a metal film, natural rubber, another suitable material, or combinations thereof. As such, the fluid impermeable barrier 102 substantially prevents the bodily fluids from passing through the fluid impermeable barrier 102. In an example, the fluid impermeable barrier 102 may be air permeable and fluid impermeable. In such an example, the fluid impermeable barrier 102 may be formed of a hydrophobic material that defines a plurality of pores. At least one or more portions of at least an outer surface 112 of the fluid impermeable barrier 102 may be formed from a soft and/or smooth material, thereby reducing chaffing.
In some examples, the fluid impermeable barrier 102 may be tubular (ignoring the opening), such as substantially cylindrical (as shown), oblong, prismatic, or flattened tubes. During use, the outer surface 112 of the fluid impermeable barrier 102 may contact the patient. The fluid impermeable barrier 102 may be sized and shaped to fit in the gluteal cleft between the legs of a female user.
The opening 108 provides an ingress route for the bodily fluids to enter the chamber 106. The opening 108 may be defined by the fluid impermeable barrier 102, such as by an inner edge of the fluid impermeable barrier 102. For example, the opening 108 is formed in and extends through the fluid impermeable barrier 102, from the outer surface 112 to the inner surface 110, thereby enabling the bodily fluids to enter the chamber 106 from outside of the fluid collection assembly 100. The opening 108 may be an elongated hole in the fluid impermeable barrier 102. For example, the opening 108 may be defined as a cut-out in the fluid impermeable barrier 102. The opening 108 may be located and shaped to be positioned adjacent to a female urethral opening.
The fluid collection assembly 100 may be positioned proximate to the female urethral opening and the bodily fluids may enter the chamber of the fluid collection assembly 100 via the opening 108. The fluid collection assembly 100 is configured to receive the bodily fluids into the chamber 106 via the opening 108. When in use, the opening 108 may have an elongated shape that extends from a first location below the urethral opening (e.g., at or near the anus or the vaginal opening) to a second location above the urethral opening (e.g., at or near the top of the vaginal opening or the mons pubis).
The opening 108 may have an elongated shape because the space between the legs of a female is relatively small when the legs of the female are closed, thereby only permitting the flow of the bodily fluids along a path that corresponds to the elongated shape of the opening 108 (e.g., longitudinally extending opening). The opening 108 in the fluid impermeable barrier 102 may exhibit a length that is measured along the longitudinal axis of the fluid collection assembly 100 that may be at least about 10% of the length of the fluid collection assembly 100, such as about 25% to about 50%, about 40% to about 60%, about 50% to about 75%, about 65% to about 85%, or about 75% to about 95% of the length of the fluid collection assembly 100.
The opening 108 in the fluid impermeable barrier 102 may exhibit a width that is measured transverse to the longitudinal axis of the fluid collection assembly 100 that may be at least about 10% of the circumference of the fluid collection assembly 100, such as about 25% to about 50%, about 40% to about 60%, about 50% to about 75%, about 65% to about 85%, or about 75% to about 100% of the circumference of the fluid collection assembly 100. The opening 108 may exhibit a width that is greater than 50% of the circumference of the fluid collection assembly 100 since the vacuum (e.g., suction) through the conduit 116 pulls the bodily fluids through the porous material 104 and into the conduit 116. In some examples, the opening 108 may be vertically oriented (e.g., having a major axis parallel to the longitudinal axis of the fluid collection assembly 100). In some examples (not shown), the opening 108 may be horizontally oriented (e.g., having a major axis perpendicular to the longitudinal axis of the fluid collection assembly 100). In an example, the fluid impermeable barrier 102 may be configured to be attached to the individual, such as adhesively attached (e.g., with a hydrogel adhesive) to the individual. According to an example, a suitable adhesive is a hydrogel layer.
In some examples, the fluid impermeable barrier 102 may define a fluid outlet 114 sized to receive the conduit 116. The at least one conduit 116 may be disposed in the chamber 106 via the fluid outlet 114. The fluid outlet 114 may be sized and shaped to form an at least substantially fluid tight seal against the conduit 116 or the at least one tube thereby substantially preventing the bodily fluids from escaping the chamber 106.
The fluid impermeable barrier 102 may include markings thereon, such as one or more markings to aid a user in aligning the fluid collection assembly 100 on the patient. For example, a line on the fluid impermeable barrier 102 (e.g., opposite the opening 108) may allow a healthcare professional to align the opening 108 over the urethral opening of the patient. In examples, the markings may include one or more of alignment guide or an orientation indicator, such as a stripe or hashes. Such markings may be positioned to align the fluid collection assembly 100 to one or more anatomical features such as a pubic bone, etc.
As previously discussed, the fluid collection assembly 100 includes the porous material 104 disposed in the chamber 106. The porous material 104 may cover at least a portion (e.g., all) of the opening 108. The porous material 104 is exposed to the environment outside of the chamber 106 through the opening 108. In an embodiment, as illustrated, the porous material 104 include at least one expandable material 118 and a fluid permeable membrane 120. However, as will be discussed in more detail below, at least one of the expandable material 118 or the fluid permeable membrane 120 may be omitted from the porous material 104. Further, the porous material 104 may include a fluid permeable support (
As previously discussed, the expandable material 118 is configured to increase in volume when the expandable material 118 is exposed to the bodily fluids. For example, the expandable material 118 may include at least one of one or more absorbent materials, one or more adsorbent materials, or one or more hydrophilic materials. Specific examples of the expandable material 118 include hydrogels, super absorbent polymers (e.g., polymers that absorb at least 10 times its weight in bodily fluids, at least 25 times its weight in bodily fluids, at least 50 times its own weight in bodily fluids, at least 100 times its own weight in bodily fluids, or at least 200 times its own weight in bodily fluids), or polymeric sponges. In an embodiment, such expandable materials 118 may retain at least some of the bodily fluids that are received thereby, such as water that is contained within the bodily fluids. The bodily fluids that are retained by the expandable material 118 may increase the volume of the expandable material 118.
Exposing the expandable material to the bodily fluids causes the expandable material 118 to expand thereby at least increasing the volume of the expandable material 118. For example,
In an embodiment, as illustrated, exposing the expandable material 118 to the bodily fluids causes the expandable material 118 to change a shape thereof. For example, the increased volume of the expandable material 118 causes the expandable material 118 to apply a force to the fluid impermeable barrier 102. When the fluid impermeable barrier 102 is formed from a relatively flexible material (e.g., silicone, neoprene, etc.), the force applied from the expandable material 118 to the fluid impermeable barrier 102 may cause the fluid impermeable barrier 102 to change a shape thereof (e.g., bow outwardly) and/or stretch. When the fluid impermeable barrier 102 is formed from a relatively stiff material (e.g., a metal), the force applied from the expandable material 118 to the fluid impermeable barrier 102 substantially does not change a shape of the fluid impermeable barrier 102. Regardless if the fluid impermeable barrier 102 is formed from a relatively flexible or relatively rigid material, the fluid impermeable barrier 102 applies a force normal to the force applied from the expandable material 118 to the fluid impermeable barrier 102. The force applied from the fluid impermeable barrier 102 to the expandable material 118 limits the volume increase of portions of the expandable material 118 adjacent to the fluid impermeable barrier 102. However, no force is directly applied from the fluid impermeable barrier 102 to the portions of the expandable material 118 adjacent to the opening 108. Thus, the volume of the portions of the expandable material 118 adjacent to the opening 108 may more freely expand than portions of the expandable material 118 adjacent to the fluid impermeable barrier 102. The difference in the expansion in portions of the expandable material 118 adjacent to the fluid impermeable barrier 102 and adjacent to the opening 108 causes the shape of the expandable material 118 to change (e.g., from a first shape to a second shape). For example, the greater expansion of the portions of the expandable material 118 adjacent to the opening 108 causes the expandable material 118 to protrude outwardly from the opening 108 to form a protrusion 122.
The protrusion 122 may exhibit a generally triangular cross-sectional shape, a generally at least partially semi-circular cross-sectional shape, or any other suitable cross-sectional shape when the protrusion 122 does not abut the region about the urethral opening of the patient. When the protrusion 122 exhibits a generally triangular cross-sectional shape, the protrusion 122 may be facilitate insertion of the protrusion 122 between the labia folds of the patient. For example, the generally triangular cross-sectional shape of the protrusion 122 may form a wedge that may separate and move between the labia folds thereby positioning the protrusion 122 adjacent to the urethral opening of the patient. In a particular embodiment, the porous material 104 (e.g., the expandable material 118) and the fluid collection assembly 100 may exhibit a generally tear-drop shape (e.g., a generally circular cross-sectional shape with a generally triangular cross-sectional shape extending therefrom) when the protrusion 122 exhibits the generally triangular cross-sectional shape. For example, the fluid collection assembly 100 may exhibit a generally circular cross-sectional shape when the expandable material 118 exhibits the first shape. This allows the fluid collection assembly 100 to include a generally cylindrical fluid impermeable barrier 102, as used in some convention fluid collection assemblies. Using a generally cylindrical fluid impermeable barrier 102 allows the use of fluid impermeable barriers that are readily available and does not require the use of specialty parts. In other words, using a generally cylindrical fluid impermeable barrier 102 may prevent logistical issues (e.g., lack of supply) caused by using non-cylindrical fluid impermeable barriers. The generally cylindrical fluid impermeable barriers 102 may be formed from silicone, neoprene, or other relatively flexible polymers. Even though the generally cylindrical fluid impermeable barrier 102 is formed from such relatively flexible materials, the generally cylindrical fluid impermeable barrier 102 may retain the generally circular cross-sectional shape thereof when the volume of the expandable material 118 increases. This may cause the expandable material 118 to extend from the opening 108 to form a protrusion 122 exhibiting the generally triangular cross-sectional shape. In other words, forming the fluid impermeable barrier 102 from readily available generally cylindrical fluid impermeable barriers may cause the fluid collection assembly 100 to exhibit the generally tear-drop shape.
The shape of the expandable material 118 may conform to the shape of the region about the urethral opening of the patient when the porous material 104 comes in contact with the region about the urethral opening. For example, the portions of the expandable material 118 that form the protrusion 122 may press, directly or indirectly, against the region about the urethral opening when the volume of the expandable material 118 increases. Similar to the fluid impermeable barrier 102, the region about the urethral opening applies a force normal to the force that the expandable material 118 applies to the region about the urethral opening which restricts volume increases of the expandable material 118. However, at least initially, only a portion of the region about urethral opening contacts the porous material 104. Thus, at least initially, the region about the urethral opening only restricts the volume increase of the portion of the expandable material 118 that contacts (directly or indirectly) the region about the urethral opening. The portions of the expandable material 118 that does not contact the region about the urethral opening substantially do not have the volume increases thereof restricted which allows such portions the expandable material 118 to expand into gaps between the porous material 104 and the region about the urethral opening. Thus, the expandable material 118, and in particular the portions of the expandable material 118 that form the protrusion 122, conform to the region about the urethral opening and prevent the formation of gaps.
As previously discussed, the fluid collection assembly 100 may include the fluid permeable membrane 120 disposed in the chamber 106. The fluid permeable membrane 120 may cover at least a portion (e.g., all) of the opening 108.
In an embodiment, the fluid permeable membrane 120 is exposed to the environment outside of the chamber 106 through the opening 108. The fluid permeable membrane 120 may be configured to wick any bodily fluids away from the opening 108, thereby preventing the fluid from escaping the chamber 106. The permeable properties referred to herein may be wicking, capillary action, diffusion, or other similar properties or processes, and are referred to herein as “permeable” and/or “wicking.” Such “wicking” may not include absorption of fluid into the wicking material. Put another way, substantially no absorption of fluid into the material may take place after the material is exposed to the fluid and removed from the fluid for a time. While no absorption is desired, the term “substantially no absorption” may allow for nominal amounts of absorption of fluid into the wicking material (e.g., absorbency), such as less than about 30 wt % of the dry weight of the wicking material, less than about 20 wt %, less than about 15 wt %, less than about 10 wt %, less than about 7 wt %, less than about 5 wt %, less than about 3 wt %, less than about 2 wt %, less than about 1 wt %, or less than about 0.5 wt % of the dry weight of the wicking material. Thus, the fluid permeable membrane 120 may remove the bodily fluids away from the region about the urethral opening and inhibit bodily fluids that are present in the expandable material 118 from back flowing to the region about the urethral opening. In other words, the fluid permeable membrane 120 may maintain the region about the urethral opening dry when the fluid permeable membrane 120 is configured to wick the bodily fluids away from the opening 108. The fluid permeable membrane 120 may also wick the fluid generally towards an interior of the chamber 106, as discussed in more detail below.
The fluid permeable membrane 120 may include any material that may wick the bodily fluids. For example, the fluid permeable membrane 120 may include fabric, such as a gauze (e.g., a silk, linen, or cotton gauze), another soft fabric, or another smooth fabric. Forming the fluid permeable membrane 120 from gauze, soft fabric, and/or smooth fabric may reduce chaffing caused by the fluid collection assembly 100. In an example, the fluid permeable membrane 120 may include spun nylon fibers. In an embodiment, the fluid permeable membrane 120 may include at least one absorbent or adsorbent material instead of or in addition to at least one wicking material.
In an embodiment, the fluid permeable membrane 120 may provide structure to the porous material 104. For example, the expandable material 118 may be formed from a material that has no structure. As used herein, “no structure” refers to a material that, in bulk, is substantially unable to resist shear forces. Examples of expandable materials 118 that have no structure include some hydrogels, some super absorbent polymers, powders, and beads. Expandable materials 118 that have no structure may be unable to remain in the chamber 106 when the porous material 104 only includes such expandable materials. However, the fluid permeable membrane 120 may at least partially enclose expandable material 118. Thus, the fluid permeable membrane 120 may maintain the expandable materials 118 that have no structure in the chamber 106.
In an embodiment, the fluid permeable membrane 120 is sufficiently flexible (e.g., the fluid permeable membrane 120 is formed from certain gauzes) that the minimal force applied from the fluid permeable membrane 120 to the expandable material 118 is at most about 50% (e.g., at most about 40%, at most about 30%, at most about 25%, at most about 20%, at most about 15%, at most about 10%, at most about 7.5%, at most about 5%, at most about 2.5%, or at most about 1%) the force applied to the expandable material 118 from the fluid impermeable barrier 102 or the region about the urethral opening of the patient during normal use. For example, the fluid permeable membrane 120 may applied a normal force of 5 N or less to the expandable material 118 if the fluid impermeable barrier 102 applies a normal force of 10 N to the expandable material 118. As such, in such an embodiment, the shape of the expandable material 118 is more controlled by the fluid impermeable barrier 102 and, more particularly, the region about the urethral opening of the patient than the fluid permeable membrane 120 which allows the expandable material 118 to exhibit a shape that corresponds to the shape of the region about the urethral opening when the expandable material 118 expands (e.g., receives the bodily fluids). In other words, the fluid permeable membrane 120 substantially does not prevent the expandable material 118 from conforming to the shape of the region about the urethral opening of the patient.
In an embodiment, the fluid permeable membrane 120 is sufficiently rigid that the minimal normal force applied from the fluid permeable membrane 120 to the expandable material 118 is 50% or greater the force applied to the expandable material 118 from the fluid impermeable barrier 102 or the region about the urethral opening of the patient during normal use. In such an embodiment, the fluid permeable membrane 120 may limit the shape of the expandable material 118 may take as the volume of the expandable material 118 increases. For example, the fluid permeable membrane 120 may exhibit such rigidity when the fluid permeable membrane 120 exhibits a Young's modulus and/or percent elongation that with 10% or greater than the fluid impermeable barrier 102. Limiting the shape of the expandable material 118 with the fluid permeable membrane 120 may prevent over expansion of the expandable material 118 which may push the fluid impermeable barrier 102 and the chamber 106 away from the patient and prevent oversaturation of the expandable material 118, either of which may promote leaks of the bodily fluids.
Regardless if the fluid permeable membrane 120 is configured to apply a force to the expandable material 118 that is less than or greater than 50% the force applied from the fluid impermeable barrier 102 and the region about the urethral opening during normal use, the fluid permeable membrane 120 may at least partially control the shape of the protrusion 122. For example, before the protrusion 122 contacts the urethral opening, the fluid permeable membrane 120 may apply a force to the expandable material 118 that controls the shape of the protrusion 122. In an embodiment, the fluid permeable membrane 120 may be configured to cause the protrusion 122 to exhibit a generally triangular shape.
The porous material 104 may at least substantially completely fill the portions of the chamber 106 that are not occupied by the conduit 116. In some examples, the porous material 104 may not substantially completely fill the portions of the chamber 106 that are not occupied by the conduit 116. In such an example, the fluid collection assembly 100 includes the fluid reservoir 124 (
The fluid reservoir 124 is a substantially unoccupied portion of the chamber 106. The fluid reservoir 124 may be defined between the fluid impermeable barrier 102 and porous material 104. The bodily fluids that are in the chamber 106 may flow through the porous material 104 to the fluid reservoir 124. The fluid reservoir 124 may retain of the bodily fluids therein.
The bodily fluids that are in the chamber 106 may flow through the porous material 104 to the fluid reservoir 124. The fluid impermeable barrier 102 may retain the bodily fluids in the fluid reservoir 124. While depicted in the distal end region 126, the fluid reservoir 124 may be located in any portion of the chamber 106 such as the proximal end region 128. The fluid reservoir 124 may be located in a portion of the chamber 106 that is designed to be located in a gravimetrically low point of the fluid collection assembly 100 when the fluid collection assembly 100 is worn.
In some examples (not shown), the fluid collection assembly 100 may include multiple reservoirs, such as a first reservoir that is located at the portion of the chamber 106 at the distal end region 126 and a second reservoir that is located at the portion of the of the chamber 106 that at the proximal end region 128. In another example, the porous material 104 is spaced from at least a portion of the conduit, and the fluid reservoir 124 may be the space between the porous material 104 and the conduit 116.
The conduit 116 may be at least partially disposed in the chamber 106. The conduit 116 may be used to remove the bodily fluids from the chamber 106. The conduit 116 (e.g., a tube) includes an inlet and an outlet positioned downstream from the inlet. The outlet may be operably coupled to a suction source, such as a vacuum pump for withdrawing fluid form the chamber through the conduit 116. For example, the conduit 116 may extend into the fluid impermeable barrier 102 from the proximal end region 128 and may extend to the distal end region 126 to a point proximate to the fluid reservoir 124 therein such that the inlet is in fluid communication with the fluid reservoir 124. The conduit 116 fluidly couples the chamber 106 with the fluid storage container (not shown) or the vacuum source (not shown).
The conduit 116 may include a flexible material such as plastic tubing (e.g., medical tubing). Such plastic tubing may include a thermoplastic elastomer, polyvinyl chloride, ethylene vinyl acetate, polytetrafluoroethylene, etc., tubing. In some examples, the conduit 116 may include silicon or latex. In some examples, the conduit 116 may include one or more portions that are resilient, such as to by having one or more of a diameter or wall thickness that allows the conduit to be flexible.
As shown in
Locating the inlet of the conduit 116 at or near a location expected to be the gravimetrically low point of the chamber 106 when worn by a user enables the conduit 116 to receive more of the bodily fluids than if inlet of the conduit 116 was located elsewhere and reduce the likelihood of pooling (e.g., pooling of the bodily fluids may cause microbe growth and foul odors). For instance, the bodily fluids in the porous material 104 may flow in any direction due to capillary forces. However, the bodily fluids may exhibit a preference to flow in the direction of gravity, especially when at least a portion of the porous material 104 is saturated with the bodily fluids. Accordingly, one or more of the inlet of the conduit 116 or the fluid reservoir 124 may be located in the fluid collection assembly 100 in a position expected to be the gravimetrically low point in the fluid collection assembly 100 when worn by a patient, such as the distal end region 126.
In an example, the conduit 116 is configured to be at least insertable into the chamber 106. In such an example, the conduit 116 may include one or more markers (not shown) on an exterior thereof that are located to facilitate insertion of the conduit 116 into the chamber 106. For example, the conduit 116 may include one or more markings thereon that are configured to prevent over or under insertion of the conduit 116, such as when the conduit 116 defines an inlet that is configured to be disposed in or adjacent to the fluid reservoir 124. In another example, the conduit 116 may include one or more markings thereon that are configured to facilitate correct rotation of the conduit 116 relative to the chamber 106. The one or more markings may include a line, a dot, a sticker, or any other suitable marking.
As described in more detail below, the conduit 116 is configured to be coupled to, and at least partially extend between, one or more of the fluid storage container (not shown) and the vacuum source (not shown). In an example, the conduit 116 is configured to be directly connected to the vacuum source. In such an example, the conduit 116 may extend from the fluid impermeable barrier 102 by at least one foot, at least two feet, at least three feet, or at least six feet. In another example, the conduit 116 is configured to be indirectly connected to at least one of the fluid storage container (not shown) and the vacuum source (not shown). In some examples, the conduit is secured to a wearer's skin with a catheter securement device, such as a STATLOCK® catheter securement device available from C. R. Bard, Inc., including but not limited to those disclosed in U.S. Pat. Nos. 6,117,163; 6,123,398; and 8,211,063, the disclosures of which are all incorporated herein by reference in their entirety.
The inlet and the outlet of the conduit 116 are configured to fluidly couple (e.g., directly or indirectly) the vacuum source (not shown) to the chamber 106 (e.g., the fluid reservoir 124). As the vacuum source (
The fluid collection assemblies disclosed herein may exhibit different cross-sectional shapes that the cross-sectional shapes shown in
At least a portion of the fluid collection assembly 200 exhibits a generally triangular cross-sectional shape. The fluid collection assembly 200 exhibit a generally triangular cross-sectional shape when the fluid collection assembly 200 form three apex 230 and three edges 232 (e.g., straight or curved edges) extending between adjacent edges 232. The fluid impermeable barrier 202 (ignoring the opening 208) and the porous material 204 (e.g., the expandable material 218 and the fluid permeable membrane 220) may also exhibit a generally triangular cross-sectional shape. The generally triangular cross-sectional shape of the fluid collection assembly 200 may cause the protrusion 222 formed by the porous material 204 to exhibit a generally triangular cross-sectional shape. Further, the apexes 230 that do not form the protrusion 222 may be more likely to contact the thighs of the patient than if the fluid collection assembly 200 exhibited a generally cylindrical shape. In some embodiments, the contact between the fluid impermeable barrier 202 and the thighs of the patient may be used to maintain the shape and position of the fluid collection assembly 200. As such, the generally triangular shape of the fluid collection assembly 200 may help maintain the shape and position of the fluid collection assembly 200.
In an embodiment, the fluid collection assembly 200 may exhibit the generally triangular cross-sectional shape before the expandable material 218 is exposed to the one or more bodily fluids. In such an embodiment, the fluid impermeable barrier 202 and the porous material 204 are provided while exhibiting the generally triangular cross-sectional shape. The generally triangular shape of the protrusion 222 may facilitate positioning the protrusion 222 between the labia folds of the patient before the urethral opening discharges the bodily fluids. The expandable material 218 may then expand when the expandable material 218 is exposed to the bodily fluids such that the protrusion 222 increases in volume. The increase in volume of the protrusion 222 may include at least one of increasing the distance the protrusion 222 extends from the opening 208 or causing the protrusion 222 to fill any gaps remaining after positioning the protrusion 222 between the labia folds. It is noted that the fluid collection assembly 200 may be provided while the fluid collection assembly 200 exhibits a generally tear-drop cross-sectional shape (e.g., the porous material 204 exhibits a generally tear-drop cross-sectional shape) or any of the other cross-sectional shapes disclosed herein.
In an embodiment, the fluid collection assembly 200 may exhibit the generally triangular cross-sectional shape only after the expandable material 218 is exposed to the one or more bodily fluids. In an example, at least a portion of the fluid collection assembly 200 is provided exhibiting a generally trapezoidal shape. In such an example, the fluid impermeable barrier 202 may be provided while exhibiting a generally trapezoidal cross-sectional shape or, ignoring the opening 208, a generally triangular cross-sectional shape. Also, the porous material 204 does not initially include the protrusion 222 or the protrusion 222 does not exhibit a generally triangular shape. Instead, the porous material 204 may at least one of extend across the opening 208 in a generally planar manner, extend across the opening 208 in a generally concave manner, or extend outwardly from the opening 208 in a generally non-triangular manner. The expandable material 218 may be exposed to the one or more bodily fluids and expand such that the fluid collection assembly 200 exhibits the generally triangular cross-sectional shape illustrated in
As previously discussed, the porous material used in any of the fluid collection assemblies disclosed herein may include a fluid permeable support in addition to the expandable material and, optionally, the permeable membrane.
Referring to
In an embodiment, the fluid permeable support 334 may include any material that may wick the bodily fluids (e.g., substantially no absorption of fluid into the material may take place after the material is exposed to the fluid and removed from the fluid for a time). Thus, the fluid permeable support 334 may remove the bodily fluids away from the region about the urethral opening and inhibit bodily fluids from back flowing to the region about the urethral opening. In other words, the fluid permeable support 334 may maintain the region about the urethral opening dry. The fluid permeable support 334 may also wick the fluid generally towards an interior of the chamber 306 For example, the expandable material 318 may retain at least some of the bodily fluids therein. However, the wicking properties of the fluid permeable support 334 may induce at least some of the bodily fluids to flow from the expandable material 318 to the fluid permeable support 334, especially when the expandable material 318 is saturated by bodily fluids. The bodily fluids present in the fluid permeable support 334 may flow towards the conduit 316 due to the wicking properties thereof and, thus, the fluid permeable support 334 may prevent the bodily fluids from leaking. The fluid permeable support 334 may be formed from any of the wicking materials disclosed herein, such as any of the fluid permeable membrane materials disclosed herein above. For example, the fluid permeable membrane material(s) may be utilized in a more dense or rigid form than in the fluid permeable membrane 320 when used as the fluid permeable support 334. The fluid permeable support 334 may be formed from any fluid permeable material that is less deformable than the fluid permeable membrane 320. For example, the fluid permeable support 334 may include a porous polymer (e.g., nylon, polyester, polyurethane, polyethylene, polypropylene, etc.) structure or an open cell foam. For instance, the fluid permeable support 334 may be formed from spun nylon fibers. In some examples, the fluid permeable support 334 may be formed from a natural material, such as cotton, wool, silk, or combinations thereof. In such examples, the material may have a coating to prevent or limit absorption of fluid into the material, such as a water repellent coating. In some examples, the fluid permeable support 334 may be formed from fabric, felt, gauze, or combinations thereof. In an embodiment, the fluid permeable support 334 may include any material that absorbs or adsorbs the bodily fluids.
The fluid permeable support 334 may have a greater ability to wick fluids than the fluid permeable membrane 320, such as to move the fluid inwardly from the outer surface of the fluid collection assembly 300. In some examples, the wicking ability of the fluid permeable support 334 and the fluid permeable membrane 320 may be substantially the same.
The expandable material 318, the fluid permeable membrane 320, and the fluid permeable support 334 may be arranged generally concentrically. For example, the fluid permeable support 334 may form an inner layer, the fluid permeable membrane 320 may form an outer layer that extends generally concentrically relative to the fluid permeable support 334, and the expandable material 318 may be positioned between and concentrically relative to the fluid permeable membrane 320 and the fluid permeable support 334. However, it is noted that the expandable material, the fluid permeable membrane, and the fluid permeable support may exhibit other configurations.
Referring to
The expandable material 418 may be in the form of a rod that is positioned between the fluid permeable membrane 420 and the fluid permeable support 434. The expandable material 418 is or includes a rod when the expandable material 418 extends longitudinally and is not concentric relative to the fluid permeable membrane 420 or the fluid permeable support 434. In an example, when the expandable material 418 is a rod, the expandable material 418 may exhibit a generally circular cross-sectional shape, a generally oblong cross-sectional shape (as shown), a generally crescent cross-sectional shape, a generally rectangular (e.g., square) cross-sectional shape, or any other suitable cross-sectional shape.
Forming the expandable material 418 as a rod allows the expandable material 418 to be easily positioned between the fluid permeable membrane 420 and the fluid permeable support 434. In an example, some conventional porous materials include a fluid permeable membrane disposed concentrically around the fluid permeable support. The rod-shape expandable material 418 may be inserted between the fluid permeable membrane and the fluid permeable support of such conventional porous materials to form the porous material 404 shown in
In an embodiment, the expandable material 418 is disposed between a portion of the fluid permeable membrane 420 and a corresponding portion of the fluid permeable support 434 that are adjacent to the opening 408. In such an embodiment, the expandable material 418 may cause the porous material 404 to form a protrusion 422 before the expandable material 418 is exposed to the bodily fluids. When the fluid impermeable barrier 402 exhibits a generally circular cross-sectional shape, ignoring the opening 408, the expandable material 418 may cause the fluid collection assembly 400 to exhibit a generally tear-drop cross-sectional shape. Further, positioning the expandable material 418 adjacent to the opening 408 may cause the expandable material 418 to not press against or minimize a magnitude that the expandable material 418 presses against the fluid impermeable barrier 402 as the expandable material 418 increases in volume. As such, the force applied from the fluid impermeable barrier 402 to the expandable material 418 is minimized or non-existent.
As previously discussed, the expandable material may be omitted from the porous materials disclosed herein.
Referring to
The fluid collection assembly 500 may exhibit a generally tear-drop cross-sectional shape. For example, the fluid impermeable barrier 502, ignoring the opening 508, may exhibit a generally circular cross-sectional shape. The portion of the porous material 504 that is disposed in the chamber 506 defined by the fluid impermeable barrier 502 may also exhibit a generally circular cross-sectional shape. The porous material 504 includes a protrusion 522 extending outwardly from the opening 508. The protrusion 522 may exhibit a generally triangular cross-sectional shape.
In an embodiment, the porous material 504 exhibits the generally tear-drop cross-sectional shape without having one or more external forces applied thereto. In an embodiment, the porous material 504 may be molded (e.g., one or more external forces are applied thereto) to exhibit the generally tear-drop shape. For example, the porous material 504 may be provided while exhibiting a generally circular cross-sectional shape. The portion of the porous material 504 may be pitched (i.e., one or more external forces are applied thereto) to form the protrusion 522. It has been unexpectedly found that pinching the portion of the porous material 504 that extend across the opening 508 forms the protrusion 522 and the protrusion 522 remains after pinching the porous material 504. In an example, the protrusion 522 may remain after pinching the porous material 504 because the pinching action plastically deforms one or more portions of the porous material 504. In an example, the protrusion 522 may remain after pinching the porous material 504 because friction between the individual layers of the porous material 504 and between the porous material 504 and the fluid impermeable barrier 502 maintains the protrusion 522. In such an example, pinching the porous material 504 may cause at least some of the portions of the porous material 504 that form the protrusion 522 to be in compression while at least some of the portions of the porous material 504 that do not form the protrusion 522 to be in tension. However, the compressive and tensile forces applied to different portions of the porous material 504 are not sufficient to overcome the kinetic friction forces and, thus, the friction maintains the protrusion 522.
Referring to
The fluid collection assembly 600 includes at least one additional material 636 that is distinct from the fluid impermeable barrier 602, the fluid permeable membrane 620, and the fluid permeable support 634. The additional material 636 may be formed from at least one of a wicking material, an absorbent and/or adsorbent non-expandable material, or a fluid impermeable material (e.g., non-porous polymer or metal).
The additional material 636 is configured to affect the shape of the fluid collection assembly 600. In an embodiment, the additional material 636 is shaped and positioned to cause the porous material 604 to exhibit a protrusion 622. For example, the additional material 636 may cause the fluid collection assembly 600 to exhibit a generally tear-drop cross-sectional shape (as shown), a triangular cross-sectional shape, or any other suitable cross-sectional shape. The additional material 636 may include a rod or a plurality of distinct portions (e.g., beads). The additional material 636 may positioned within the porous material 604 to be adjacent to the opening 608 to form the protrusion 622. For example, the additional material 636 may be positioned between the fluid permeable membrane 620 and the fluid permeable support 634 which allows the additional material 636 to be easily inserted into some conventional porous materials or co-extruded, similar to the expandable material 418 of
Referring to
The fluid collection assemblies shown in
The sheath 852 includes (e.g., may be formed from) a fluid impermeable barrier 802 that is sized and shaped to fit into the hollowed region of the receptacle 850. For example, the sheath 852 may be generally tubular or cup-shaped, as shown. The generally tubular or cup-shaped fluid impermeable barrier 102 may at least partially define the outer surface 812 of the sheath 852. The fluid impermeable barrier 802 may be similar or identical to any of the fluid impermeable barriers disclosed herein, in one or more aspects. For example, the fluid impermeable barrier 802 may be constructed of any of the fluid impermeable materials disclosed herein. The fluid impermeable barrier 802 at least partially defines the chamber 806. For example, the inner surface 810 of the fluid impermeable barrier 802 at least partially defines the perimeter of the chamber 806. The chamber 806 may at least temporarily retain fluids therein. As shown, the fluid collection assembly 800 may include the porous material 804 therein. The porous material 804 may be similar or identical to the porous materials disclosed herein in one or more aspects. For example, the porous material 804 may include one or more of at least one expandable material 818, a fluid permeable membrane 820, or a fluid permeable support (not shown). The fluid impermeable barrier 802 may also define an opening 808 extending through the fluid impermeable barrier 802 that is configured to have a male urethral opening positioned therethrough.
The sheath 852 and fluid impermeable barrier 802 may also include at least one aperture 862 (e.g., vacuum relief hole) that allows the chamber 806 to remain substantially at atmospheric pressure. The at least one aperture 862 may be located at any point on the sheath 852, such as near or nearer the opening 856. In some examples (not shown), the aperture 862 may extend through the cap 866 or be disposed beneath the cap 866. In some examples, the fluid collection assembly 800 may not include the aperture 862, such as when a more complete seal as desired for the chamber 806.
The sheath 852 also includes at least a portion of the conduit 816 therein, such as at least partially disposed in the chamber 806. The bodily fluid may be removed from the chamber 806 via the conduit 816.
In an example, portions of the chamber 806 may be substantially empty due to the varying sizes and rigidity of the male penis. However, in some examples, the outermost regions of the chamber 806 (e.g., periphery of the interior regions of the sheath 852) may include porous material 804 (e.g., one or more of the fluid permeable membrane 820 and fluid permeable support). For example, the porous material 804 may be bonded to the inner surface 810 of the fluid impermeable barrier 802. The porous material 804 may be positioned (e.g., at the distal end of the chamber 806) to blunt a stream of urine from the male urethral opening thereby limiting splashing and/or to direct the bodily fluids to a selected region of the chamber 806. Since the chamber 806 is substantially empty (e.g., substantially all of the chamber 806 forms a reservoir), the bodily fluids are likely to pool at a gravimetrically low point of the chamber 806. The gravimetrically low point of the chamber 806 may be at an intersection of the skin of an individual and the fluid collection assembly 800, a corner formed in the sheath 852, or another suitable location depending on the orientation of the patient.
As previously discussed, the porous material 804 may include one or more of at least one expandable material 818, the fluid permeable membrane 820, or the fluid permeable support (now shown). The expandable material 818, the fluid permeable membrane 818 and the fluid permeable support may be similar or identical to any of the expandable materials, the fluid permeable membranes, or the fluid permeable supports, respectively, disclosed herein, in one or more aspects such as material make-up or wicking ability. One or more of expandable material 818, the fluid permeable membrane 820, or the fluid permeable support may be disposed between the fluid impermeable barrier 802 and a penis inserted into the chamber 806. The fluid permeable membrane 820 may be positioned between the fluid impermeable barrier 802 and a penis inserted into the chamber 806, such as between the expandable material 818 and penis of a patient, as shown. The expandable material 818 may be positioned between the fluid permeable membrane 820 and the fluid impermeable barrier 802. The inner surface 810, optionally including the end of the chamber 806 substantially opposite the opening 808, may be covered with the fluid permeable membrane 820.
As previously discussed, the expandable material 818 is configured to increase in volume when the expandable material 818 is exposed to the bodily fluids. Increasing the volume of the expandable material 818 may substantially fill at least some of the space in the chamber 806 that is not occupied by the porous material 804 and the penis. Filling such space with the expandable material 818 may reduce pooling of the bodily fluids in the chamber 806. Such pooling of the bodily fluids may cause body odor, skin degradation, and patient discomfort.
In some examples, the fluid collection assembly 800 includes a cap 866 at a distal region 826. The cap 866 defines an interior channel through which the fluids may be removed from the fluid collection assembly 800. The interior channel is in fluid communication with the chamber 806. The cap 866 may be disposed over at least a portion of a distal region 826 of one or more of the fluid impermeable barrier 802 or the porous material 804. The cap 866 may be made of a polymer, rubber, or any other fluid impermeable material. The cap 866 may be attached to one or more of the fluid impermeable barrier 802, the porous material 804, or the conduit 816. The cap 866 may have a laterally extending flange 870 and a longitudinally extending flange 872. The laterally extending flange 870 may cover at least a portion of the distal region 826 of the fluid collection assembly 800. The longitudinally extending flange 872 may laterally extend a distance from the sheath 852. The longitudinally extending flange 872 is sized and configured to receive and fluidly seal against the conduit 816, such as within the interior channel. The conduit 816 may extend a distance within or through the cap 866, such as to the porous material 804, through the porous material 804, or to a point set-off from the porous material 804. In the latter example, as depicted in
The reservoir 824 is an unoccupied portion of fluid collection assembly 800 such as in the cap 866 and is void of other material. In some examples, the reservoir 824 is defined at least partially by the porous material 804 and the cap 866. During use, the fluids that are in the chamber 806 may flow through the porous material 804 to the reservoir 824. The reservoir 824 may store at least some of the fluids therein and/or position the fluids for removal by the conduit 816. In some examples, at least a portion of the porous material 804 may extend continuously between at least a portion of the opening of the interior channel and chamber 806 to wick any fluid from the opening directly to the reservoir 824.
In some examples (not shown), the fluid impermeable barrier 802 may be disposed on or over the cap 866, such as enclosing the cap 866 within the chamber 806.
In some examples, the sheath 852 may include at least a portion of the conduit 816 therein, such as at least partially disposed in the chamber 806. For example, the conduit 816 may extend from the sheath 852 to a region at least proximate to the opening 856. The inlet of the conduit 816 may be positioned adjacent to the annular base 854. The inlet of the conduit 816 may be positioned to be adjacent or proximate to the gravimetrically low point of the chamber 806, such as adjacent to the annular base 854. For example, the inlet may be co-extensive with or offset from the opening 856. In examples, the inlet may be positioned adjacent to the distal region 826 of the sheath 852 (e.g., substantially opposite the opening).
The proximal region 828 may be disposed near or on the skin around the male urethral opening (e.g., around the penis) and the inlet of the conduit 816 may be positioned in the proximal region 842. The outlet of the conduit 816 may be directly or indirectly coupled to a vacuum source. Accordingly, fluid may be removed from the proximal region 842 of the chamber 806 via the conduit 816.
The receptacle 850, the sheath 852, the cap 866, and the conduit 816 may be attached together using any suitable method. For example, at least two of the receptacle 850, the sheath 852, the cap 866, or the conduit 816 may be attached together using at least one of an interference fit, an adhesive, stitching, welding (e.g., ultrasonic welding), tape, any other suitable method, or combinations thereof.
In some examples (not shown), the fluid collection assembly 800 may have a one piece design, with one or more of the sheath 852, the receptacle 850, and the cap 866 being a single, integrally formed piece.
Also as shown, the conduit 816 may be at least partially disposed with the chamber 806 of a fluid collection assembly 800. The conduit 816 may extend from the distal region 826 to the proximal region 828. For example, the conduit 816 may extend through the cap 866 to a point adjacent to the receptacle 850. The conduit 816 is sized and positioned to be coupled to a fluid storage container or the vacuum source (
In some examples, the vacuum source may be remotely located from the fluid collection assembly 800. In such examples, the conduit 816 may be fluidly connected to the fluid storage container, which may be disposed between the vacuum source and the fluid collection assembly 800.
During operation, a male using the fluid collection assembly 800 may discharge the bodily fluids (e.g., urine) into the chamber 806. The bodily fluids may pool or otherwise be collected in the chamber 806. At least some of the bodily fluids may be pulled through the interior of the conduit 816 via the inlet. The bodily fluids may be drawn out of the fluid collection assembly 800 via the vacuum/suction provided by the vacuum source. During operation, the aperture 862 may substantially maintain the pressure in the chamber 806 at atmospheric pressure even though fluid is introduced into and subsequently removed from the chamber 806.
Other examples of male fluid collection assemblies that may include at least one expandable material are disclosed in International Application No. WO 2021/016026 filed on Jul. 16, 2020, U.S. patent application Ser. No. 16/433,773 filed on Apr. 3, 2020, and International Application No. PCT/2021/039866 filed on Jun. 30, 2021, the disclosure of each of which is incorporated herein, in its entirety, by this reference.
The suction force may be applied to the outlet of the conduit 916 by the vacuum source 909 either directly or indirectly. The suction force may be applied indirectly via the fluid storage container 907. For example, the outlet of the conduit 916 may be disposed within the fluid storage container 907 and an additional conduit 916 may extend from the fluid storage container 907 to the vacuum source 909. Accordingly, the vacuum source 909 may apply suction to the fluid collection assembly 900 via the fluid storage container 907. The suction force may be applied directly via the vacuum source 909. For example, the outlet of the conduit 916 may be disposed within the vacuum source 909. An additional conduit 916 may extend from the vacuum source 909 to a point outside of the fluid collection assembly 900, such as to the fluid storage container 907. In such examples, the vacuum source 909 may be disposed between the fluid collection assembly 900 and the fluid storage container 907.
The fluid collection assembly 900 may be similar or identical to any of the fluid collection assemblies disclosed herein (e.g., 100 and 300-1300) in one or more aspects. The fluid collection assembly 900 may be shaped and sized to be positioned adjacent to a female urethral opening or have a male urethral opening positioned therethrough (e.g., receive a penis therein). For example, the fluid collection assembly 900 may include a fluid impermeable barrier at least partially defining a chamber (e.g., interior region) of the fluid collection assembly 900. The fluid impermeable barrier also defines an opening extending therethrough from the external environment. The opening may be positioned adjacent to a female urethral opening or have a male urethral opening positioned therethrough. The fluid collection assembly 900 may include a fluid permeable membrane disposed within the fluid impermeable barrier. The fluid collection assembly 900 may include wicking material disposed in the chamber such as one or more of a fluid permeable support and a fluid permeable membrane. The fluid collection assembly 900 includes the shape memory material on or incorporated in one or more components thereof. The shape memory material is sized, shaped, and positioned to retain a selected geometric configuration as disclosed herein. The conduit 916 may extend into the fluid collection assembly 900 at a first end (e.g., proximal) region, through one or more of the fluid impermeable barrier, fluid permeable membrane, or the fluid permeable support to a second end (e.g., distal) region of the fluid collection assembly 900. The conduit 916 includes an inlet and an outlet, the outlet being fluidly coupled to the fluid storage container and the inlet being positioned in a portion of the chamber selected to be at a gravimetrically low point of the fluid collection assembly when worn.
The fluid storage container 907 is sized and shaped to retain a fluid therein. The fluid storage container 907 may include a bag (e.g., drainage bag), a bottle or cup (e.g., collection jar), or any other enclosed container for storing bodily fluid(s) such as urine. In some examples, the conduit 916 may extend from the fluid collection assembly 900 and attach to the fluid storage container 907 at a first point therein. An additional conduit 916 may attach to the fluid storage container 907 at a second point thereon and may extend and attach to the vacuum source 909. Accordingly, a vacuum (e.g., suction) may be drawn through fluid collection assembly 900 via the fluid storage container 907. Fluid, such as urine, may be drained from the fluid collection assembly 900 using the vacuum source 909.
The vacuum source 909 may include one or more of a manual vacuum pump, and electric vacuum pump, a diaphragm pump, a centrifugal pump, a displacement pump, a magnetically driven pump, a peristaltic pump, or any pump configured to produce a vacuum. The vacuum source 909 may provide a vacuum or suction to remove fluid from the fluid collection assembly 900. In some examples, the vacuum source 909 may be powered by one or more of a power cord (e.g., connected to a power socket), one or more batteries, or even manual power (e.g., a hand operated vacuum pump). In some examples, the vacuum source 909 may be sized and shaped to fit outside of, on, or within the fluid collection assembly 900. For example, the vacuum source 909 may include one or more miniaturized pumps or one or more micro pumps. The vacuum sources 909 disclosed herein may include one or more of a switch, a button, a plug, a remote, or any other device suitable to activate the vacuum source 909.
While various aspects and embodiments have been disclosed herein, other aspects and embodiments are contemplated. The various aspects and embodiments disclosed herein are for purposes of illustration and are not intended to be limiting.
Terms of degree (e.g., “about,” “substantially,” “generally,” etc.) indicate structurally or functionally insignificant variations. In an example, when the term of degree is included with a term indicating quantity, the term of degree is interpreted to mean±10%, ±5%, or +2% of the term indicating quantity. In an example, when the term of degree is used to modify a shape, the term of degree indicates that the shape being modified by the term of degree has the appearance of the disclosed shape. For instance, the term of degree may be used to indicate that the shape may have rounded corners instead of sharp corners, curved edges instead of straight edges, one or more protrusions extending therefrom, is oblong, is the same as the disclosed shape, etc.
This application claims priority to U.S. Provisional Patent Application No. 63/094,608 filed on Oct. 21, 2020, the disclosure of which is incorporated herein, in its entirety, by this reference.
| Number | Name | Date | Kind |
|---|---|---|---|
| 737443 | Mooers | Aug 1903 | A |
| 1015905 | Northrop | Jan 1912 | A |
| 1032841 | Koenig | Jul 1912 | A |
| 1178644 | Johnson | Apr 1916 | A |
| 1387726 | Karge | Aug 1921 | A |
| 1742080 | Jones | Dec 1929 | A |
| 1979899 | Obrien et al. | Nov 1934 | A |
| 2241010 | Chipley | May 1941 | A |
| 2262772 | Peder | Nov 1941 | A |
| 2326881 | Packer | Aug 1943 | A |
| 2379346 | Farrell | Jun 1945 | A |
| 2485555 | Bester | Oct 1949 | A |
| 2571357 | Charles | Oct 1951 | A |
| 2613670 | Edward | Oct 1952 | A |
| 2616426 | Gordon | Nov 1952 | A |
| 2644234 | Earl | Jul 1953 | A |
| 2648335 | Chambers | Aug 1953 | A |
| 2859786 | Tupper | Nov 1958 | A |
| 2944551 | Carl | Jul 1960 | A |
| 2968046 | Duke | Jan 1961 | A |
| 2971512 | Reinhardt | Feb 1961 | A |
| 3032038 | Swinn | May 1962 | A |
| 3077883 | Hill | Feb 1963 | A |
| 3087938 | Hans et al. | Apr 1963 | A |
| 3169528 | Knox et al. | Feb 1965 | A |
| 3171506 | Therkel | Mar 1965 | A |
| 3194238 | Breece | Jul 1965 | A |
| 3198994 | Hildebrandt et al. | Aug 1965 | A |
| 3221742 | Egon | Dec 1965 | A |
| 3312221 | Overment | Apr 1967 | A |
| 3312981 | Mcguire et al. | Apr 1967 | A |
| 3349768 | Keane | Oct 1967 | A |
| 3362590 | Gene | Jan 1968 | A |
| 3366116 | Huck | Jan 1968 | A |
| 3398848 | Donovan | Aug 1968 | A |
| 3400717 | Bruce et al. | Sep 1968 | A |
| 3406688 | Bruce | Oct 1968 | A |
| 3424163 | Gravdahl | Jan 1969 | A |
| 3425471 | Yates | Feb 1969 | A |
| 3511241 | Lee | May 1970 | A |
| 3512185 | Ellis | May 1970 | A |
| 3520300 | Flower | Jul 1970 | A |
| 3528423 | Lee | Sep 1970 | A |
| 3613123 | Langstrom | Oct 1971 | A |
| 3648700 | Warner | Mar 1972 | A |
| 3651810 | Ormerod | Mar 1972 | A |
| 3661155 | Lindan | May 1972 | A |
| 3683918 | Pizzella | Aug 1972 | A |
| 3699815 | Holbrook | Oct 1972 | A |
| 3726277 | Hirschman | Apr 1973 | A |
| 3742952 | Magers et al. | Jul 1973 | A |
| 3757355 | Allen et al. | Sep 1973 | A |
| 3788324 | Lim | Jan 1974 | A |
| 3843016 | Bornhorst et al. | Oct 1974 | A |
| 3863638 | Rogers et al. | Feb 1975 | A |
| 3863798 | Kurihara et al. | Feb 1975 | A |
| 3864759 | Horiuchi | Feb 1975 | A |
| 3865109 | Elmore et al. | Feb 1975 | A |
| 3881486 | Fenton | May 1975 | A |
| 3881489 | Hartwell | May 1975 | A |
| 3915189 | Holbrook et al. | Oct 1975 | A |
| 3998228 | Poidomani | Dec 1976 | A |
| 3999550 | Martin | Dec 1976 | A |
| 4015604 | Csillag | Apr 1977 | A |
| 4020843 | Kanall | May 1977 | A |
| 4022213 | Stein | May 1977 | A |
| 4027776 | Douglas | Jun 1977 | A |
| 4064962 | Hunt | Dec 1977 | A |
| 4096897 | Cammarata | Jun 1978 | A |
| 4116197 | Bermingham | Sep 1978 | A |
| 4180178 | Turner | Dec 1979 | A |
| 4187953 | Turner | Feb 1980 | A |
| 4194508 | Anderson | Mar 1980 | A |
| 4200102 | Duhamel et al. | Apr 1980 | A |
| 4202058 | Anderson | May 1980 | A |
| 4203503 | Bertotti et al. | May 1980 | A |
| 4209076 | Bertotti et al. | Jun 1980 | A |
| 4223677 | Anderson | Sep 1980 | A |
| 4233025 | Larson et al. | Nov 1980 | A |
| 4233978 | Hickey | Nov 1980 | A |
| 4246901 | Frosch et al. | Jan 1981 | A |
| 4253542 | Ruspa et al. | Mar 1981 | A |
| 4257418 | Hessner | Mar 1981 | A |
| 4270539 | Frosch et al. | Jun 1981 | A |
| 4281655 | Terauchi | Aug 1981 | A |
| 4292916 | Bradley et al. | Oct 1981 | A |
| 4330239 | Gannaway | May 1982 | A |
| 4352356 | Tong | Oct 1982 | A |
| 4360933 | Kimura et al. | Nov 1982 | A |
| 4365363 | Windauer | Dec 1982 | A |
| 4375841 | Vielbig | Mar 1983 | A |
| 4387726 | Denard | Jun 1983 | A |
| 4403991 | Hill | Sep 1983 | A |
| 4425130 | Desmarais | Jan 1984 | A |
| 4446986 | Bowen et al. | May 1984 | A |
| 4453938 | Brendling | Jun 1984 | A |
| 4457314 | Knowles | Jul 1984 | A |
| 4476879 | Jackson | Oct 1984 | A |
| 4526688 | Schmidt et al. | Jul 1985 | A |
| 4528703 | Kraus | Jul 1985 | A |
| D280438 | Wendt | Sep 1985 | S |
| 4551141 | McNeil | Nov 1985 | A |
| 4553968 | Komis | Nov 1985 | A |
| 4581026 | Schneider | Apr 1986 | A |
| 4589516 | Inoue et al. | May 1986 | A |
| 4601716 | Smith | Jul 1986 | A |
| 4610675 | Triunfol | Sep 1986 | A |
| 4620333 | Ritter | Nov 1986 | A |
| 4626250 | Schneider | Dec 1986 | A |
| 4627846 | Ternstroem | Dec 1986 | A |
| 4631061 | Martin | Dec 1986 | A |
| 4650477 | Johnson | Mar 1987 | A |
| 4655754 | Richmond et al. | Apr 1987 | A |
| 4656675 | Fajnsztajn | Apr 1987 | A |
| 4681570 | Dalton | Jul 1987 | A |
| 4681577 | Stern et al. | Jul 1987 | A |
| 4692160 | Nussbaumer | Sep 1987 | A |
| 4707864 | Ikematsu et al. | Nov 1987 | A |
| 4713065 | Koot | Dec 1987 | A |
| 4713066 | Komis | Dec 1987 | A |
| 4723953 | Pratt et al. | Feb 1988 | A |
| 4735841 | Sourdet | Apr 1988 | A |
| 4743236 | Manschot | May 1988 | A |
| 4747166 | Kuntz | May 1988 | A |
| 4752944 | Conrads et al. | Jun 1988 | A |
| 4769215 | Ehrenkranz | Sep 1988 | A |
| 4771484 | Mozell | Sep 1988 | A |
| 4772280 | Rooyakkers | Sep 1988 | A |
| 4784654 | Beecher | Nov 1988 | A |
| 4790830 | Hamacher | Dec 1988 | A |
| 4790835 | Elias | Dec 1988 | A |
| 4791686 | Taniguchi et al. | Dec 1988 | A |
| 4795449 | Schneider et al. | Jan 1989 | A |
| 4798603 | Meyer et al. | Jan 1989 | A |
| 4799928 | Crowley | Jan 1989 | A |
| 4804377 | Hanifl et al. | Feb 1989 | A |
| 4812053 | Bhattacharjee | Mar 1989 | A |
| 4813943 | Smith | Mar 1989 | A |
| 4820297 | Kaufman et al. | Apr 1989 | A |
| 4846818 | Keldahl et al. | Jul 1989 | A |
| 4846909 | Klug et al. | Jul 1989 | A |
| 4865595 | Heyden | Sep 1989 | A |
| 4880417 | Yabrov et al. | Nov 1989 | A |
| 4882794 | Stewart | Nov 1989 | A |
| 4883465 | Brennan | Nov 1989 | A |
| 4886498 | Newton | Dec 1989 | A |
| 4886508 | Washington | Dec 1989 | A |
| 4886509 | Mattsson | Dec 1989 | A |
| 4889532 | Metz et al. | Dec 1989 | A |
| 4889533 | Beecher | Dec 1989 | A |
| 4890691 | Ching-ho | Jan 1990 | A |
| 4903254 | Haas | Feb 1990 | A |
| 4904248 | Vaillancourt | Feb 1990 | A |
| 4905692 | More | Mar 1990 | A |
| 4936838 | Cross et al. | Jun 1990 | A |
| 4950262 | Takagi | Aug 1990 | A |
| 4955922 | Terauchi | Sep 1990 | A |
| 4957487 | Gerow | Sep 1990 | A |
| 4965460 | Tanaka et al. | Oct 1990 | A |
| 4986823 | Anderson et al. | Jan 1991 | A |
| 4987849 | Sherman | Jan 1991 | A |
| 5002541 | Conkling et al. | Mar 1991 | A |
| 5004463 | Nigay | Apr 1991 | A |
| 5031248 | Kemper | Jul 1991 | A |
| 5045077 | Blake | Sep 1991 | A |
| 5045283 | Patel | Sep 1991 | A |
| 5049144 | Payton | Sep 1991 | A |
| 5053339 | Patel | Oct 1991 | A |
| 5057092 | Webster | Oct 1991 | A |
| 5058088 | Haas et al. | Oct 1991 | A |
| 5071347 | Mcguire | Dec 1991 | A |
| 5078707 | Peter | Jan 1992 | A |
| 5084037 | Barnett | Jan 1992 | A |
| 5100396 | Zamierowski | Mar 1992 | A |
| 5112324 | Wallace | May 1992 | A |
| 5147301 | Ruvio | Sep 1992 | A |
| 5176667 | Debring | Jan 1993 | A |
| 5195997 | Carns | Mar 1993 | A |
| 5196654 | Diflora et al. | Mar 1993 | A |
| 5203699 | Mcguire | Apr 1993 | A |
| 5244458 | Takasu | Sep 1993 | A |
| 5246454 | Peterson | Sep 1993 | A |
| 5267988 | Farkas | Dec 1993 | A |
| 5275307 | Freese | Jan 1994 | A |
| 5282795 | Finney | Feb 1994 | A |
| 5294983 | Ersoz et al. | Mar 1994 | A |
| 5295983 | Kubo | Mar 1994 | A |
| 5300052 | Kubo | Apr 1994 | A |
| 5304749 | Crandell | Apr 1994 | A |
| 5312383 | Kubalak | May 1994 | A |
| 5318550 | Cermak et al. | Jun 1994 | A |
| 5330459 | Lavon et al. | Jul 1994 | A |
| 5340840 | Park et al. | Aug 1994 | A |
| 5382244 | Telang | Jan 1995 | A |
| 5409014 | Napoli et al. | Apr 1995 | A |
| 5411495 | Willingham | May 1995 | A |
| 5423784 | Metz | Jun 1995 | A |
| 5456246 | Schmieding et al. | Oct 1995 | A |
| 5466229 | Elson et al. | Nov 1995 | A |
| 5478334 | Bernstein | Dec 1995 | A |
| 5499977 | Marx | Mar 1996 | A |
| 5543042 | Filan et al. | Aug 1996 | A |
| D373928 | Green | Sep 1996 | S |
| 5582604 | Ahr et al. | Dec 1996 | A |
| 5592950 | Kopelowicz | Jan 1997 | A |
| 5605161 | Cross | Feb 1997 | A |
| 5618277 | Goulter | Apr 1997 | A |
| 5628735 | Skow | May 1997 | A |
| 5636643 | Argenta et al. | Jun 1997 | A |
| 5637104 | Ball et al. | Jun 1997 | A |
| 5674212 | Osborn et al. | Oct 1997 | A |
| 5678564 | Lawrence et al. | Oct 1997 | A |
| 5678654 | Uzawa | Oct 1997 | A |
| 5687429 | Rahlff | Nov 1997 | A |
| 5695485 | Duperret et al. | Dec 1997 | A |
| 5700254 | Mcdowall et al. | Dec 1997 | A |
| 5701612 | Daneshvar | Dec 1997 | A |
| 5705777 | Flanigan et al. | Jan 1998 | A |
| 5752944 | Dann et al. | May 1998 | A |
| 5763333 | Suzuki et al. | Jun 1998 | A |
| 5772644 | Bark et al. | Jun 1998 | A |
| 5792132 | Garcia | Aug 1998 | A |
| 5827243 | Palestrant | Oct 1998 | A |
| 5827247 | Kay | Oct 1998 | A |
| 5827250 | Fujioka et al. | Oct 1998 | A |
| 5827257 | Fujioka et al. | Oct 1998 | A |
| D401699 | Herchenbach et al. | Nov 1998 | S |
| 5859393 | Cummins et al. | Jan 1999 | A |
| 5865378 | Hollinshead et al. | Feb 1999 | A |
| 5876393 | Ahr et al. | Mar 1999 | A |
| 5887291 | Bellizzi | Mar 1999 | A |
| 5891125 | Plumley | Apr 1999 | A |
| 5894608 | Birbara | Apr 1999 | A |
| D409303 | Oepping | May 1999 | S |
| 5911222 | Lawrence et al. | Jun 1999 | A |
| 5957904 | Holland | Sep 1999 | A |
| 5968026 | Osborn et al. | Oct 1999 | A |
| 5972505 | Phillips et al. | Oct 1999 | A |
| 6007526 | Passalaqua et al. | Dec 1999 | A |
| 6039060 | Rower | Mar 2000 | A |
| 6050983 | Moore et al. | Apr 2000 | A |
| 6059762 | Boyer et al. | May 2000 | A |
| 6063064 | Tuckey et al. | May 2000 | A |
| 6098625 | Winkler | Aug 2000 | A |
| 6105174 | Karlsten et al. | Aug 2000 | A |
| 6113582 | Dwork | Sep 2000 | A |
| 6117163 | Bierman | Sep 2000 | A |
| 6123398 | Arai et al. | Sep 2000 | A |
| 6129718 | Wada et al. | Oct 2000 | A |
| 6131964 | Sareshwala | Oct 2000 | A |
| 6152902 | Christian et al. | Nov 2000 | A |
| 6164569 | Hollinshead et al. | Dec 2000 | A |
| 6177606 | Etheredge et al. | Jan 2001 | B1 |
| 6209142 | Mattsson et al. | Apr 2001 | B1 |
| 6220050 | Cooksey | Apr 2001 | B1 |
| 6244311 | Hand et al. | Jun 2001 | B1 |
| 6248096 | Dwork et al. | Jun 2001 | B1 |
| 6263887 | Dunn | Jul 2001 | B1 |
| 6283246 | Nishikawa | Sep 2001 | B1 |
| 6311339 | Kraus | Nov 2001 | B1 |
| 6336919 | Davis et al. | Jan 2002 | B1 |
| 6338729 | Wada et al. | Jan 2002 | B1 |
| 6352525 | Wakabayashi | Mar 2002 | B1 |
| 6394988 | Hashimoto | May 2002 | B1 |
| 6398742 | Kim | Jun 2002 | B1 |
| 6406463 | Brown | Jun 2002 | B1 |
| 6409712 | Dutari et al. | Jun 2002 | B1 |
| 6416500 | Wada et al. | Jul 2002 | B1 |
| 6423045 | Wise et al. | Jul 2002 | B1 |
| 6428521 | Droll | Aug 2002 | B1 |
| 6428522 | Dipalma et al. | Aug 2002 | B1 |
| 6446454 | Lee et al. | Sep 2002 | B1 |
| 6475198 | Lipman et al. | Nov 2002 | B1 |
| 6479726 | Cole et al. | Nov 2002 | B1 |
| 6491673 | Palumbo et al. | Dec 2002 | B1 |
| 6508794 | Palumbo et al. | Jan 2003 | B1 |
| 6524292 | Dipalma et al. | Feb 2003 | B1 |
| 6540729 | Wada et al. | Apr 2003 | B1 |
| 6547771 | Robertson et al. | Apr 2003 | B2 |
| 6569133 | Cheng et al. | May 2003 | B2 |
| D476518 | Doppelt | Jul 2003 | S |
| 6592560 | Snyder et al. | Jul 2003 | B2 |
| 6610038 | Dipalma et al. | Aug 2003 | B1 |
| 6618868 | Minnick | Sep 2003 | B2 |
| 6620142 | Flueckiger | Sep 2003 | B1 |
| 6629651 | Male et al. | Oct 2003 | B1 |
| 6635038 | Scovel | Oct 2003 | B2 |
| 6652495 | Walker | Nov 2003 | B1 |
| 6666850 | Ahr et al. | Dec 2003 | B1 |
| 6685684 | Falconer | Feb 2004 | B1 |
| 6695828 | Dipalma et al. | Feb 2004 | B1 |
| 6699174 | Bennett | Mar 2004 | B1 |
| 6700034 | Lindsay et al. | Mar 2004 | B1 |
| 6702793 | Sweetser et al. | Mar 2004 | B1 |
| 6706027 | Harvie et al. | Mar 2004 | B2 |
| 6732384 | Scott | May 2004 | B2 |
| 6736977 | Hall et al. | May 2004 | B1 |
| 6740066 | Wolff et al. | May 2004 | B2 |
| 6764477 | Chen et al. | Jul 2004 | B1 |
| 6783519 | Samuelsson | Aug 2004 | B2 |
| 6796974 | Palumbo et al. | Sep 2004 | B2 |
| 6814547 | Childers et al. | Nov 2004 | B2 |
| 6849065 | Schmidt et al. | Feb 2005 | B2 |
| 6857137 | Otto | Feb 2005 | B2 |
| 6885690 | Aggerstam et al. | Apr 2005 | B2 |
| 6888044 | Fell et al. | May 2005 | B2 |
| 6893425 | Dunn et al. | May 2005 | B2 |
| 6912737 | Ernest et al. | Jul 2005 | B2 |
| 6918899 | Harvie | Jul 2005 | B2 |
| 6979324 | Bybordi et al. | Dec 2005 | B2 |
| 7018366 | Easter | Mar 2006 | B2 |
| 7066411 | Male et al. | Jun 2006 | B2 |
| 7122023 | Hinoki | Oct 2006 | B1 |
| 7125399 | Miskie | Oct 2006 | B2 |
| 7131964 | Harvie | Nov 2006 | B2 |
| 7135012 | Harvie | Nov 2006 | B2 |
| 7141043 | Harvie | Nov 2006 | B2 |
| D533972 | La | Dec 2006 | S |
| 7160273 | Greter et al. | Jan 2007 | B2 |
| 7171699 | Ernest et al. | Feb 2007 | B2 |
| 7171871 | Kozak | Feb 2007 | B2 |
| 7179951 | Krishnaswamy-mirle et al. | Feb 2007 | B2 |
| 7181781 | Trabold et al. | Feb 2007 | B1 |
| 7186245 | Cheng et al. | Mar 2007 | B1 |
| 7192424 | Cooper | Mar 2007 | B2 |
| 7219764 | Forbes | May 2007 | B1 |
| 7220250 | Suzuki et al. | May 2007 | B2 |
| D562975 | Otto | Feb 2008 | S |
| 7335189 | Harvie | Feb 2008 | B2 |
| 7358282 | Krueger et al. | Apr 2008 | B2 |
| 7390320 | Machida et al. | Jun 2008 | B2 |
| 7438706 | Koizumi et al. | Oct 2008 | B2 |
| 7488310 | Yang | Feb 2009 | B2 |
| 7491194 | Oliwa | Feb 2009 | B1 |
| D591106 | Dominique et al. | Apr 2009 | S |
| 7513381 | Heng et al. | Apr 2009 | B2 |
| 7520872 | Biggie et al. | Apr 2009 | B2 |
| D593801 | Wilson et al. | Jun 2009 | S |
| 7540364 | Sanderson | Jun 2009 | B2 |
| 7549511 | Marocco | Jun 2009 | B2 |
| 7549512 | Newberry | Jun 2009 | B2 |
| 7585293 | Vermaak | Sep 2009 | B2 |
| 7588560 | Dunlop | Sep 2009 | B1 |
| 7637905 | Saadat et al. | Dec 2009 | B2 |
| 7665359 | Barber | Feb 2010 | B2 |
| 7682347 | Parks et al. | Mar 2010 | B2 |
| 7687004 | Allen | Mar 2010 | B2 |
| 7695459 | Gilbert et al. | Apr 2010 | B2 |
| 7695460 | Wada et al. | Apr 2010 | B2 |
| 7699818 | Gilbert | Apr 2010 | B2 |
| 7699831 | Bengtson et al. | Apr 2010 | B2 |
| 7722584 | Tanaka et al. | May 2010 | B2 |
| 7727206 | Gorres | Jun 2010 | B2 |
| 7740620 | Gilbert et al. | Jun 2010 | B2 |
| 7749205 | Tazoe et al. | Jul 2010 | B2 |
| 7755497 | Wada et al. | Jul 2010 | B2 |
| 7766887 | Burns et al. | Aug 2010 | B2 |
| D625407 | Koizumi et al. | Oct 2010 | S |
| 7806879 | Brooks et al. | Oct 2010 | B2 |
| 7811272 | Lindsay et al. | Oct 2010 | B2 |
| 7815067 | Matsumoto et al. | Oct 2010 | B2 |
| 7833169 | Hannon | Nov 2010 | B2 |
| 7857806 | Karpowicz et al. | Dec 2010 | B2 |
| 7866942 | Harvie | Jan 2011 | B2 |
| 7871385 | Levinson et al. | Jan 2011 | B2 |
| 7875010 | Frazier et al. | Jan 2011 | B2 |
| 7901389 | Mombrinie | Mar 2011 | B2 |
| 7927320 | Goldwasser et al. | Apr 2011 | B2 |
| 7927321 | Marland | Apr 2011 | B2 |
| 7931634 | Swiecicki et al. | Apr 2011 | B2 |
| 7939706 | Okabe et al. | May 2011 | B2 |
| 7946443 | Stull et al. | May 2011 | B2 |
| 7947025 | Buglino et al. | May 2011 | B2 |
| 7963419 | Burney et al. | Jun 2011 | B2 |
| 7976519 | Bubb et al. | Jul 2011 | B2 |
| 7993318 | Olsson et al. | Aug 2011 | B2 |
| 8015627 | Baker et al. | Sep 2011 | B2 |
| 8016071 | Martinus et al. | Sep 2011 | B1 |
| 8028460 | Williams | Oct 2011 | B2 |
| 8047398 | Dimartino et al. | Nov 2011 | B2 |
| 8083094 | Caulfield et al. | Dec 2011 | B2 |
| 8128608 | Thevenin | Mar 2012 | B2 |
| 8181651 | Pinel | May 2012 | B2 |
| 8181819 | Burney et al. | May 2012 | B2 |
| 8211063 | Bierman et al. | Jul 2012 | B2 |
| 8221369 | Parks et al. | Jul 2012 | B2 |
| 8241262 | Mahnensmith | Aug 2012 | B2 |
| 8277426 | Wilcox et al. | Oct 2012 | B2 |
| 8287508 | Sanchez | Oct 2012 | B1 |
| 8303554 | Tsai et al. | Nov 2012 | B2 |
| 8322565 | Caulfield et al. | Dec 2012 | B2 |
| 8337477 | Parks et al. | Dec 2012 | B2 |
| D674241 | Bickert et al. | Jan 2013 | S |
| 8343122 | Gorres | Jan 2013 | B2 |
| 8343125 | Kawazoe et al. | Jan 2013 | B2 |
| 8353074 | Krebs | Jan 2013 | B2 |
| 8353886 | Bester et al. | Jan 2013 | B2 |
| D676241 | Merrill | Feb 2013 | S |
| 8388588 | Wada et al. | Mar 2013 | B2 |
| D679807 | Burgess et al. | Apr 2013 | S |
| 8425482 | Khoubnazar | Apr 2013 | B2 |
| 8434586 | Pawelski et al. | May 2013 | B2 |
| 8449510 | Martini et al. | May 2013 | B2 |
| D684260 | Lund et al. | Jun 2013 | S |
| 8470230 | Caulfield et al. | Jun 2013 | B2 |
| 8479941 | Matsumoto et al. | Jul 2013 | B2 |
| 8479949 | Henkel | Jul 2013 | B2 |
| 8500719 | Simpson et al. | Aug 2013 | B1 |
| 8512301 | Ma | Aug 2013 | B2 |
| 8529530 | Koch et al. | Sep 2013 | B2 |
| 8535284 | Joder et al. | Sep 2013 | B2 |
| 8546639 | Wada et al. | Oct 2013 | B2 |
| 8551075 | Bengtson | Oct 2013 | B2 |
| 8568376 | Delattre et al. | Oct 2013 | B2 |
| D694404 | Burgess et al. | Nov 2013 | S |
| 8585683 | Bengtson et al. | Nov 2013 | B2 |
| 8586583 | Hamblin et al. | Nov 2013 | B2 |
| 8652112 | Johannison et al. | Feb 2014 | B2 |
| 8669412 | Fernkvist et al. | Mar 2014 | B2 |
| D702973 | Norland et al. | Apr 2014 | S |
| 8703032 | Menon et al. | Apr 2014 | B2 |
| D704330 | Cicatelli | May 2014 | S |
| D704510 | Mason et al. | May 2014 | S |
| D705423 | Walsh Cutler | May 2014 | S |
| D705926 | Burgess et al. | May 2014 | S |
| 8714394 | Wulf | May 2014 | B2 |
| 8715267 | Bengtson et al. | May 2014 | B2 |
| 8757425 | Copeland | Jun 2014 | B2 |
| 8777032 | Biesecker et al. | Jul 2014 | B2 |
| 8808260 | Koch et al. | Aug 2014 | B2 |
| 8864730 | Conway et al. | Oct 2014 | B2 |
| 8881923 | Higginson | Nov 2014 | B2 |
| 8882731 | Suzuki et al. | Nov 2014 | B2 |
| 8936585 | Carson et al. | Jan 2015 | B2 |
| D729581 | Boroski | May 2015 | S |
| 9028460 | Medeiros | May 2015 | B2 |
| 9056698 | Noer | Jun 2015 | B2 |
| 9078792 | Ruiz | Jul 2015 | B2 |
| 9145879 | Pirovano et al. | Sep 2015 | B2 |
| 9173602 | Gilbert | Nov 2015 | B2 |
| 9173799 | Tanimoto et al. | Nov 2015 | B2 |
| 9187220 | Biesecker et al. | Nov 2015 | B2 |
| 9199772 | Krippendorf | Dec 2015 | B2 |
| 9233020 | Matsumiya | Jan 2016 | B2 |
| 9248058 | Conway et al. | Feb 2016 | B2 |
| 9308118 | Dupree et al. | Apr 2016 | B1 |
| 9309029 | Incorvia et al. | Apr 2016 | B2 |
| 9333281 | Giezendanner et al. | May 2016 | B2 |
| 9381108 | Longoni et al. | Jul 2016 | B2 |
| 9382047 | Schmidtner et al. | Jul 2016 | B2 |
| 9402424 | Roy | Aug 2016 | B2 |
| 9456937 | Ellis | Oct 2016 | B2 |
| 9480595 | Baham et al. | Nov 2016 | B2 |
| 9517865 | Albers et al. | Dec 2016 | B2 |
| D777941 | Piramoon | Jan 2017 | S |
| 9533806 | Ding et al. | Jan 2017 | B2 |
| 9550611 | Hodge | Jan 2017 | B2 |
| 9555930 | Campbell et al. | Jan 2017 | B2 |
| 9623159 | Locke | Apr 2017 | B2 |
| D789522 | Burgess et al. | Jun 2017 | S |
| 9687849 | Bruno et al. | Jun 2017 | B2 |
| 9694949 | Hendricks et al. | Jul 2017 | B2 |
| 9709048 | Kinjo | Jul 2017 | B2 |
| 9713547 | Lee et al. | Jul 2017 | B2 |
| 9732754 | Huang et al. | Aug 2017 | B2 |
| 9752564 | Arceno et al. | Sep 2017 | B2 |
| 9788992 | Harvie | Oct 2017 | B2 |
| D804907 | Sandoval | Dec 2017 | S |
| 9868564 | Mcgirr et al. | Jan 2018 | B2 |
| D814239 | Arora | Apr 2018 | S |
| D817484 | Lafond | May 2018 | S |
| 10037640 | Gordon | Jul 2018 | B2 |
| 10058470 | Phillips | Aug 2018 | B2 |
| 10098990 | Koch et al. | Oct 2018 | B2 |
| D835264 | Mozzicato et al. | Dec 2018 | S |
| D835779 | Mozzicato et al. | Dec 2018 | S |
| D840533 | Mozzicato et al. | Feb 2019 | S |
| D840534 | Mozzicato et al. | Feb 2019 | S |
| 10225376 | Perez Martinez | Mar 2019 | B2 |
| 10226376 | Sanchez et al. | Mar 2019 | B2 |
| 10258517 | Maschino et al. | Apr 2019 | B1 |
| D848612 | Mozzicato et al. | May 2019 | S |
| 10307305 | Hodges | Jun 2019 | B1 |
| 10335121 | Desai | Jul 2019 | B2 |
| D856512 | Cowart et al. | Aug 2019 | S |
| 10376406 | Newton | Aug 2019 | B2 |
| 10376407 | Newton | Aug 2019 | B2 |
| 10390989 | Sanchez et al. | Aug 2019 | B2 |
| D858144 | Fu | Sep 2019 | S |
| 10406039 | Villarreal | Sep 2019 | B2 |
| 10407222 | Allen | Sep 2019 | B2 |
| 10478356 | Griffin | Nov 2019 | B2 |
| 10500108 | Maschino et al. | Dec 2019 | B1 |
| 10538366 | Pentelovitch et al. | Jan 2020 | B2 |
| 10569938 | Zhao et al. | Feb 2020 | B2 |
| 10577156 | Dagnelie et al. | Mar 2020 | B2 |
| RE47930 | Cho | Apr 2020 | E |
| 10618721 | Vazin | Apr 2020 | B2 |
| D884390 | Wang | May 2020 | S |
| 10669079 | Freedman et al. | Jun 2020 | B2 |
| D892315 | Airy | Aug 2020 | S |
| 10730672 | Bertram et al. | Aug 2020 | B2 |
| 10737848 | Philip et al. | Aug 2020 | B2 |
| 10765854 | Law et al. | Sep 2020 | B2 |
| 10766670 | Kittmann | Sep 2020 | B2 |
| 10799386 | Harrison | Oct 2020 | B1 |
| 10806642 | Tagomori et al. | Oct 2020 | B2 |
| D901214 | Hu | Nov 2020 | S |
| 10849799 | Nishikawa et al. | Dec 2020 | B2 |
| 10857025 | Davis et al. | Dec 2020 | B2 |
| 10865017 | Cowart et al. | Dec 2020 | B1 |
| 10889412 | West et al. | Jan 2021 | B2 |
| 10913581 | Stahlecker | Feb 2021 | B2 |
| D912244 | Rehm et al. | Mar 2021 | S |
| 10952889 | Newton et al. | Mar 2021 | B2 |
| 10973378 | Ryu et al. | Apr 2021 | B2 |
| 10973678 | Newton et al. | Apr 2021 | B2 |
| 10974874 | Ragias et al. | Apr 2021 | B2 |
| 11000401 | Ecklund et al. | May 2021 | B2 |
| D923365 | Wang | Jun 2021 | S |
| 11026829 | Harvie | Jun 2021 | B2 |
| 11027900 | Liu | Jun 2021 | B2 |
| 11045346 | Argent et al. | Jun 2021 | B2 |
| D928946 | Sanchez et al. | Aug 2021 | S |
| 11090183 | Sanchez et al. | Aug 2021 | B2 |
| 11160695 | Febo et al. | Nov 2021 | B2 |
| 11160697 | Maschino et al. | Nov 2021 | B2 |
| 11168420 | Kinugasa et al. | Nov 2021 | B2 |
| 11179506 | Barr et al. | Nov 2021 | B2 |
| 11207206 | Sharma et al. | Dec 2021 | B2 |
| 11226376 | Yamauchi et al. | Jan 2022 | B2 |
| 11253389 | Sharma et al. | Feb 2022 | B2 |
| 11253407 | Miao et al. | Feb 2022 | B2 |
| 11326586 | Milner et al. | May 2022 | B2 |
| 11369508 | Ecklund et al. | Jun 2022 | B2 |
| 11369524 | Hubbard et al. | Jun 2022 | B2 |
| 11376152 | Sanchez et al. | Jul 2022 | B2 |
| 11382786 | Sanchez et al. | Jul 2022 | B2 |
| 11382788 | Hjorth et al. | Jul 2022 | B2 |
| 11389318 | Radl et al. | Jul 2022 | B2 |
| 11395871 | Radl et al. | Jul 2022 | B2 |
| 11399990 | Suyama | Aug 2022 | B2 |
| 11426303 | Davis et al. | Aug 2022 | B2 |
| 11504265 | Godinez et al. | Nov 2022 | B2 |
| 11529252 | Glithero et al. | Dec 2022 | B2 |
| 11547788 | Radl et al. | Jan 2023 | B2 |
| 11806266 | Sanchez et al. | Nov 2023 | B2 |
| 11839567 | Davis et al. | Dec 2023 | B2 |
| D1010109 | Ecklund et al. | Jan 2024 | S |
| 11857716 | Lee et al. | Jan 2024 | B2 |
| 11865030 | Davis et al. | Jan 2024 | B2 |
| 11890221 | Ulreich et al. | Feb 2024 | B2 |
| 11925575 | Newton | Mar 2024 | B2 |
| 11938053 | Austermann et al. | Mar 2024 | B2 |
| 11944740 | Hughett et al. | Apr 2024 | B2 |
| 12023457 | Mann et al. | Jul 2024 | B2 |
| 12042422 | Davis et al. | Jul 2024 | B2 |
| D1038385 | Ecklund et al. | Aug 2024 | S |
| 12090083 | Ecklund et al. | Sep 2024 | B2 |
| 20010037097 | Cheng et al. | Nov 2001 | A1 |
| 20010054426 | Knudson et al. | Dec 2001 | A1 |
| 20020019614 | Woon | Feb 2002 | A1 |
| 20020026161 | Grundke | Feb 2002 | A1 |
| 20020087131 | Wolff et al. | Jul 2002 | A1 |
| 20020091364 | Prabhakar | Jul 2002 | A1 |
| 20020189992 | Schmidt et al. | Dec 2002 | A1 |
| 20020193760 | Thompson | Dec 2002 | A1 |
| 20030004436 | Schmidt et al. | Jan 2003 | A1 |
| 20030032931 | Grundke et al. | Feb 2003 | A1 |
| 20030032944 | Cawood | Feb 2003 | A1 |
| 20030073964 | Palumbo et al. | Apr 2003 | A1 |
| 20030120178 | Heki | Jun 2003 | A1 |
| 20030157859 | Ishikawa | Aug 2003 | A1 |
| 20030181880 | Schwartz | Sep 2003 | A1 |
| 20030195484 | Harvie | Oct 2003 | A1 |
| 20030204173 | Burns et al. | Oct 2003 | A1 |
| 20030233079 | Parks et al. | Dec 2003 | A1 |
| 20040006321 | Cheng et al. | Jan 2004 | A1 |
| 20040015141 | Cheng et al. | Jan 2004 | A1 |
| 20040056122 | Male et al. | Mar 2004 | A1 |
| 20040084465 | Luburic | May 2004 | A1 |
| 20040127872 | Petryk et al. | Jul 2004 | A1 |
| 20040128749 | Scott | Jul 2004 | A1 |
| 20040143229 | Easter | Jul 2004 | A1 |
| 20040147863 | Diaz et al. | Jul 2004 | A1 |
| 20040147894 | Mizutani et al. | Jul 2004 | A1 |
| 20040158221 | Mizutani et al. | Aug 2004 | A1 |
| 20040176731 | Cheng et al. | Sep 2004 | A1 |
| 20040176746 | Forral | Sep 2004 | A1 |
| 20040191919 | Unger et al. | Sep 2004 | A1 |
| 20040200936 | Opperthauser | Oct 2004 | A1 |
| 20040207530 | Nielsen | Oct 2004 | A1 |
| 20040236292 | Tazoe et al. | Nov 2004 | A1 |
| 20040243075 | Harvie | Dec 2004 | A1 |
| 20040254547 | Okabe et al. | Dec 2004 | A1 |
| 20050010182 | Parks et al. | Jan 2005 | A1 |
| 20050033248 | Machida et al. | Feb 2005 | A1 |
| 20050065471 | Kuntz | Mar 2005 | A1 |
| 20050070861 | Okabe et al. | Mar 2005 | A1 |
| 20050070862 | Tazoe et al. | Mar 2005 | A1 |
| 20050082300 | Modrell et al. | Apr 2005 | A1 |
| 20050097662 | Leimkuhler et al. | May 2005 | A1 |
| 20050101924 | Elson et al. | May 2005 | A1 |
| 20050119630 | Harvie | Jun 2005 | A1 |
| 20050137557 | Swiecicki et al. | Jun 2005 | A1 |
| 20050154360 | Harvie | Jul 2005 | A1 |
| 20050177070 | Levinson et al. | Aug 2005 | A1 |
| 20050197639 | Mombrinie | Sep 2005 | A1 |
| 20050273920 | Marinas | Dec 2005 | A1 |
| 20050277904 | Chase et al. | Dec 2005 | A1 |
| 20050279359 | LeBlanc et al. | Dec 2005 | A1 |
| 20060004332 | Marx | Jan 2006 | A1 |
| 20060015080 | Mahnensmith | Jan 2006 | A1 |
| 20060015081 | Suzuki et al. | Jan 2006 | A1 |
| 20060016778 | Park | Jan 2006 | A1 |
| 20060069359 | Dipalma et al. | Mar 2006 | A1 |
| 20060079854 | Kay et al. | Apr 2006 | A1 |
| 20060111648 | Vermaak | May 2006 | A1 |
| 20060155214 | Wightman | Jul 2006 | A1 |
| 20060171997 | Gruenbacher et al. | Aug 2006 | A1 |
| 20060200102 | Cooper | Sep 2006 | A1 |
| 20060229575 | Boiarski | Oct 2006 | A1 |
| 20060229576 | Conway et al. | Oct 2006 | A1 |
| 20060231648 | Male et al. | Oct 2006 | A1 |
| 20060235266 | Nan | Oct 2006 | A1 |
| 20060235359 | Marland | Oct 2006 | A1 |
| 20060241553 | Harvie | Oct 2006 | A1 |
| 20060269439 | White | Nov 2006 | A1 |
| 20060277670 | Baker et al. | Dec 2006 | A1 |
| 20070006368 | Key et al. | Jan 2007 | A1 |
| 20070010797 | Nishtala et al. | Jan 2007 | A1 |
| 20070016152 | Karpowicz et al. | Jan 2007 | A1 |
| 20070038194 | Wada et al. | Feb 2007 | A1 |
| 20070055209 | Patel et al. | Mar 2007 | A1 |
| 20070073252 | Forgrave | Mar 2007 | A1 |
| 20070117880 | Elson et al. | May 2007 | A1 |
| 20070118993 | Bates | May 2007 | A1 |
| 20070135786 | Schmidt et al. | Jun 2007 | A1 |
| 20070137718 | Rushlander et al. | Jun 2007 | A1 |
| 20070149935 | Dirico | Jun 2007 | A1 |
| 20070191804 | Coley | Aug 2007 | A1 |
| 20070203464 | Green et al. | Aug 2007 | A1 |
| 20070214553 | Carromba et al. | Sep 2007 | A1 |
| 20070225663 | Watt et al. | Sep 2007 | A1 |
| 20070225666 | Otto | Sep 2007 | A1 |
| 20070225668 | Otto | Sep 2007 | A1 |
| 20070266486 | Ramirez | Nov 2007 | A1 |
| 20070282309 | Bengtson et al. | Dec 2007 | A1 |
| 20080004576 | Tanaka et al. | Jan 2008 | A1 |
| 20080015526 | Reiner et al. | Jan 2008 | A1 |
| 20080015527 | House | Jan 2008 | A1 |
| 20080033386 | Okabe et al. | Feb 2008 | A1 |
| 20080041869 | Backaert | Feb 2008 | A1 |
| 20080091153 | Harvie | Apr 2008 | A1 |
| 20080091158 | Yang | Apr 2008 | A1 |
| 20080114327 | Barge | May 2008 | A1 |
| 20080167634 | Kouta et al. | Jul 2008 | A1 |
| 20080183157 | Walters | Jul 2008 | A1 |
| 20080215031 | Belfort et al. | Sep 2008 | A1 |
| 20080234642 | Patterson et al. | Sep 2008 | A1 |
| 20080269703 | Collins et al. | Oct 2008 | A1 |
| 20080281282 | Finger et al. | Nov 2008 | A1 |
| 20080287894 | Van Den Heuvel et al. | Nov 2008 | A1 |
| 20080312550 | Nishtala et al. | Dec 2008 | A1 |
| 20090025717 | Pinel | Jan 2009 | A1 |
| 20090048570 | Jensen | Feb 2009 | A1 |
| 20090056003 | Ivie et al. | Mar 2009 | A1 |
| 20090069761 | Vogel | Mar 2009 | A1 |
| 20090069765 | Wortham | Mar 2009 | A1 |
| 20090120179 | Nylander et al. | May 2009 | A1 |
| 20090192482 | Dodge et al. | Jul 2009 | A1 |
| 20090234312 | Otoole et al. | Sep 2009 | A1 |
| 20090251510 | Noro et al. | Oct 2009 | A1 |
| 20090264840 | Virginio | Oct 2009 | A1 |
| 20090270822 | Medeiros | Oct 2009 | A1 |
| 20090281510 | Fisher | Nov 2009 | A1 |
| 20090283982 | Thomas | Nov 2009 | A1 |
| 20100004612 | Thevenin | Jan 2010 | A1 |
| 20100058660 | Williams | Mar 2010 | A1 |
| 20100121289 | Parks et al. | May 2010 | A1 |
| 20100160882 | Lowe | Jun 2010 | A1 |
| 20100174250 | Hu et al. | Jul 2010 | A1 |
| 20100179493 | Heagle et al. | Jul 2010 | A1 |
| 20100185168 | Graauw et al. | Jul 2010 | A1 |
| 20100198172 | Wada et al. | Aug 2010 | A1 |
| 20100211032 | Tsai et al. | Aug 2010 | A1 |
| 20100234820 | Tsai et al. | Sep 2010 | A1 |
| 20100241104 | Gilbert | Sep 2010 | A1 |
| 20100263113 | Shelton et al. | Oct 2010 | A1 |
| 20100310845 | Bond et al. | Dec 2010 | A1 |
| 20110028920 | Johannison | Feb 2011 | A1 |
| 20110028922 | Kay et al. | Feb 2011 | A1 |
| 20110034889 | Smith | Feb 2011 | A1 |
| 20110036837 | Shang | Feb 2011 | A1 |
| 20110040267 | Wada et al. | Feb 2011 | A1 |
| 20110040271 | Rogers et al. | Feb 2011 | A1 |
| 20110054426 | Stewart et al. | Mar 2011 | A1 |
| 20110060299 | Wada et al. | Mar 2011 | A1 |
| 20110060300 | Weig et al. | Mar 2011 | A1 |
| 20110077495 | Gilbert | Mar 2011 | A1 |
| 20110077606 | Wilcox et al. | Mar 2011 | A1 |
| 20110087337 | Forsell | Apr 2011 | A1 |
| 20110137273 | Muellejans et al. | Jun 2011 | A1 |
| 20110145993 | Rader et al. | Jun 2011 | A1 |
| 20110152802 | Dicamillo et al. | Jun 2011 | A1 |
| 20110164147 | Takahashi et al. | Jul 2011 | A1 |
| 20110172620 | Khambatta | Jul 2011 | A1 |
| 20110172625 | Wada et al. | Jul 2011 | A1 |
| 20110202024 | Cozzens | Aug 2011 | A1 |
| 20110238023 | Slayton | Sep 2011 | A1 |
| 20110240648 | Tucker | Oct 2011 | A1 |
| 20110251572 | Nishtala et al. | Oct 2011 | A1 |
| 20110265889 | Tanaka et al. | Nov 2011 | A1 |
| 20110276020 | Mitsui | Nov 2011 | A1 |
| 20120029452 | Roedsten | Feb 2012 | A1 |
| 20120035577 | Tomes et al. | Feb 2012 | A1 |
| 20120041400 | Christensen | Feb 2012 | A1 |
| 20120059328 | Dikeman et al. | Mar 2012 | A1 |
| 20120066825 | Birbara et al. | Mar 2012 | A1 |
| 20120103347 | Wheaton et al. | May 2012 | A1 |
| 20120137420 | Gordon et al. | Jun 2012 | A1 |
| 20120165768 | Sekiyama et al. | Jun 2012 | A1 |
| 20120165786 | Chappa et al. | Jun 2012 | A1 |
| 20120210503 | Anzivino et al. | Aug 2012 | A1 |
| 20120233761 | Huang | Sep 2012 | A1 |
| 20120245541 | Suzuki et al. | Sep 2012 | A1 |
| 20120245542 | Suzuki et al. | Sep 2012 | A1 |
| 20120245547 | Wilcox et al. | Sep 2012 | A1 |
| 20120253303 | Suzuki et al. | Oct 2012 | A1 |
| 20120271259 | Ulert | Oct 2012 | A1 |
| 20120296305 | Barraza Khaled et al. | Nov 2012 | A1 |
| 20120316522 | Carter et al. | Dec 2012 | A1 |
| 20120330256 | Wilcox et al. | Dec 2012 | A1 |
| 20130006206 | Wada et al. | Jan 2013 | A1 |
| 20130045651 | Esteves et al. | Feb 2013 | A1 |
| 20130053804 | Soerensen et al. | Feb 2013 | A1 |
| 20130096523 | Chang et al. | Apr 2013 | A1 |
| 20130110059 | Kossow et al. | May 2013 | A1 |
| 20130138064 | Stroebech et al. | May 2013 | A1 |
| 20130150813 | Gordon et al. | Jun 2013 | A1 |
| 20130218112 | Thompson | Aug 2013 | A1 |
| 20130245496 | Wells et al. | Sep 2013 | A1 |
| 20130245586 | Jha | Sep 2013 | A1 |
| 20130292537 | Dirico | Nov 2013 | A1 |
| 20130330501 | Aizenberg et al. | Dec 2013 | A1 |
| 20140005647 | Shuffler et al. | Jan 2014 | A1 |
| 20140031774 | Bengtson | Jan 2014 | A1 |
| 20140039432 | Dunbar et al. | Feb 2014 | A1 |
| 20140107599 | Fink et al. | Apr 2014 | A1 |
| 20140157499 | Suzuki et al. | Jun 2014 | A1 |
| 20140171889 | Hopman et al. | Jun 2014 | A1 |
| 20140182051 | Tanimoto et al. | Jul 2014 | A1 |
| 20140196189 | Lee et al. | Jul 2014 | A1 |
| 20140276501 | Cisko | Sep 2014 | A1 |
| 20140303582 | Wright et al. | Oct 2014 | A1 |
| 20140316381 | Reglin | Oct 2014 | A1 |
| 20140325746 | Block | Nov 2014 | A1 |
| 20140348139 | Gomez Martinez | Nov 2014 | A1 |
| 20140352050 | Yao et al. | Dec 2014 | A1 |
| 20140371628 | Desai | Dec 2014 | A1 |
| 20150045757 | Lee et al. | Feb 2015 | A1 |
| 20150047114 | Ramirez | Feb 2015 | A1 |
| 20150048089 | Robertson | Feb 2015 | A1 |
| 20150135423 | Sharpe et al. | May 2015 | A1 |
| 20150157300 | Ealovega et al. | Jun 2015 | A1 |
| 20150209194 | Heyman | Jul 2015 | A1 |
| 20150290425 | Macy et al. | Oct 2015 | A1 |
| 20150320583 | Harvie | Nov 2015 | A1 |
| 20150329255 | Rzepecki | Nov 2015 | A1 |
| 20150342799 | Michiels et al. | Dec 2015 | A1 |
| 20150359660 | Harvie | Dec 2015 | A1 |
| 20150366699 | Nelson | Dec 2015 | A1 |
| 20160029998 | Brister et al. | Feb 2016 | A1 |
| 20160030228 | Jones | Feb 2016 | A1 |
| 20160038356 | Yao et al. | Feb 2016 | A1 |
| 20160058322 | Brister et al. | Mar 2016 | A1 |
| 20160060001 | Wada et al. | Mar 2016 | A1 |
| 20160100976 | Conway et al. | Apr 2016 | A1 |
| 20160106604 | Timm | Apr 2016 | A1 |
| 20160113809 | Kim | Apr 2016 | A1 |
| 20160183689 | Miner | Jun 2016 | A1 |
| 20160256022 | Le | Sep 2016 | A1 |
| 20160270982 | Raycheck et al. | Sep 2016 | A1 |
| 20160278662 | Brister et al. | Sep 2016 | A1 |
| 20160357400 | Penha et al. | Dec 2016 | A1 |
| 20160366699 | Zhang et al. | Dec 2016 | A1 |
| 20160367226 | Newton et al. | Dec 2016 | A1 |
| 20160367411 | Justiz et al. | Dec 2016 | A1 |
| 20160374848 | Sanchez | Dec 2016 | A1 |
| 20170007438 | Harvie | Jan 2017 | A1 |
| 20170014560 | Minskoff et al. | Jan 2017 | A1 |
| 20170100276 | Joh | Apr 2017 | A1 |
| 20170128638 | Giezendanner et al. | May 2017 | A1 |
| 20170136209 | Burnett et al. | May 2017 | A1 |
| 20170143534 | Sanchez | May 2017 | A1 |
| 20170165100 | Jackson et al. | Jun 2017 | A1 |
| 20170165405 | Muser et al. | Jun 2017 | A1 |
| 20170189225 | Voorhees et al. | Jul 2017 | A1 |
| 20170202692 | Laniado | Jul 2017 | A1 |
| 20170216081 | Accosta | Aug 2017 | A1 |
| 20170246026 | Laniado | Aug 2017 | A1 |
| 20170252014 | Siller Gonzalez et al. | Sep 2017 | A1 |
| 20170252202 | Sanchez et al. | Sep 2017 | A9 |
| 20170266031 | Sanchez et al. | Sep 2017 | A1 |
| 20170266658 | Bruno et al. | Sep 2017 | A1 |
| 20170281399 | Vanmiddendorp et al. | Oct 2017 | A1 |
| 20170312116 | Laniado | Nov 2017 | A1 |
| 20170325788 | Ealovega et al. | Nov 2017 | A1 |
| 20170333244 | Laniado | Nov 2017 | A1 |
| 20170042748 | Griffin | Dec 2017 | A1 |
| 20170348139 | Newton et al. | Dec 2017 | A1 |
| 20170354532 | Holt | Dec 2017 | A1 |
| 20170354551 | Gawley et al. | Dec 2017 | A1 |
| 20170367873 | Grannum | Dec 2017 | A1 |
| 20180002075 | Lee | Jan 2018 | A1 |
| 20180008451 | Stroebech | Jan 2018 | A1 |
| 20180008804 | Laniado | Jan 2018 | A1 |
| 20180021218 | Brosch et al. | Jan 2018 | A1 |
| 20180028349 | Newton et al. | Feb 2018 | A1 |
| 20180037384 | Archeny et al. | Feb 2018 | A1 |
| 20180049910 | Newton | Feb 2018 | A1 |
| 20180064572 | Wiltshire | Mar 2018 | A1 |
| 20180104131 | Killian | Apr 2018 | A1 |
| 20180127187 | Sewell | May 2018 | A1 |
| 20180193215 | Davies et al. | Jul 2018 | A1 |
| 20180200101 | Su | Jul 2018 | A1 |
| 20180228642 | Davis et al. | Aug 2018 | A1 |
| 20180256384 | Kasirye | Sep 2018 | A1 |
| 20180271694 | Fernandez et al. | Sep 2018 | A1 |
| 20180317892 | Catlin | Nov 2018 | A1 |
| 20180325748 | Sharma et al. | Nov 2018 | A1 |
| 20190001030 | Braga et al. | Jan 2019 | A1 |
| 20190021899 | Vlet | Jan 2019 | A1 |
| 20190038451 | Harvie | Feb 2019 | A1 |
| 20190046102 | Kushnir et al. | Feb 2019 | A1 |
| 20190059938 | Holsten | Feb 2019 | A1 |
| 20190091059 | Gabriel | Mar 2019 | A1 |
| 20190100362 | Meyers et al. | Apr 2019 | A1 |
| 20190133814 | Tammen et al. | May 2019 | A1 |
| 20190142624 | Sanchez et al. | May 2019 | A1 |
| 20190224036 | Sanchez et al. | Jul 2019 | A1 |
| 20190247222 | Ecklund et al. | Aug 2019 | A1 |
| 20190247223 | Brun et al. | Aug 2019 | A1 |
| 20190282391 | Johannes et al. | Sep 2019 | A1 |
| 20190314189 | Acosta | Oct 2019 | A1 |
| 20190314190 | Sanchez et al. | Oct 2019 | A1 |
| 20190321587 | Mcmenamin et al. | Oct 2019 | A1 |
| 20190344934 | Faerber et al. | Nov 2019 | A1 |
| 20190365307 | Laing et al. | Dec 2019 | A1 |
| 20190365561 | Newton et al. | Dec 2019 | A1 |
| 20190374373 | Joh | Dec 2019 | A1 |
| 20200008985 | Nguyen et al. | Jan 2020 | A1 |
| 20200016012 | Dutkiewicz | Jan 2020 | A1 |
| 20200030595 | Boukidjian et al. | Jan 2020 | A1 |
| 20200046544 | Godinez et al. | Feb 2020 | A1 |
| 20200055638 | Lau et al. | Feb 2020 | A1 |
| 20200070392 | Huber et al. | Mar 2020 | A1 |
| 20200085609 | Schelch et al. | Mar 2020 | A1 |
| 20200085610 | Cohn et al. | Mar 2020 | A1 |
| 20200086090 | Von Weymarn-Schärli et al. | Mar 2020 | A1 |
| 20200107518 | Hiroshima et al. | Apr 2020 | A1 |
| 20200129322 | Leuckel | Apr 2020 | A1 |
| 20200171217 | Braga et al. | Jun 2020 | A9 |
| 20200206039 | Mclain | Jul 2020 | A1 |
| 20200214910 | Varona et al. | Jul 2020 | A1 |
| 20200216898 | Hubbell | Jul 2020 | A1 |
| 20200216989 | Kinugasa et al. | Jul 2020 | A1 |
| 20200229964 | Staali et al. | Jul 2020 | A1 |
| 20200231343 | Freedman et al. | Jul 2020 | A1 |
| 20200232841 | Satish et al. | Jul 2020 | A1 |
| 20200246172 | Ho | Aug 2020 | A1 |
| 20200246203 | Tulk et al. | Aug 2020 | A1 |
| 20200255189 | Liu | Aug 2020 | A1 |
| 20200261280 | Heyman | Aug 2020 | A1 |
| 20200276046 | Staali et al. | Sep 2020 | A1 |
| 20200306075 | Newton et al. | Oct 2020 | A1 |
| 20200315837 | Radl et al. | Oct 2020 | A1 |
| 20200315838 | Eckert | Oct 2020 | A1 |
| 20200315872 | Viens et al. | Oct 2020 | A1 |
| 20200315874 | Viens et al. | Oct 2020 | A1 |
| 20200331672 | Bertram et al. | Oct 2020 | A1 |
| 20200345332 | Duval | Nov 2020 | A1 |
| 20200353135 | Gregory et al. | Nov 2020 | A1 |
| 20200367677 | Silsby et al. | Nov 2020 | A1 |
| 20200369444 | Silsby et al. | Nov 2020 | A1 |
| 20200375781 | Staali et al. | Dec 2020 | A1 |
| 20200375810 | Carlin et al. | Dec 2020 | A1 |
| 20200385179 | Mccourt | Dec 2020 | A1 |
| 20200390591 | Glithero et al. | Dec 2020 | A1 |
| 20200390592 | Merrill | Dec 2020 | A1 |
| 20200405521 | Glasroe | Dec 2020 | A1 |
| 20210008771 | Huber et al. | Jan 2021 | A1 |
| 20210009323 | Markarian et al. | Jan 2021 | A1 |
| 20210020072 | Moehring et al. | Jan 2021 | A1 |
| 20210023279 | Radl et al. | Jan 2021 | A1 |
| 20210059853 | Davis et al. | Mar 2021 | A1 |
| 20210061523 | Bytheway | Mar 2021 | A1 |
| 20210069005 | Sanchez et al. | Mar 2021 | A1 |
| 20210069008 | Blabas et al. | Mar 2021 | A1 |
| 20210069009 | Im | Mar 2021 | A1 |
| 20210069030 | Nishikawa et al. | Mar 2021 | A1 |
| 20210077993 | Nazareth et al. | Mar 2021 | A1 |
| 20210113749 | Radl et al. | Apr 2021 | A1 |
| 20210121318 | Pinlac | Apr 2021 | A1 |
| 20210137724 | Ecklund et al. | May 2021 | A1 |
| 20210138190 | Erbey et al. | May 2021 | A1 |
| 20210154055 | Villarreal | May 2021 | A1 |
| 20210170079 | Radl et al. | Jun 2021 | A1 |
| 20210178390 | Oueslati et al. | Jun 2021 | A1 |
| 20210186742 | Newton et al. | Jun 2021 | A1 |
| 20210212865 | Wallajapet et al. | Jul 2021 | A1 |
| 20210220162 | Jamison | Jul 2021 | A1 |
| 20210220163 | Mayrand | Jul 2021 | A1 |
| 20210228400 | Glithero | Jul 2021 | A1 |
| 20210228401 | Becker et al. | Jul 2021 | A1 |
| 20210228795 | Hughett et al. | Jul 2021 | A1 |
| 20210229877 | Ragias et al. | Jul 2021 | A1 |
| 20210236323 | Austermann et al. | Aug 2021 | A1 |
| 20210236324 | Sweeney | Aug 2021 | A1 |
| 20210251814 | Jönegren et al. | Aug 2021 | A1 |
| 20210267787 | Nazemi | Sep 2021 | A1 |
| 20210275343 | Sanchez et al. | Sep 2021 | A1 |
| 20210275344 | Wing | Sep 2021 | A1 |
| 20210290454 | Yamada | Sep 2021 | A1 |
| 20210315727 | Jiang | Oct 2021 | A1 |
| 20210353450 | Sharma et al. | Nov 2021 | A1 |
| 20210361469 | Liu et al. | Nov 2021 | A1 |
| 20210369495 | Cheng et al. | Dec 2021 | A1 |
| 20210386925 | Hartwell et al. | Dec 2021 | A1 |
| 20210393433 | Godinez et al. | Dec 2021 | A1 |
| 20220023091 | Ecklund et al. | Jan 2022 | A1 |
| 20220031523 | Pierpoint | Feb 2022 | A1 |
| 20220039995 | Johannes et al. | Feb 2022 | A1 |
| 20220047410 | Walthall | Feb 2022 | A1 |
| 20220062027 | Mitchell et al. | Mar 2022 | A1 |
| 20220062028 | Mitchell et al. | Mar 2022 | A1 |
| 20220062029 | Johannes et al. | Mar 2022 | A1 |
| 20220066825 | Saraf et al. | Mar 2022 | A1 |
| 20220071811 | Cheng et al. | Mar 2022 | A1 |
| 20220071826 | Kulkarni et al. | Mar 2022 | A1 |
| 20220104965 | Vaninetti et al. | Apr 2022 | A1 |
| 20220104976 | Hoeger et al. | Apr 2022 | A1 |
| 20220104981 | Jones | Apr 2022 | A1 |
| 20220117773 | Davis et al. | Apr 2022 | A1 |
| 20220117774 | Meyer et al. | Apr 2022 | A1 |
| 20220117775 | Jones et al. | Apr 2022 | A1 |
| 20220133524 | Davis | May 2022 | A1 |
| 20220151817 | Mann | May 2022 | A1 |
| 20220160949 | Simiele et al. | May 2022 | A1 |
| 20220168159 | Triado et al. | Jun 2022 | A1 |
| 20220193312 | Lee et al. | Jun 2022 | A1 |
| 20220211536 | Johannes et al. | Jul 2022 | A1 |
| 20220218510 | Metzger et al. | Jul 2022 | A1 |
| 20220229053 | Levin et al. | Jul 2022 | A1 |
| 20220241106 | Johannes et al. | Aug 2022 | A1 |
| 20220247407 | Yamamoto et al. | Aug 2022 | A1 |
| 20220248836 | Cagle et al. | Aug 2022 | A1 |
| 20220257407 | Johannes et al. | Aug 2022 | A1 |
| 20220265460 | Coker | Aug 2022 | A1 |
| 20220265462 | Alder et al. | Aug 2022 | A1 |
| 20220270711 | Feala et al. | Aug 2022 | A1 |
| 20220273482 | Johannes et al. | Sep 2022 | A1 |
| 20220280357 | Jagannathan et al. | Sep 2022 | A1 |
| 20220287689 | Johannes | Sep 2022 | A1 |
| 20220287867 | Jones et al. | Sep 2022 | A1 |
| 20220287868 | Garvey et al. | Sep 2022 | A1 |
| 20220296408 | Evans et al. | Sep 2022 | A1 |
| 20220305191 | Joseph et al. | Sep 2022 | A1 |
| 20220313222 | Austermann et al. | Oct 2022 | A1 |
| 20220313474 | Kriscovich et al. | Oct 2022 | A1 |
| 20220331170 | Erdem et al. | Oct 2022 | A1 |
| 20220339024 | Johannes et al. | Oct 2022 | A1 |
| 20220354685 | Davis et al. | Nov 2022 | A1 |
| 20220362049 | Austermann et al. | Nov 2022 | A1 |
| 20220370231 | Wang et al. | Nov 2022 | A1 |
| 20220370234 | Hughett et al. | Nov 2022 | A1 |
| 20220370235 | Johannes et al. | Nov 2022 | A1 |
| 20220370237 | Parmar et al. | Nov 2022 | A1 |
| 20220387001 | Askenazi et al. | Dec 2022 | A1 |
| 20220395390 | Brooks | Dec 2022 | A1 |
| 20220395391 | Saunders et al. | Dec 2022 | A1 |
| 20220409422 | Schneider et al. | Dec 2022 | A1 |
| 20230018845 | Lee | Jan 2023 | A1 |
| 20230020563 | Sharma et al. | Jan 2023 | A1 |
| 20230031640 | Hughett et al. | Feb 2023 | A1 |
| 20230037159 | Brennan et al. | Feb 2023 | A1 |
| 20230052238 | Oluwasogo | Feb 2023 | A1 |
| 20230062944 | Vollenberg et al. | Mar 2023 | A1 |
| 20230062994 | Ecklund et al. | Mar 2023 | A1 |
| 20230070347 | Watson et al. | Mar 2023 | A1 |
| 20230073708 | Xu et al. | Mar 2023 | A1 |
| 20230089032 | Hughett et al. | Mar 2023 | A1 |
| 20230099821 | Radl et al. | Mar 2023 | A1 |
| 20230099991 | Bianchi et al. | Mar 2023 | A1 |
| 20230105001 | Whittome | Apr 2023 | A1 |
| 20230110577 | Choi | Apr 2023 | A1 |
| 20230138269 | Abdelal et al. | May 2023 | A1 |
| 20230145365 | Martin et al. | May 2023 | A1 |
| 20230155253 | Yin et al. | May 2023 | A1 |
| 20230210504 | Kuroda et al. | Jul 2023 | A1 |
| 20230210685 | Fallows | Jul 2023 | A1 |
| 20230218426 | Hughett | Jul 2023 | A1 |
| 20230240884 | Davis et al. | Aug 2023 | A1 |
| 20230248562 | Sanchez et al. | Aug 2023 | A1 |
| 20230248564 | Mann et al. | Aug 2023 | A1 |
| 20230255812 | Sanchez et al. | Aug 2023 | A1 |
| 20230255813 | Sanchez et al. | Aug 2023 | A1 |
| 20230255815 | Newton | Aug 2023 | A1 |
| 20230263650 | Sanchez et al. | Aug 2023 | A1 |
| 20230263655 | Johannes et al. | Aug 2023 | A1 |
| 20230277362 | Davis et al. | Sep 2023 | A1 |
| 20230285178 | Sanchez et al. | Sep 2023 | A1 |
| 20230293339 | James | Sep 2023 | A1 |
| 20230301846 | Greenwood | Sep 2023 | A1 |
| 20230355423 | Stevenson et al. | Nov 2023 | A1 |
| 20230404791 | Ecklund et al. | Dec 2023 | A1 |
| 20240008444 | Su et al. | Jan 2024 | A1 |
| 20240009023 | Johannes et al. | Jan 2024 | A1 |
| 20240024170 | Scott | Jan 2024 | A1 |
| 20240041638 | Johannes et al. | Feb 2024 | A1 |
| 20240058161 | Ulreich et al. | Feb 2024 | A1 |
| 20240065881 | Kuroda et al. | Feb 2024 | A1 |
| 20240099874 | Sanchez et al. | Mar 2024 | A1 |
| 20240110318 | Bendt et al. | Apr 2024 | A1 |
| 20240123134 | Kharkar et al. | Apr 2024 | A1 |
| 20240261131 | Garvey et al. | Aug 2024 | A1 |
| Number | Date | Country |
|---|---|---|
| 2018216821 | Aug 2019 | AU |
| 2021299304 | Feb 2023 | AU |
| 2269203 | Dec 1997 | CA |
| 2165286 | Sep 1999 | CA |
| 2354132 | Jun 2000 | CA |
| 2359091 | Sep 2003 | CA |
| 1720888 | Jan 2006 | CA |
| 2488867 | Aug 2007 | CA |
| 107847384 | Mar 2018 | CA |
| 3050918 | Aug 2018 | CA |
| 3098571 | Nov 2019 | CA |
| 1332620 | Jan 2002 | CN |
| 1434693 | Aug 2003 | CN |
| 1533755 | Oct 2004 | CN |
| 1602825 | Apr 2005 | CN |
| 2936204 | Aug 2007 | CN |
| 101262836 | Sep 2008 | CN |
| 101522148 | Sep 2009 | CN |
| 102159159 | Aug 2011 | CN |
| 202184840 | Apr 2012 | CN |
| 102481441 | May 2012 | CN |
| 202463712 | Oct 2012 | CN |
| 202950810 | May 2013 | CN |
| 103533968 | Jan 2014 | CN |
| 103717180 | Apr 2014 | CN |
| 204562697 | Aug 2015 | CN |
| 105411783 | Mar 2016 | CN |
| 105451693 | Mar 2016 | CN |
| 105534632 | May 2016 | CN |
| 205849719 | Jan 2017 | CN |
| 106726089 | May 2017 | CN |
| 107920912 | Apr 2018 | CN |
| 108420590 | Aug 2018 | CN |
| 209285902 | Aug 2019 | CN |
| 110381883 | Oct 2019 | CN |
| 211198839 | Aug 2020 | CN |
| 112566550 | Mar 2021 | CN |
| 112603184 | Apr 2021 | CN |
| 114007493 | Feb 2022 | CN |
| 114375187 | Apr 2022 | CN |
| 116096332 | May 2023 | CN |
| 79818 | Oct 1893 | DE |
| 1516466 | Jun 1969 | DE |
| 2721330 | Nov 1977 | DE |
| 2742298 | Mar 1978 | DE |
| 9407554.9 | May 1995 | DE |
| 4443710 | Jun 1995 | DE |
| 4416094 | Nov 1995 | DE |
| 4236097 | Oct 1996 | DE |
| 19619597 | Nov 1997 | DE |
| 102005037762 | Sep 2006 | DE |
| 102011103783 | Dec 2012 | DE |
| 102012112818 | Jun 2014 | DE |
| 202015104597 | Jul 2016 | DE |
| 102020121462 | Jan 2022 | DE |
| 9600118 | Nov 1996 | DK |
| 0032138 | Jul 1981 | EP |
| 0066070 | Dec 1982 | EP |
| 0068712 | Jan 1983 | EP |
| 0140470 | May 1985 | EP |
| 0140471 | May 1988 | EP |
| 0274753 | Jul 1988 | EP |
| 0119143 | Nov 1988 | EP |
| 0483592 | May 1992 | EP |
| 0610638 | Aug 1994 | EP |
| 0613355 | Sep 1994 | EP |
| 0613355 | Jan 1997 | EP |
| 0787472 | Aug 1997 | EP |
| 0966936 | Dec 1999 | EP |
| 0987293 | Mar 2000 | EP |
| 1063953 | Jan 2001 | EP |
| 0653928 | Oct 2002 | EP |
| 1332738 | Aug 2003 | EP |
| 1382318 | Jan 2004 | EP |
| 1089684 | Oct 2004 | EP |
| 1616542 | Jan 2006 | EP |
| 1382318 | May 2006 | EP |
| 1063953 | Jan 2007 | EP |
| 1872752 | Jan 2008 | EP |
| 2180907 | May 2010 | EP |
| 2380532 | Oct 2011 | EP |
| 2389908 | Nov 2011 | EP |
| 2601916 | Jun 2013 | EP |
| 2676643 | Dec 2013 | EP |
| 2997950 | Mar 2016 | EP |
| 2879534 | Mar 2017 | EP |
| 3424471 | Jan 2019 | EP |
| 3169292 | Nov 2019 | EP |
| 3753492 | Dec 2020 | EP |
| 3788992 | Mar 2021 | EP |
| 3576689 | Mar 2022 | EP |
| 3752110 | Mar 2022 | EP |
| 3787570 | Mar 2022 | EP |
| 4025163 | Jul 2022 | EP |
| 3463180 | Mar 2023 | EP |
| 3569205 | Jun 2023 | EP |
| 4382082 | Jun 2024 | EP |
| 871820 | Jul 1961 | GB |
| 1011517 | Dec 1965 | GB |
| 1467144 | Mar 1977 | GB |
| 2106395 | Apr 1983 | GB |
| 2106784 | Apr 1983 | GB |
| 2148126 | May 1985 | GB |
| 2171315 | Aug 1986 | GB |
| 2181953 | May 1987 | GB |
| 2148126 | Jul 1987 | GB |
| 2191095 | Dec 1987 | GB |
| 2199750 | Jul 1988 | GB |
| 2260907 | May 1993 | GB |
| 2462267 | Feb 2010 | GB |
| 2469496 | Oct 2010 | GB |
| 2490327 | Oct 2012 | GB |
| 2507318 | Apr 2014 | GB |
| 2612752 | May 2023 | GB |
| 201800009129 | Apr 2020 | IT |
| S498638 | Jan 1974 | JP |
| S5410596 | Jan 1979 | JP |
| S5410596 | May 1979 | JP |
| S54155729 | Oct 1979 | JP |
| S55155618 | Dec 1980 | JP |
| S56152629 | Nov 1981 | JP |
| S57142534 | Sep 1982 | JP |
| S5888596 | Jun 1983 | JP |
| S58188016 | Dec 1983 | JP |
| S63107780 | Jul 1988 | JP |
| H0267530 | Mar 1990 | JP |
| H02103871 | Apr 1990 | JP |
| H02131422 | May 1990 | JP |
| H02131422 | Nov 1990 | JP |
| H0460220 | Feb 1992 | JP |
| H05123349 | May 1993 | JP |
| H05123350 | May 1993 | JP |
| H0626264 | Apr 1994 | JP |
| 3087938 | Oct 1995 | JP |
| H085630 | Jan 1996 | JP |
| H1040141 | Feb 1998 | JP |
| H10225430 | Aug 1998 | JP |
| H11113946 | Apr 1999 | JP |
| H11290365 | Oct 1999 | JP |
| 2000116690 | Apr 2000 | JP |
| 2000185068 | Jul 2000 | JP |
| 2001054531 | Feb 2001 | JP |
| 2001070331 | Mar 2001 | JP |
| 2001224616 | Aug 2001 | JP |
| 2001276107 | Oct 2001 | JP |
| 2001276108 | Oct 2001 | JP |
| 2002028173 | Jan 2002 | JP |
| 2003038563 | Feb 2003 | JP |
| 2003505152 | Feb 2003 | JP |
| 2003126242 | May 2003 | JP |
| 2003180722 | Jul 2003 | JP |
| 2003528691 | Sep 2003 | JP |
| 2004057578 | Feb 2004 | JP |
| 2004130056 | Apr 2004 | JP |
| 2004267530 | Sep 2004 | JP |
| 2005052219 | Mar 2005 | JP |
| 2005066011 | Mar 2005 | JP |
| 2005066325 | Mar 2005 | JP |
| 2005102978 | Apr 2005 | JP |
| 2005518237 | Jun 2005 | JP |
| 3749097 | Dec 2005 | JP |
| 2006026108 | Feb 2006 | JP |
| 3123547 | Jun 2006 | JP |
| 2006136492 | Jun 2006 | JP |
| 2006204868 | Aug 2006 | JP |
| 2007044494 | Feb 2007 | JP |
| 3132659 | May 2007 | JP |
| 2007209687 | Aug 2007 | JP |
| 4039641 | Nov 2007 | JP |
| 2008005975 | Jan 2008 | JP |
| 2009509570 | Mar 2009 | JP |
| 2009165887 | Jul 2009 | JP |
| 2009525776 | Jul 2009 | JP |
| 2010504150 | Feb 2010 | JP |
| 2010081981 | Apr 2010 | JP |
| 4640772 | Dec 2010 | JP |
| 2010536439 | Dec 2010 | JP |
| 2011500225 | Jan 2011 | JP |
| 2011030962 | Feb 2011 | JP |
| 4747166 | May 2011 | JP |
| 2011087823 | May 2011 | JP |
| 4801218 | Aug 2011 | JP |
| 2011218130 | Nov 2011 | JP |
| 2011224070 | Nov 2011 | JP |
| 3175719 | Apr 2012 | JP |
| 2012523869 | Oct 2012 | JP |
| 2013238608 | Nov 2013 | JP |
| 2014521960 | Aug 2014 | JP |
| 2015092945 | May 2015 | JP |
| 3198994 | Jul 2015 | JP |
| 2016521191 | Jul 2016 | JP |
| 2017014698 | Jan 2017 | JP |
| 2019076342 | May 2019 | JP |
| 2019525811 | Sep 2019 | JP |
| 2019170942 | Oct 2019 | JP |
| 2019533492 | Nov 2019 | JP |
| 2020520775 | Jul 2020 | JP |
| 2021120686 | Aug 2021 | JP |
| 2021522009 | Aug 2021 | JP |
| 2021522013 | Aug 2021 | JP |
| 7129493 | Aug 2022 | JP |
| 2023532132 | Jul 2023 | JP |
| 200290061 | Sep 2002 | KR |
| 20030047451 | Jun 2003 | KR |
| 20140039485 | Apr 2014 | KR |
| 101432639 | Aug 2014 | KR |
| 20180106659 | Oct 2018 | KR |
| 20180108774 | Oct 2018 | KR |
| 2068717 | Jun 2013 | PT |
| 505542 | Sep 1997 | SE |
| 8101957 | Jul 1981 | WO |
| 8804558 | Jun 1988 | WO |
| 9104714 | Apr 1991 | WO |
| 9104714 | Jun 1991 | WO |
| 9220299 | Feb 1993 | WO |
| 9303690 | Mar 1993 | WO |
| 9307839 | Apr 1993 | WO |
| 9309736 | May 1993 | WO |
| 9309736 | Jun 1993 | WO |
| 9514448 | Jun 1995 | WO |
| 9600096 | Jan 1996 | WO |
| 9634636 | Nov 1996 | WO |
| 9817211 | Apr 1998 | WO |
| 9830336 | Jul 1998 | WO |
| 0000112 | Jan 2000 | WO |
| 0000113 | Jan 2000 | WO |
| 0025651 | May 2000 | WO |
| 0033773 | Jun 2000 | WO |
| 0057784 | Oct 2000 | WO |
| 0069377 | Nov 2000 | WO |
| 0079497 | Dec 2000 | WO |
| 0145618 | Jun 2001 | WO |
| 0145621 | Jun 2001 | WO |
| 02094160 | Nov 2002 | WO |
| 03013967 | Feb 2003 | WO |
| 03024824 | Mar 2003 | WO |
| 03055423 | Jul 2003 | WO |
| 03071931 | Sep 2003 | WO |
| 03079942 | Oct 2003 | WO |
| 03071931 | Feb 2004 | WO |
| 2004019836 | Mar 2004 | WO |
| 2004024046 | Mar 2004 | WO |
| 2004026195 | Apr 2004 | WO |
| 2005051252 | Jun 2005 | WO |
| 2005074571 | Sep 2005 | WO |
| 2005089687 | Sep 2005 | WO |
| 2005107661 | Nov 2005 | WO |
| 2006021220 | Mar 2006 | WO |
| 2006037140 | Apr 2006 | WO |
| 2007005851 | Jan 2007 | WO |
| 2007007845 | Jan 2007 | WO |
| 2007042823 | Apr 2007 | WO |
| 2007055651 | May 2007 | WO |
| 2006098950 | Nov 2007 | WO |
| 2007134608 | Nov 2007 | WO |
| 2007128156 | Feb 2008 | WO |
| 2008026106 | Mar 2008 | WO |
| 2008078117 | Jul 2008 | WO |
| 2008104019 | Sep 2008 | WO |
| 2008141471 | Nov 2008 | WO |
| 2009004368 | Jan 2009 | WO |
| 2009004369 | Jan 2009 | WO |
| 2009052496 | Apr 2009 | WO |
| 2009052502 | Apr 2009 | WO |
| 2009007702 | Jul 2009 | WO |
| 2009101738 | Aug 2009 | WO |
| 2010058192 | May 2010 | WO |
| 2010030122 | Jul 2010 | WO |
| 2010101915 | Jan 2011 | WO |
| 2011018132 | Feb 2011 | WO |
| 2011018133 | Feb 2011 | WO |
| 2011024864 | Mar 2011 | WO |
| 2011054118 | May 2011 | WO |
| 2011079132 | Jun 2011 | WO |
| 2011107972 | Sep 2011 | WO |
| 2011108972 | Sep 2011 | WO |
| 2011117292 | Sep 2011 | WO |
| 2011123219 | Oct 2011 | WO |
| 2011132043 | Oct 2011 | WO |
| 2012012908 | Feb 2012 | WO |
| 2012065274 | May 2012 | WO |
| 2012097462 | Jul 2012 | WO |
| 2012098796 | Jul 2012 | WO |
| 2012101288 | Aug 2012 | WO |
| 2012175916 | Dec 2012 | WO |
| 2013018435 | Feb 2013 | WO |
| 2013033429 | Mar 2013 | WO |
| 2013055434 | Apr 2013 | WO |
| 2013082397 | Jun 2013 | WO |
| 2013103291 | Jul 2013 | WO |
| 2013131109 | Sep 2013 | WO |
| 2013167478 | Nov 2013 | WO |
| 2013177716 | Dec 2013 | WO |
| 2014041534 | Mar 2014 | WO |
| 2014046420 | Mar 2014 | WO |
| 2014118518 | Aug 2014 | WO |
| 2014160852 | Oct 2014 | WO |
| 2015023599 | Feb 2015 | WO |
| 2015052348 | Apr 2015 | WO |
| 2015068384 | May 2015 | WO |
| 2015169403 | Nov 2015 | WO |
| 2015170307 | Nov 2015 | WO |
| 2015197462 | Dec 2015 | WO |
| 2016051385 | Apr 2016 | WO |
| 2016055989 | Apr 2016 | WO |
| 2016071894 | May 2016 | WO |
| 2016103242 | Jun 2016 | WO |
| 2016116915 | Jul 2016 | WO |
| 2016124203 | Aug 2016 | WO |
| 2016139448 | Sep 2016 | WO |
| 2016166562 | Oct 2016 | WO |
| 2016167535 | Oct 2016 | WO |
| 2016191574 | Dec 2016 | WO |
| 2016200088 | Dec 2016 | WO |
| 2016200361 | Dec 2016 | WO |
| 2016204731 | Dec 2016 | WO |
| 2017001532 | Jan 2017 | WO |
| 2017001846 | Jan 2017 | WO |
| 2017075226 | May 2017 | WO |
| 2017152198 | Sep 2017 | WO |
| 2017153357 | Sep 2017 | WO |
| 2017162559 | Sep 2017 | WO |
| 2017205446 | Nov 2017 | WO |
| 2017209779 | Dec 2017 | WO |
| 2017210524 | Dec 2017 | WO |
| 2018022414 | Feb 2018 | WO |
| 2018044781 | Mar 2018 | WO |
| 2018056953 | Mar 2018 | WO |
| 2018090550 | May 2018 | WO |
| 2018138513 | Aug 2018 | WO |
| 2018144318 | Aug 2018 | WO |
| 2018144463 | Aug 2018 | WO |
| 2018150263 | Aug 2018 | WO |
| 2018150268 | Aug 2018 | WO |
| 2018152156 | Aug 2018 | WO |
| 2018183791 | Oct 2018 | WO |
| 2018150267 | Nov 2018 | WO |
| 2018235026 | Dec 2018 | WO |
| 2018235065 | Dec 2018 | WO |
| 2019004404 | Jan 2019 | WO |
| 2019041005 | Mar 2019 | WO |
| 2019044217 | Mar 2019 | WO |
| 2019044218 | Mar 2019 | WO |
| 2019044219 | Mar 2019 | WO |
| 2019050959 | Mar 2019 | WO |
| 2019065541 | Apr 2019 | WO |
| 2019096845 | May 2019 | WO |
| 2019150385 | Aug 2019 | WO |
| 2019161094 | Aug 2019 | WO |
| 2019188566 | Oct 2019 | WO |
| 2019190593 | Oct 2019 | WO |
| 2019212949 | Nov 2019 | WO |
| 2019212950 | Nov 2019 | WO |
| 2019212951 | Nov 2019 | WO |
| 2019212952 | Nov 2019 | WO |
| 2019212954 | Nov 2019 | WO |
| 2019212955 | Nov 2019 | WO |
| 2019212956 | Nov 2019 | WO |
| 2019214787 | Nov 2019 | WO |
| 2019214788 | Nov 2019 | WO |
| 2019226826 | Nov 2019 | WO |
| 2019239433 | Dec 2019 | WO |
| 2020000994 | Jan 2020 | WO |
| 2020020618 | Jan 2020 | WO |
| 2020038822 | Feb 2020 | WO |
| 2020088409 | May 2020 | WO |
| 2020049394 | Jun 2020 | WO |
| 2020120657 | Jun 2020 | WO |
| 2020152575 | Jul 2020 | WO |
| 2020182923 | Sep 2020 | WO |
| 2020204967 | Oct 2020 | WO |
| 2020205939 | Oct 2020 | WO |
| 2020209898 | Oct 2020 | WO |
| 2020242790 | Dec 2020 | WO |
| 2020251893 | Dec 2020 | WO |
| 2020256865 | Dec 2020 | WO |
| 2021007144 | Jan 2021 | WO |
| 2021007345 | Jan 2021 | WO |
| 2021010844 | Jan 2021 | WO |
| 2021016026 | Jan 2021 | WO |
| 2021016300 | Jan 2021 | WO |
| 2021025919 | Feb 2021 | WO |
| 2021034886 | Feb 2021 | WO |
| 2021041123 | Mar 2021 | WO |
| 2021046501 | Mar 2021 | WO |
| 2021086868 | May 2021 | WO |
| 2021094352 | May 2021 | WO |
| 2021094639 | May 2021 | WO |
| 2021097067 | May 2021 | WO |
| 2021102296 | May 2021 | WO |
| 2021107025 | Jun 2021 | WO |
| 2021138411 | Jul 2021 | WO |
| 2021138414 | Jul 2021 | WO |
| 2021154686 | Aug 2021 | WO |
| 2021155206 | Aug 2021 | WO |
| 2021170075 | Sep 2021 | WO |
| 2021173436 | Sep 2021 | WO |
| 2021188817 | Sep 2021 | WO |
| 2021195384 | Sep 2021 | WO |
| 2021205995 | Oct 2021 | WO |
| 2021207621 | Oct 2021 | WO |
| 2021211568 | Oct 2021 | WO |
| 2021211801 | Oct 2021 | WO |
| 2021211914 | Oct 2021 | WO |
| 2021216419 | Oct 2021 | WO |
| 2021216422 | Oct 2021 | WO |
| 2021231532 | Nov 2021 | WO |
| 2021247523 | Dec 2021 | WO |
| 2021257202 | Dec 2021 | WO |
| 2022006256 | Jan 2022 | WO |
| 2022031943 | Feb 2022 | WO |
| 2022035745 | Feb 2022 | WO |
| 2022051360 | Mar 2022 | WO |
| 2022054613 | Mar 2022 | WO |
| 2022066704 | Mar 2022 | WO |
| 2022067392 | Apr 2022 | WO |
| 2022069950 | Apr 2022 | WO |
| 2022071429 | Apr 2022 | WO |
| 2022076322 | Apr 2022 | WO |
| 2022076427 | Apr 2022 | WO |
| 2022086898 | Apr 2022 | WO |
| 2022090199 | May 2022 | WO |
| 2022098536 | May 2022 | WO |
| 2022099087 | May 2022 | WO |
| 2022101999 | May 2022 | WO |
| 2022115692 | Jun 2022 | WO |
| 2022125685 | Jun 2022 | WO |
| 2022140545 | Jun 2022 | WO |
| 2022145231 | Jul 2022 | WO |
| 2022150360 | Jul 2022 | WO |
| 2022150463 | Jul 2022 | WO |
| 2022159392 | Jul 2022 | WO |
| 2022170182 | Aug 2022 | WO |
| 2022182385 | Sep 2022 | WO |
| 2022187152 | Sep 2022 | WO |
| 2022192188 | Sep 2022 | WO |
| 2022192347 | Sep 2022 | WO |
| 2022204000 | Sep 2022 | WO |
| 2022216507 | Oct 2022 | WO |
| 2022216776 | Oct 2022 | WO |
| 2022222030 | Oct 2022 | WO |
| 2023286058 | Jan 2023 | WO |
| 2023014639 | Feb 2023 | WO |
| 2023014641 | Feb 2023 | WO |
| 2023018475 | Feb 2023 | WO |
| 2023023777 | Mar 2023 | WO |
| 2023034453 | Mar 2023 | WO |
| 2023038945 | Mar 2023 | WO |
| 2023038950 | Mar 2023 | WO |
| 2023049109 | Mar 2023 | WO |
| 2023049175 | Mar 2023 | WO |
| 2023086394 | May 2023 | WO |
| 2023149884 | Aug 2023 | WO |
| 2023149902 | Aug 2023 | WO |
| 2023149903 | Aug 2023 | WO |
| 2023154390 | Aug 2023 | WO |
| 2023191764 | Oct 2023 | WO |
| 2023244238 | Dec 2023 | WO |
| 2024058788 | Mar 2024 | WO |
| Entry |
|---|
| US 9,908,683 B2, 03/2018, Sandhausen et al. (withdrawn) |
| Advisory Action for U.S. Appl. No. 14/722,613 mailed Mar. 4, 2019. |
| Advisory Action for U.S. Appl. No. 14/952,591 mailed Jun. 1, 2018. |
| Advisory Action for U.S. Appl. No. 15/238,427 mailed Apr. 10, 2019. |
| Advisory Action for U.S. Appl. No. 16/899,956 mailed Jul. 9, 2021. |
| Advisory Action for U.S. Appl. No. 16/904,868 mailed Jul. 2, 2021. |
| Advisory Action for U.S. Appl. No. 16/905,400 mailed Jun. 9, 2021. |
| Corrected International Search Report and Written Opinion for International Application No. PCT/US2017/043025 mailed Jan. 11, 2018. |
| Corrected Notice of Allowability for U.S. Appl. No. 15/221,106 mailed Jul. 2, 2019. |
| Corrected Notice of Allowability for U.S. Appl. No. 15/612,325 mailed Mar. 17, 2021. |
| Final Office Action for U.S. Appl. No. 14/722,613 mailed on Nov. 29, 2018. |
| Final Office Action for U.S. Appl. No. 14/947,759 mailed Apr. 8, 2016. |
| Final Office Action for U.S. Appl. No. 14/952,591 mailed Feb. 23, 2018. |
| Final Office Action for U.S. Appl. No. 14/952,591 mailed Nov. 1, 2019. |
| Final Office Action for U.S. Appl. No. 14/952,591 mailed Nov. 27, 2020. |
| Final Office Action for U.S. Appl. No. 15/171,968 mailed Feb. 14, 2020. |
| Final Office Action for U.S. Appl. No. 15/171,968 mailed Mar. 19, 2019. |
| Final Office Action for U.S. Appl. No. 15/221,106 mailed Jan. 23, 2019. |
| Final Office Action for U.S. Appl. No. 15/238,427 mailed Jan. 2, 2019. |
| Final Office Action for U.S. Appl. No. 15/260,103 mailed Feb. 14, 2019. |
| Final Office Action for U.S. Appl. No. 15/612,325 mailed Sep. 17, 2020. |
| Final Office Action for U.S. Appl. No. 16/899,956 mailed Apr. 19, 2021. |
| Final Office Action for U.S. Appl. No. 16/904,868 mailed Mar. 26, 2021. |
| Final Office Action for U.S. Appl. No. 16/905,400 mailed Apr. 6, 2021. |
| Final Office Action for U.S. Appl. No. 17/088,272 mailed May 25, 2021. |
| Final Office Action for U.S. Appl. No. 29/624,661 mailed Feb. 18, 2020. |
| International Search Report and Written Opinion from International Application No. PCT/US2016/049274 mailed Dec. 1, 2016. |
| International Search Report and Written Opinion from International Application No. PCT/US2017/035625 mailed Aug. 15, 2017. |
| International Search Report and Written Opinion from International Application No. PCT/US2017/043025 mailed Oct. 18, 2017. |
| International Search Report and Written Opinion from International Application No. PCT/US2018/015968 mailed Apr. 6, 2018. |
| International Search Report and Written Opinion from International Application No. PCT/US2019/029608 mailed Sep. 3, 2019. |
| International Search Report and Written Opinion from International Application No. PCT/US2019/029609 mailed Sep. 3, 2019. |
| International Search Report and Written Opinion from International Application No. PCT/US2019/029610 mailed Sep. 3, 2019. |
| International Search Report and Written Opinion from International Application No. PCT/US2019/029611 mailed Jul. 3, 2019. |
| International Search Report and Written Opinion from International Application No. PCT/US2019/029613 mailed Jul. 3, 2019. |
| International Search Report and Written Opinion from International Application No. PCT/US2019/029614 mailed Sep. 26, 2019. |
| International Search Report and Written Opinion from International Application No. PCT/US2019/029616 mailed Aug. 30, 2019. |
| International Search Report and Written Opinion from International Application No. PCT/US2020/023572 mailed Jul. 6, 2020. |
| International Search Report and Written Opinion from International Application No. PCT/US2020/033064 mailed Aug. 31, 2020. |
| International Search Report and Written Opinion from International Application No. PCT/US2020/033122 mailed Aug. 31, 2020. |
| International Search Report and Written Opinion from International Application No. PCT/US2020/040860 mailed Oct. 2, 2020. |
| International Search Report and Written Opinion from International Application No. PCT/US2020/041242 mailed Nov. 17, 2020. |
| International Search Report and Written Opinion from International Application No. PCT/US2020/041249 mailed Oct. 2, 2020. |
| International Search Report and Written Opinion from International Application No. PCT/US2020/042262 mailed Oct. 14, 2020. |
| International Search Report and Written Opinion from International Application No. PCT/US2020/043059 mailed Oct. 6, 2020. |
| International Search Report and Written Opinion from International Application No. PCT/US2020/044024 mailed Nov. 12, 2020. |
| International Search Report and Written Opinion from International Application No. PCT/US2020/046914 mailed Dec. 1, 2020. |
| International Search Report and Written Opinion from International Application No. PCT/US2020/055680 mailed Dec. 15, 2020. |
| International Search Report and Written Opinion from International Application No. PCT/US2020/061563 mailed Feb. 19, 2021. |
| International Search Report and Written Opinion from International Application No. PCT/US2020/065234 mailed Apr. 12, 2021. |
| International Search Report and Written Opinion from International Application No. PCT/US2020/067451 mailed Mar. 25, 2021. |
| International Search Report and Written Opinion from International Application No. PCT/US2020/067454 mailed Mar. 29, 2021. |
| International Search Report and Written Opinion from International Application No. PCT/US2020/067455 mailed Mar. 26, 2021. |
| International Search Report and Written Opinion from International Application No. PCT/US2021/015024 mailed May 18, 2021. |
| International Search Report and Written Opinion from International Application No. PCT/US2021/015787 mailed May 27, 2021. |
| International Search Report and Written Opinion from International Application No. PCT/US2021/023001 mailed Jun. 21, 2021. |
| International Search Report and Written Opinion from International Application No. PCT/US2021/024162 mailed Jul. 8, 2021. |
| International Search Report and Written Opinion from International Application No. PCT/US2021/027061 mailed Jul. 19, 2021. |
| International Search Report and Written Opinion from International Application No. PCT/US2021/027104 mailed Jul. 6, 2021. |
| International Search Report and Written Opinion from International Application No. PCT/US2021/027314 mailed Jul. 6, 2021. |
| International Search Report and Written Opinion from International Application No. PCT/US2021/027422 mailed Aug. 12, 2021. |
| International Search Report and Written Opinion from International Application No. PCT/US2021/027425 mailed Aug. 11, 2021. |
| International Search Report and Written Opinion from International Application No. PCT/US2021/027913 mailed Jul. 12, 2021. |
| International Search Report and Written Opinion from International Application No. PCT/US2021/027917 mailed Aug. 19, 2021. |
| International Search Report and Written Opinion from International Application No. PCT/US2021/035181 mailed Sep. 16, 2021. |
| Issue Notification for U.S. Appl. No. 14/952,591 mailed Jul. 28, 2021. |
| Issue Notification for U.S. Appl. No. 15/171,968 mailed Mar. 3, 2021. |
| Issue Notification for U.S. Appl. No. 15/221,106 mailed Jul. 24, 2019. |
| Issue Notification for U.S. Appl. No. 15/238,427 mailed Jul. 24, 2019. |
| Issue Notification for U.S. Appl. No. 15/260, 103 mailed Aug. 7, 2019. |
| Issue Notification for U.S. Appl. No. 15/611,587 mailed Feb. 20, 2019. |
| Issue Notification for U.S. Appl. No. 15/612,325 mailed Mar. 24, 2021. |
| Issue Notification for U.S. Appl. No. 29/624,661 mailed Aug. 4, 2021. |
| Non-Final Office Action for U.S. Appl. No. 14/592,591 mailed Mar. 20, 2020. |
| Non-Final Office Action for U.S. Appl. No. 14/722,613 mailed Jun. 13, 2019. |
| Non-Final Office Action for U.S. Appl. No. 14/947,759 mailed Mar. 17, 2016. |
| Non-Final Office Action for U.S. Appl. No. 14/952,591 mailed Aug. 1, 2017. |
| Non-Final Office Action for U.S. Appl. No. 14/952,591 mailed Mar. 20, 2020. |
| Non-Final Office Action for U.S. Appl. No. 14/952,591 mailed Mar. 21, 2019. |
| Non-Final Office Action for U.S. Appl. No. 14/952,591 mailed Sep. 28, 2018. |
| Non-Final Office Action for U.S. Appl. No. 15/171,968 mailed May 11, 2020. |
| Non-Final Office Action for U.S. Appl. No. 15/171,968 mailed Aug. 20, 2019. |
| Non-Final Office Action for U.S. Appl. No. 15/171,968 mailed Jun. 12, 2018. |
| Non-Final Office Action for U.S. Appl. No. 15/221,106 mailed Jun. 5, 2018. |
| Non-Final Office Action for U.S. Appl. No. 15/238,427 mailed Aug. 8, 2018. |
| Non-Final Office Action for U.S. Appl. No. 15/260,103 mailed Sep. 26, 2018. |
| Non-Final Office Action for U.S. Appl. No. 15/611,587 mailed Dec. 29, 2017. |
| Non-Final Office Action for U.S. Appl. No. 15/611,587 mailed Jul. 13, 2018. |
| Non-Final Office Action for U.S. Appl. No. 15/612,325 mailed Mar. 19, 2020. |
| Non-Final Office Action for U.S. Appl. No. 16/452,145 mailed Sep. 28, 2021. |
| Non-Final Office Action for U.S. Appl. No. 16/452,258 mailed Sep. 28, 2021. |
| Non-Final Office Action for U.S. Appl. No. 16/899,956 mailed Oct. 16, 2020. |
| Non-Final Office Action for U.S. Appl. No. 16/899,956 mailed Sep. 2, 2021. |
| Non-Final Office Action for U.S. Appl. No. 16/904,868 mailed Nov. 25, 2020. |
| Non-Final Office Action for U.S. Appl. No. 16/904,868 mailed Oct. 5, 2021. |
| Non-Final Office Action for U.S. Appl. No. 16/905,400 mailed Dec. 2, 2020. |
| Non-Final Office Action for U.S. Appl. No. 16/905,400 mailed Jul. 22, 2021. |
| Non-Final Office Action for U.S. Appl. No. 17/088,272 mailed Jan. 25, 2021. |
| Non-Final Office Action for U.S. Appl. No. 17/330,657 mailed Aug. 11, 2021. |
| Non-Final Office Action for U.S. Appl. No. 29/624,661 mailed Jul. 18, 2019. |
| Non-Final Office Action for U.S. Appl. No. 29/694,002 mailed Jun. 24, 2020. |
| Notice of Allowance for U.S. Appl. No. 14/952,591 mailed Apr. 5, 2021. |
| Notice of Allowance for U.S. Appl. No. 14/952,591 mailed Jul. 8, 2021. |
| Notice of Allowance for U.S. Appl. No. 15/171,968 mailed Feb. 16, 2021. |
| Notice of Allowance for U.S. Appl. No. 15/171,968 mailed Nov. 6, 2020. |
| Notice of Allowance for U.S. Appl. No. 15/221,106 mailed May 1, 2019. |
| Notice of Allowance for U.S. Appl. No. 15/238,427 mailed May 23, 2019. |
| Notice of Allowance for U.S. Appl. No. 15/260,103 mailed Jun. 7, 2019. |
| Notice of Allowance for U.S. Appl. No. 15/611,587 mailed Dec. 21, 2018. |
| Notice of Allowance for U.S. Appl. No. 15/612,325 mailed Feb. 19, 2021. |
| Notice of Allowance for U.S. Appl. No. 15/612,325 mailed Jan. 21, 2021. |
| Notice of Allowance for U.S. Appl. No. 17/088,272 mailed Aug. 5, 2021. |
| Notice of Allowance for U.S. Appl. No. 29/624,661 mailed Apr. 28, 2021. |
| Notice of Allowance for U.S. Appl. No. 29/624,661 mailed Jul. 10, 2020. |
| Notice of Allowance for U.S. Appl. No. 29/624,661 mailed May 14, 2020. |
| Notice of Allowance for U.S. Appl. No. 29/624,661 mailed Sep. 29, 2020. |
| Notice of Allowance for U.S. Appl. No. 29/694,002 mailed Apr. 29, 2021. |
| Notice of Allowance for U.S. Appl. No. 29/694,002 mailed Jan. 29, 2021. |
| Notice of Allowance for U.S. Appl. No. 29/694,002 mailed Oct. 16, 2020. |
| Notice to File Missing Parts for U.S. Appl. No. 17/179,116 mailed Mar. 3, 2021. |
| Restriction Requirement for U.S. Appl. No. 16/478,180 mailed May 25, 2021. |
| U.S. Appl. No. 14/433,773, filed Apr. 3, 2020. |
| U.S. Appl. No. 15/171,968, filed Jun. 2, 2016. |
| U.S. Appl. No. 15/221,106, filed Jul. 27, 2016. |
| U.S. Appl. No. 15/611,587, filed Jun. 1, 2017. |
| U.S. Appl. No. 15/612,325, filed Jun. 2, 2017. |
| U.S. Appl. No. 16/369,676, filed Mar. 29, 2019. |
| U.S. Appl. No. 16/433,773, filed Jun. 6, 2019. |
| U.S. Appl. No. 16/449,039, filed Jun. 21, 2019. |
| U.S. Appl. No. 16/452,145, filed Jun. 25, 2019. |
| U.S. Appl. No. 16/452,258, filed Jun. 25, 2019. |
| U.S. Appl. No. 16/478,180, filed Jul. 16, 2019. |
| U.S. Appl. No. 16/904,868, filed Jun. 18, 2020. |
| U.S. Appl. No. 16/905,400, filed Jun. 18, 2020. |
| U.S. Appl. No. 17/051,550, filed Oct. 29, 2020. |
| U.S. Appl. No. 17/051,554, filed Oct. 29, 2020. |
| U.S. Appl. No. 17/051,585, filed Oct. 29, 2020. |
| U.S. Appl. No. 17/051,600, filed Oct. 29, 2020. |
| U.S. Appl. No. 17/088,272, filed Nov. 3, 2020. |
| U.S. Appl. No. 17/179,116, filed Feb. 18, 2021. |
| U.S. Appl. No. 17/330,657, filed May 26, 2021. |
| U.S. Appl. No. 17/378,015, filed Jul. 16, 2021. |
| U.S. Appl. No. 17/412,864, filed Aug. 26, 2021. |
| U.S. Appl. No. 17/444,825, filed Aug. 10, 2021. |
| U.S. Appl. No. 17/446,256, filed Aug. 27, 2021. |
| U.S. Appl. No. 17/446,654, filed Sep. 1, 2021. |
| U.S. Appl. No. 17/447,123, filed Sep. 8, 2021. |
| U.S. Appl. No. 17/461,036 mailed Aug. 30, 2021. |
| U.S. Appl. No. 17/494,578, filed Oct. 5, 2021. |
| U.S. Appl. No. 29/741,751, filed Jul. 15, 2020. |
| U.S. Appl. No. 62/452,437, filed Jan. 31, 2017. |
| U.S. Appl. No. 62/665,297, filed May 1, 2018. |
| U.S. Appl. No. 62/665,302, filed May 1, 2018. |
| U.S. Appl. No. 62/665,317, filed May 1, 2018. |
| U.S. Appl. No. 62/665,321, filed May 1, 2018. |
| U.S. Appl. No. 62/665,331, filed May 1, 2018. |
| U.S. Appl. No. 62/665,335, filed May 1, 2018. |
| U.S. Appl. No. 62/853,279, filed May 28, 2019. |
| U.S. Appl. No. 62/853,889, filed May 29, 2019. |
| U.S. Appl. No. 62/864,656, filed Jun. 21, 2019. |
| U.S. Appl. No. 62/873,045, filed Jul. 11, 2019. |
| U.S. Appl. No. 62/873,048, filed Jul. 11, 2019. |
| U.S. Appl. No. 62/876,500, filed Jul. 19, 2019. |
| U.S. Appl. No. 62/877,558, filed Jul. 23, 2019. |
| U.S. Appl. No. 62/883,172, filed Aug. 6, 2019. |
| U.S. Appl. No. 62/889,149, filed Aug. 20, 2019. |
| U.S. Appl. No. 62/938,447, filed Nov. 21, 2019. |
| U.S. Appl. No. 62/949,187, filed Dec. 17, 2019. |
| U.S. Appl. No. 62/956,756, filed Jan. 3, 2020. |
| U.S. Appl. No. 62/956,767, filed Jan. 3, 2020. |
| U.S. Appl. No. 62/956,770, filed Jan. 3, 2020. |
| U.S. Appl. No. 62/994,912, filed Mar. 26, 2020. |
| U.S. Appl. No. 63/011,445, filed Apr. 17, 2020. |
| U.S. Appl. No. 63/011,487, filed Apr. 17, 2020. |
| U.S. Appl. No. 63/011,571, filed Apr. 17, 2020. |
| U.S. Appl. No. 63/011,657, filed Apr. 17, 2020. |
| U.S. Appl. No. 63/011,760, filed Apr. 17, 2020. |
| U.S. Appl. No. 63/012,347, filed Apr. 20, 2020. |
| U.S. Appl. No. 63/012,384, filed Apr. 20, 2020. |
| U.S. Appl. No. 63/030,685, filed May 27, 2020. |
| U.S. Appl. No. 63/033,310, filed Jun. 2, 2020. |
| U.S. Appl. No. 63/047,374, filed Jul. 2, 2020. |
| U.S. Appl. No. 63/061,241, filed Aug. 5, 2020. |
| U.S. Appl. No. 63/061,244, filed Aug. 5, 2020. |
| U.S. Appl. No. 63/061,834, filed Aug. 6, 2020. |
| U.S. Appl. No. 63/064,017, filed Aug. 11, 2020. |
| U.S. Appl. No. 63/064,126, filed Aug. 11, 2020. |
| U.S. Appl. No. 63/067,542, filed Aug. 19, 2020. |
| U.S. Appl. No. 63/071,438, filed Aug. 28, 2020. |
| U.S. Appl. No. 63/071,821, filed Aug. 28, 2020. |
| U.S. Appl. No. 63/073,545, filed Sep. 2, 2020. |
| U.S. Appl. No. 63/073,553, filed Sep. 2, 2020. |
| U.S. Appl. No. 63/074,051, filed Sep. 3, 2020. |
| U.S. Appl. No. 63/074,066, filed Sep. 3, 2020. |
| U.S. Appl. No. 63/076,032, filed Sep. 9, 2020. |
| U.S. Appl. No. 63/076,474, filed Sep. 10, 2020. |
| U.S. Appl. No. 63/076,477, filed Sep. 10, 2020. |
| U.S. Appl. No. 63/082,261, filed Sep. 23, 2020. |
| U.S. Appl. No. 63/088,506, filed Oct. 7, 2020. |
| U.S. Appl. No. 63/088,511, filed Oct. 7, 2020. |
| U.S. Appl. No. 63/088,539, filed Oct. 7, 2020. |
| U.S. Appl. No. 63/094,464, filed Oct. 21, 2020. |
| U.S. Appl. No. 63/094,498, filed Oct. 21, 2020. |
| U.S. Appl. No. 63/094,594, filed Oct. 21, 2020. |
| U.S. Appl. No. 63/094,608, filed Oct. 21, 2020. |
| U.S. Appl. No. 63/094,626, filed Oct. 21, 2020. |
| U.S. Appl. No. 63/109,066, filed Nov. 3, 2020. |
| U.S. Appl. No. 63/112,417, filed Nov. 11, 2020. |
| U.S. Appl. No. 63/119,161, filed Nov. 30, 2020. |
| U.S. Appl. No. 63/124,271, filed Dec. 11, 2020. |
| U.S. Appl. No. 63/134,287, filed Jan. 6, 2021. |
| U.S. Appl. No. 63/134,450, filed Jan. 6, 2021. |
| U.S. Appl. No. 63/134,631, filed Jan. 7, 2021. |
| U.S. Appl. No. 63/134,632, filed Jan. 7, 2021. |
| U.S. Appl. No. 63/134,754, filed Jan. 7, 2021. |
| U.S. Appl. No. 63/146,946, filed Feb. 8, 2021. |
| U.S. Appl. No. 63/147,013, filed Feb. 8, 2021. |
| U.S. Appl. No. 63/147,299, filed Feb. 9, 2021. |
| U.S. Appl. No. 63/148,723, filed Feb. 12, 2021. |
| U.S. Appl. No. 63/154,248, filed Feb. 26, 2021. |
| U.S. Appl. No. 63/155,395, filed Mar. 2, 2021. |
| U.S. Appl. No. 63/157,007, filed Mar. 5, 2021. |
| U.S. Appl. No. 63/157,014, filed Mar. 5, 2021. |
| U.S. Appl. No. 63/159,142, filed Mar. 10, 2021. |
| U.S. Appl. No. 63/159,186, filed Mar. 10, 2021. |
| U.S. Appl. No. 63/159,210, filed Mar. 10, 2021. |
| U.S. Appl. No. 63/159,280, filed Mar. 10, 2021. |
| U.S. Appl. No. 63/165,273, filed Mar. 24, 2021. |
| U.S. Appl. No. 63/165,384, filed Mar. 24, 2021. |
| U.S. Appl. No. 63/171,165, filed Apr. 6, 2021. |
| U.S. Appl. No. 63/172,975, filed Apr. 9, 2021. |
| U.S. Appl. No. 63/181,695, filed Apr. 29, 2021. |
| U.S. Appl. No. 63/192,274, filed May 24, 2021. |
| U.S. Appl. No. 63/193,235, filed May 26, 2021. |
| U.S. Appl. No. 63/193,406, filed May 26, 2021. |
| U.S. Appl. No. 63/193,891, filed May 27, 2021. |
| U.S. Appl. No. 63/214,551, filed Jun. 24, 2021. |
| U.S. Appl. No. 63/214,570, filed Jun. 24, 2021. |
| U.S. Appl. No. 63/215,017, filed Jun. 25, 2021. |
| U.S. Appl. No. 63/228,244, filed Aug. 2, 2021. |
| U.S. Appl. No. 63/228,252, filed Aug. 2, 2021. |
| U.S. Appl. No. 63/228,258, filed Aug. 2, 2021. |
| U.S. Appl. No. 63/230,894, filed Aug. 9, 2021. |
| U.S. Appl. No. 63/238,457, filed Aug. 30, 2021. |
| U.S. Appl. No. 63/238,477, filed Aug. 30, 2021. |
| U.S. Appl. No. 63/241,562, filed Sep. 8, 2021. |
| U.S. Appl. No. 63/241,564, filed Sep. 8, 2021. |
| U.S. Appl. No. 63/241,575, filed Sep. 8, 2021. |
| U.S. Appl. No. 63/246,972, filed Sep. 22, 2021. |
| U.S. Appl. No. 63/247,375, filed Sep. 23, 2021. |
| U.S. Appl. No. 63/247,478, filed Sep. 23, 2021. |
| U.S. Appl. No. 63/247,491, filed Sep. 23, 2021. |
| Defendant and Counterclaim Plaintiff Sage Products, LLC's Answer, Defenses, and Counterclaims To Plaintiff's Amended Complaint, Nov. 1, 2019. |
| Memorandum Order, Feb. 2021, 14 pgs. |
| Sage's Initial Invalidity Contentions Regarding U.S. Pat. Nos. 8,287,508; 10,226,375; and 10,390,989, May 29, 2020, 193 pages. |
| Exhibit A to PureWick's Fourth Supplemental Response to Interrogatory No. 3, Mar. 2021, 21 pages. |
| PureWick's Supplemental Response to Interrogatory No. 6 Exhibit C: U.S. Pat. No. 6,287,508, Sep. 2020, 21 pages. |
| Exhibit B to PureWick's Supplemental Response to Interrogatory No. 6: U.S. Pat. No. 8,287,508, 25 pages. |
| Exhibit B to PureWick's Supplemental Response to Interrogatory No. 6: U.S. Pat. No. 10,390,989, 26 pages. |
| Sage's Supplemental and Initial Invalidity Contentions Regarding U.S. Pat. Nos. 8,287,508; 10,226,375; 10,390,989 and Initial Invalidity Contentions Regarding U.S. Pat. No. 10,376,407, Aug. 21, 2020, 277 pages. |
| Sage's Second Supplemental Invalidity Contentions Regarding U.S. Pat. Nos. 8,287,508, 10,226,375, 10,390,989, and 10,376,407, 292 pages. |
| Boehringer CareDry System—Second Generation for Non-Invasive Urinary Management for Females, Mar. 2021, 3 pgs. |
| Exhibit B to PureWick's Supplemental Response to Interrogatory No. 6: U.S. Pat. No. 10,226,376, 38 pages. |
| Excerpts from the 508 (U.S. Pat. No. 8,278,508) Patent's Prosecution History, 2020, 99 pages. |
| Sage's Second Notice of Deposition of PureWick Corporation, C.A. No. 19-1508-MN, Feb. 2021, 10 pages. |
| Sage's First Notice of Deposition of PureWick Corporation, C.A. No. 19-1508-MN, Feb. 2021, 14 pages. |
| Sage's Supplemental Statement Regarding References and Combinations, C.A. No. 19-1508-MN, 3 pages. |
| Sixth Supplemental Responses to Sage Products' First Set of Interrogatories (No. 1-11) to PureWick Corporation, C.A. No. 19-1508-MN, Apr. 2021, 39 pages. |
| Seventh Supplemental Responses to Sage Products' First Set of Interrogatories (No. 1-11) to PureWick Corporation, C.A. No. 19-1508-MN, Apr. 2021, 41 pages. |
| Plaintiff's Opening Claim Construction Brief, Case No. 19-1508-MN, Oct. 16, 2020, 26 pages. |
| Plaintiff's Identification of Claim Terms and Proposed Constructions, Case No. 19-1508-MN, 3 pages. |
| PureWick's Response to Interrogatory No. 9 in PureWick, LLC v. Sage Products, LLC, Case No. 19-1508-MN, Mar. 23, 2020, 6 pages. |
| Sage's Preliminary Identification of Claim Elements and Proposed Constructions for U.S. Pat. Nos. 8,287,508, 10,226,376, 10,390,989 and 10,376,407, Case No. 19-1508-MN, 7 pages. |
| Decision Granting Institution of Inter Partes Review for U.S. Pat. No. 8,287,508, Case No. 2020-01426, Feb. 17, 2021, 39 pages. |
| Corrected Certificate of Service, Case No. IPR2020-01426, U.S. Pat. No. 8,287,508, 2020, 2 pages. |
| Declaration of Diane K. Newman Curriculum Vitae, Petition for Interparties Review, 2020, pp. 1-199. |
| “3 Devices Take Top Honors in Dare-To-Dream Medtech Design Contest”, R+D Digest, Nov. 2013, 1 page. |
| “Advanced Mission Extender Device (AMDX) Products”, Omni Medical Systems, Inc., 15 pages. |
| “AMXD Control Starter Kit Brochure”, https://www.omnimedicalsys.com/index.php?page=products, Omni Medical, 8 pages. |
| “AMXDmax In-Flight Bladder Relief”, Omni Medical; Omni Medical Systems, Inc., 2015. |
| “AMXDX—Advanced Mission Extender Device Brochure”, Omni Medical, Omni Brochure—http://www.omnimedicalsys.com/uploads/AMXDFixedWing.pdf, 2 pages. |
| “External Urine Management for Female Anatomy”, https://www.stryker.com/us/en/sage/products/sage-primafit.html, Jul. 2020, 4 pages. |
| “High Absorbancy Cellulose Acetate Electrospun Nanofibers for Feminine Hygiene Application”, https://www.sciencedirect.com/science/article/abs/pii/S2352940716300701?via%3Dihub, Jul. 2016, 3 pages. |
| “How Period Panties Work”, www.shethinx.com/pages/thinx-itworks, 2020, 10 pages. |
| “Hydrogel properties of electrospun polyvinylpyrrolidone and polyvinylpyrrolidone/poly(acrylic acid) blend nanofibers”, https://pubs.rsc.org/en/content/articlelanding/2015/ra/c5ra07514a#!divAbstract, 2015, 5 pages. |
| “In Flight Bladder Relief”, Omni Medical, Omni Presentation https://www.omnimedicalsys.com/uploads/AMXDmax_HSD.pdf, 14 pages. |
| “Making Women's Sanitary Products Safer and Cheaper”, https://www.elsevier.com/connect/making-womens-sanitary-products-safer-and-cheaper, Sep. 2016, 10 pages. |
| “Novel Nanofibers Make Safe and Effective Absorbent for Sanitary Products”, https://www.materialstoday.com/nanomaterials/news/nanofibers-make-safe-and-effective-absorbent/, Oct. 2016, 3 pages. |
| “Research and Development Work Relating to Assistive Technology 2005-06”, British Department of Health, Nov. 2006, 40 pages. |
| “Step by Step How Ur24 WorksHome”, http://medicalpatentur24.com, last accessed Dec. 6, 2017, Aug. 30, 2017, 4 pages. |
| “Underwear that absorbs your period”, Thinx!, https://www.shethinx.com/pages/thinx-it-works last accessed Jun. 24, 2020, 7 pages. |
| “User & Maintenance Guide”, Omni Medical, 2007, 16 pages. |
| “Winners Announced for Dare-to-Dream Medtech Design Challenge”, https://www.mddionline.com/design-engineering/winners-announced-dare-dream-medtech-design-challenge, MD&DI, 2014, 4 pages. |
| Hollister, Female Urinary and Pouch and Male Urinary Pouch Brochure, 2011, 1 page. |
| Hollister, “Male Urinary Pouch External Collection Device”, http://www.hollister.com/en/products/Continence-Care-Products/Urine-Collectors/Urine-Collection-Accessories/Male-Urinary-Pouch-External-Collection-Device, last accessed Feb. 8, 2018. |
| Hollister, “Retracted Penis Pouch by Hollister”, Vitality Medical.com, https://www.vitalitymedical.com/hollister-retracted-penis-pouch.html last accessed Jun. 24, 2020, 6 pages. |
| Jennewein, “CONNECT Graduates 7 Startups in Tech, Life Sciences”, https://timesofsandiego.com/business/2015/08/16/connect-graduates-7-startups-in-tech-life-sciences/, Aug. 2015, 2 pages. |
| Macaulay, et al., “A Noninvasive Continence Management System: Development and Evaluation of a Novel Toileting Device for Women”, The Wound, Ostomy and Continence Nurses Society, vol. 34 No. 6, 2007, pp. 641-648. |
| Newman, et al., “The Urinary Incontinence Sourcebook”, Petition for Interparties Review, 1997, 23 pages. |
| Newton, et al., “Measuring Safety, Effectiveness and Ease of Use of PureWick in the Management of Urinary Incontinence in Bedbound Women: Case Studies”, Jan. 8, 2016, 11 pages. |
| Parmar, “10 Finalists Chosen for Dare-to-Dream Medtech Design Challenge (PureWick)”, Design Services, Nov. 10, 2014, 3 pages. |
| Purewick, “Incontinence Relief for Women”, Presentation, Sep. 23, 2015, 7 pages. |
| Pytlik, “Super Absorbent Polymers”, University of Buffalo, http://www.courses.sens.buffalo.edu/ce435/Diapers/Diapers.html, accessed on Feb. 17, 2017. |
| Sachtman, “New Relief for Pilots? It Depends”, Wired, https://www.wired.com/2008/05/pilot-relief/, 2008, 2 pages. |
| Advisory Action for U.S. Appl. No. 16/245,726 mailed Apr. 19, 2023. |
| Advisory Action for U.S. Appl. No. 16/369,676 mailed Mar. 24, 2023. |
| Advisory Action for U.S. Appl. No. 16/433,773 mailed Feb. 15, 2023. |
| Advisory Action for U.S. Appl. No. 16/452,258 mailed Oct. 26, 2022. |
| Advisory Action for U.S. Appl. No. 16/478,180 mailed Sep. 21, 2022. |
| Advisory Action for U.S. Appl. No. 16/904,868 mailed Jun. 15, 2022. |
| Advisory Action for U.S. Appl. No. 16/905,400 mailed Feb. 16, 2022. |
| Advisory Action for U.S. Appl. No. 17/662,700 mailed Jan. 30, 2023. |
| Corrected Notice of Allowability for U.S. Appl. No. 17/330,657 mailed Dec. 9, 2021. |
| Final Office Action for U.S. Appl. No. 16/245,726 mailed Nov. 25, 2022. |
| Final Office Action for U.S. Appl. No. 16/369,676 mailed Dec. 5, 2022. |
| Final Office Action for U.S. Appl. No. 16/433,773 mailed Oct. 25, 2022. |
| Final Office Action for U.S. Appl. No. 16/449,039 mailed Aug. 1, 2022. |
| Final Office Action for U.S. Appl. No. 16/452,145 mailed Mar. 25, 2022. |
| Final Office Action for U.S. Appl. No. 16/452,258 mailed Jun. 14, 2022. |
| Final Office Action for U.S. Appl. No. 16/478,180 mailed Jun. 22, 2022. |
| Final Office Action for U.S. Appl. No. 16/478,180 mailed May 31, 2023. |
| Final Office Action for U.S. Appl. No. 16/904,868 mailed Mar. 10, 2022. |
| Final Office Action for U.S. Appl. No. 16/905,400 mailed Dec. 9, 2021. |
| Final Office Action for U.S. Appl. No. 17/051,399 mailed Mar. 9, 2023. |
| Final Office Action for U.S. Appl. No. 17/051,550 mailed May 23, 2023. |
| Final Office Action for U.S. Appl. No. 17/051,585 mailed Jul. 27, 2023. |
| Final Office Action for U.S. Appl. No. 17/444,792 mailed Jun. 15, 2023. |
| Final Office Action for U.S. Appl. No. 17/448,811 mailed Aug. 3, 2023. |
| Final Office Action for U.S. Appl. No. 17/451,345 mailed May 3, 2023. |
| Final Office Action for U.S. Appl. No. 17/662,700 mailed Sep. 30, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/IB2021/057173 mailed Nov. 5, 2021. |
| International Search Report and Written Opinion from International Application No. PCT/US2020/057562 mailed Jan. 27, 2021. |
| International Search Report and Written Opinion from International Application No. PCT/US2021/026607 mailed Jul. 29, 2021. |
| International Search Report and Written Opinion from International Application No. PCT/US2021/039866 mailed Oct. 7, 2021. |
| International Search Report and Written Opinion from International Application No. PCT/US2021/043893 mailed Nov. 22, 2021. |
| International Search Report and Written Opinion from International Application No. PCT/US2021/044699 mailed Nov. 22, 2021. |
| International Search Report and Written Opinion from International Application No. PCT/US2021/045188 mailed Jan. 26, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2021/047536 mailed Dec. 23, 2021. |
| International Search Report and Written Opinion from International Application No. PCT/US2021/048211 mailed Dec. 22, 2021. |
| International Search Report and Written Opinion from International Application No. PCT/US2021/048661 mailed Feb. 14, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2021/049404 mailed Jan. 18, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2021/051456 mailed Jan. 19, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2021/053593 mailed Apr. 11, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2021/055515 mailed Jan. 28, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2021/056566 mailed Feb. 11, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2021/060993 mailed Mar. 18, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2021/062440 mailed Mar. 28, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/011108 mailed Apr. 22, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/011281 mailed Apr. 25, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/011419 mailed Jun. 7, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/011421 mailed Jun. 13, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/012794 mailed May 3, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/014285 mailed Sep. 28, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/014749 mailed Sep. 28, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/015026 mailed Oct. 31, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/015045 mailed Sep. 9, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/015073 mailed Sep. 8, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/015418 mailed Nov. 11, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/015420 mailed Nov. 18, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/015471 mailed May 16, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/015492 mailed Apr. 26, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/015781 mailed May 6, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/016942 mailed Jun. 8, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/018159 mailed Dec. 12, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/018170 mailed May 31, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/019254 mailed Jun. 7, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/019480 mailed Jun. 13, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/021103 mailed Jun. 23, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/022111 mailed Oct. 26, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/023594 mailed Jul. 12, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/026667 mailed Aug. 22, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/030685 mailed Oct. 31, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/031032 mailed Sep. 9, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/032424 mailed Oct. 11, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/034457 mailed Oct. 12, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/034744 mailed Dec. 9, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/039018 mailed Jan. 10, 2023. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/039022 mailed Jan. 10, 2023. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/039711 mailed Jan. 12, 2023. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/039714 mailed Nov. 22, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/041085 mailed Mar. 16, 2023. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/041688 mailed Nov. 21, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/042719 mailed Dec. 5, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/042725 mailed Dec. 19, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/043818 mailed Mar. 24, 2023. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/044107 mailed Dec. 23, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/044208 mailed May 8, 2023. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/044212 mailed Jan. 20, 2023. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/044243 mailed Feb. 24, 2023. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/049300 mailed Jun. 6, 2023. |
| Issue Notification for U.S. Appl. No. 16/899,956 mailed Mar. 29, 2023. |
| Issue Notification for U.S. Appl. No. 16/905,400 mailed Nov. 30, 2022. |
| Issue Notification for U.S. Appl. No. 17/088,272 mailed Jun. 15, 2022. |
| Issue Notification for U.S. Appl. No. 17/330,657 mailed Jun. 22, 2022. |
| Non-Final Office Action for U.S. Appl. No. 16/245,726 mailed Jan. 21, 2022. |
| Non-Final Office Action for U.S. Appl. No. 16/369,676 mailed Mar. 31, 2022. |
| Non-Final Office Action for U.S. Appl. No. 16/433,773 mailed Apr. 11, 2023. |
| Non-Final Office Action for U.S. Appl. No. 16/433,773 mailed Apr. 21, 2022. |
| Non-Final Office Action for U.S. Appl. No. 16/449,039 mailed Apr. 27, 2023. |
| Non-Final Office Action for U.S. Appl. No. 16/449,039 mailed Dec. 8, 2021. |
| Non-Final Office Action for U.S. Appl. No. 16/452,145 mailed Mar. 28, 2023. |
| Non-Final Office Action for U.S. Appl. No. 16/452,258 mailed Apr. 26, 2023. |
| Non-Final Office Action for U.S. Appl. No. 16/478,180 mailed Dec. 20, 2022. |
| Non-Final Office Action for U.S. Appl. No. 16/478,180 mailed Oct. 22, 2021. |
| Non-Final Office Action for U.S. Appl. No. 16/904,868 mailed Mar. 15, 2023. |
| Non-Final Office Action for U.S. Appl. No. 16/905,400 mailed Apr. 27, 2022. |
| Non-Final Office Action for U.S. Appl. No. 17/051,399 mailed Aug. 18, 2023. |
| Non-Final Office Action for U.S. Appl. No. 17/051,550 mailed Dec. 15, 2022. |
| Non-Final Office Action for U.S. Appl. No. 17/051,585 mailed Mar. 29, 2023. |
| Non-Final Office Action for U.S. Appl. No. 17/179,116 mailed Mar. 24, 2023. |
| Non-Final Office Action for U.S. Appl. No. 17/326,980 mailed Jul. 11, 2023. |
| Non-Final Office Action for U.S. Appl. No. 17/444,792 mailed Feb. 10, 2023. |
| Non-Final Office Action for U.S. Appl. No. 17/446,256 mailed Apr. 13, 2023. |
| Non-Final Office Action for U.S. Appl. No. 17/448,811 mailed Mar. 1, 2023. |
| Non-Final Office Action for U.S. Appl. No. 17/450,864 mailed May 10, 2023. |
| Non-Final Office Action for U.S. Appl. No. 17/451,345 mailed Dec. 7, 2022. |
| Non-Final Office Action for U.S. Appl. No. 17/451,354 mailed May 3, 2023. |
| Non-Final Office Action for U.S. Appl. No. 17/453,260 mailed Mar. 14, 2023. |
| Non-Final Office Action for U.S. Appl. No. 17/646,771 mailed Jul. 5, 2023. |
| Non-Final Office Action for U.S. Appl. No. 17/653,137 mailed Apr. 7, 2023. |
| Non-Final Office Action for U.S. Appl. No. 17/655,464 mailed Mar. 14, 2023. |
| Non-Final Office Action for U.S. Appl. No. 17/661,090 mailed Jul. 6, 2023. |
| Non-Final Office Action for U.S. Appl. No. 17/662,700 mailed Jul. 22, 2022. |
| Non-Final Office Action for U.S. Appl. No. 17/663,330 mailed Jun. 29, 2023. |
| Non-Final Office Action for U.S. Appl. No. 17/664,487 mailed Jun. 8, 2023. |
| Non-Final Office Action for U.S. Appl. No. 18/139,521 mailed Aug. 17, 2023. |
| Non-Final Office Action for U.S. Appl. No. 29/741,751 mailed Jan. 18, 2022. |
| Notice of Allowance for U.S. Appl. No. 16/245,726 mailed Jul. 6, 2023. |
| Notice of Allowance for U.S. Appl. No. 16/449,039 mailed Dec. 15, 2022. |
| Notice of Allowance for U.S. Appl. No. 16/899,956 mailed Apr. 19, 2022. |
| Notice of Allowance for U.S. Appl. No. 16/899,956 mailed Aug. 10, 2022. |
| Notice of Allowance for U.S. Appl. No. 16/899,956 mailed Dec. 1, 2022. |
| Notice of Allowance for U.S. Appl. No. 16/899,956 mailed Dec. 29, 2021. |
| Notice of Allowance for U.S. Appl. No. 16/905,400 mailed Aug. 17, 2022. |
| Notice of Allowance for U.S. Appl. No. 17/051,554 mailed Jul. 6, 2023. |
| Notice of Allowance for U.S. Appl. No. 17/088,272 mailed Mar. 4, 2022. |
| Notice of Allowance for U.S. Appl. No. 17/088,272 mailed Nov. 24, 2021. |
| Notice of Allowance for U.S. Appl. No. 17/330,657 mailed Mar. 16, 2022. |
| Notice of Allowance for U.S. Appl. No. 17/330,657 mailed Nov. 26, 2021. |
| Notice of Allowance for U.S. Appl. No. 17/461,036 mailed Feb. 22, 2023. |
| Notice of Allowance for U.S. Appl. No. 17/461,036 mailed Jun. 30, 2023. |
| Notice of Allowance for U.S. Appl. No. 17/461,036 mailed Oct. 6, 2022. |
| Notice of Allowance for U.S. Appl. No. 17/662,700 mailed Jul. 28, 2023. |
| Notice of Allowance for U.S. Appl. No. 17/662,700 mailed Mar. 28, 2023. |
| Notice of Allowance for U.S. Appl. No. 17/663,046 mailed Jan. 30, 2023. |
| Notice of Allowance for U.S. Appl. No. 18/299,788 mailed Jul. 24, 2023. |
| Notice of Allowance for U.S. Appl. No. 29/741,751 mailed Jun. 9, 2022. |
| Restriction Requirement for U.S. Appl. No. 16/433,773 mailed Dec. 7, 2021. |
| Restriction Requirement for U.S. Appl. No. 17/326,980 mailed Mar. 20, 2023. |
| Restriction Requirement for U.S. Appl. No. 17/446,256 mailed Jan. 23, 2023. |
| Restriction Requirement for U.S. Appl. No. 17/645,821 mailed Jul. 12, 2023. |
| Restriction Requirement for U.S. Appl. No. 17/646,771 mailed Apr. 6, 2023. |
| Restriction Requirement for U.S. Appl. No. 17/657,474 mailed Jun. 30, 2023. |
| Text Messages to Lorena Eckert Re Prototype PureWick Holder dated Apr. 16, 2022. |
| U.S. Appl. No. 14/625,469, filed Feb. 28, 2015. |
| U.S. Appl. No. 14/947,759, filed Nov. 20, 2015. |
| U.S. Appl. No. 14/952,591, filed Nov. 25, 2015. |
| U.S. Appl. No. 15/260,103, filed Sep. 8, 2016. |
| U.S. Appl. No. 15/384,196, filed Dec. 19, 2016. |
| U.S. Appl. No. 16/245,726, filed Jan. 11, 2019. |
| U.S. Appl. No. 17/394,055, filed Aug. 4, 2021. |
| U.S. Appl. No. 17/450,864, filed Oct. 14, 2021. |
| U.S. Appl. No. 17/451,345, filed Oct. 19, 2021. |
| U.S. Appl. No. 17/451,354, filed Oct. 19, 2021. |
| U.S. Appl. No. 17/453,260, filed Nov. 2, 2021. |
| U.S. Appl. No. 17/453,560, filed Nov. 4, 2021. |
| U.S. Appl. No. 17/595,747, filed Nov. 23, 2021. |
| U.S. Appl. No. 17/597,408, filed Jan. 5, 2022. |
| U.S. Appl. No. 17/597,673, filed Jan. 18, 2022. |
| U.S. Appl. No. 17/614,173, filed Nov. 24, 2021. |
| U.S. Appl. No. 17/631,619, filed Jan. 31, 2022. |
| U.S. Appl. No. 17/645,821, filed Dec. 23, 2021. |
| U.S. Appl. No. 17/646,771, filed Jan. 3, 2022. |
| U.S. Appl. No. 17/653,314, filed Mar. 3, 2022. |
| U.S. Appl. No. 17/653,920, filed Mar. 8, 2022. |
| U.S. Appl. No. 17/655,464, filed Mar. 18, 2022. |
| U.S. Appl. No. 17/657,474, filed Mar. 31, 2022. |
| U.S. Appl. No. 17/661,090, filed Apr. 28, 2022. |
| U.S. Appl. No. 17/662,700, filed May 10, 2022. |
| U.S. Appl. No. 17/663,046, filed May 12, 2022. |
| U.S. Appl. No. 17/664,487, filed May 23, 2022. |
| U.S. Appl. No. 17/664,914, filed May 25, 2022. |
| U.S. Appl. No. 17/749,340, filed May 20, 2022. |
| U.S. Appl. No. 17/754,736, filed Apr. 11, 2022. |
| U.S. Appl. No. 17/756,201, filed May 19, 2022. |
| U.S. Appl. No. 17/758,152, filed Jun. 29, 2022. |
| U.S. Appl. No. 17/758,316, filed Jul. 1, 2022. |
| U.S. Appl. No. 17/759,697, filed Jul. 28, 2022. |
| U.S. Appl. No. 17/878,268, filed Aug. 1, 2022. |
| U.S. Appl. No. 17/907,125, filed Sep. 23, 2022. |
| U.S. Appl. No. 17/912,147, filed Sep. 16, 2022. |
| U.S. Appl. No. 17/929,887, filed Sep. 6, 2022. |
| U.S. Appl. No. 17/930,238, filed Sep. 7, 2022. |
| U.S. Appl. No. 17/933,590, filed Sep. 20, 2022. |
| U.S. Appl. No. 17/996,064, filed Oct. 12, 2022. |
| U.S. Appl. No. 17/996,155, filed Oct. 13, 2022. |
| U.S. Appl. No. 17/996,253, filed Oct. 14, 2022. |
| U.S. Appl. No. 17/996,468, filed Oct. 18, 2022. |
| U.S. Appl. No. 17/996,556, filed Oct. 19, 2022. |
| U.S. Appl. No. 18/003,029, filed Dec. 22, 2022. |
| U.S. Appl. No. 18/006,807, filed Jan. 25, 2023. |
| U.S. Appl. No. 18/007,105, filed Jan. 27, 2023. |
| U.S. Appl. No. 18/041,109, filed Feb. 9, 2023. |
| U.S. Appl. No. 18/042,842, filed Feb. 24, 2023. |
| U.S. Appl. No. 18/043,618, filed Mar. 1, 2023. |
| U.S. Appl. No. 18/115,444, filed Feb. 28, 2023. |
| U.S. Appl. No. 18/134,857, filed Apr. 14, 2023. |
| U.S. Appl. No. 18/140,163, filed Apr. 27, 2023. |
| U.S. Appl. No. 18/140,751, filed Apr. 28, 2023. |
| U.S. Appl. No. 18/164,800, filed Feb. 6, 2023. |
| U.S. Appl. No. 18/198,464, filed May 17, 2023. |
| U.S. Appl. No. 18/246,121, filed Mar. 21, 2023. |
| U.S. Appl. No. 18/247,986, filed Apr. 5, 2023. |
| U.S. Appl. No. 18/259,626, filed Jun. 28, 2023. |
| U.S. Appl. No. 18/260,122, filed Jun. 30, 2023. |
| U.S. Appl. No. 18/260,391, filed Jul. 5, 2023. |
| U.S. Appl. No. 18/260,394, filed Jul. 5, 2023. |
| U.S. Appl. No. 18/263,800, filed Aug. 1, 2023. |
| U.S. Appl. No. 18/264,004, filed Aug. 2, 2023. |
| U.S. Appl. No. 18/265,736, filed Jun. 7, 2023. |
| U.S. Appl. No. 18/299,788, filed Apr. 13, 2023. |
| U.S. Appl. No. 18/335,579, filed Jun. 15, 2023. |
| U.S. Appl. No. 61/955,537, filed Mar. 19, 2014. |
| U.S. Appl. No. 62/082,279, filed Nov. 20, 2014. |
| U.S. Appl. No. 62/084,078, filed Nov. 25, 2014. |
| U.S. Appl. No. 62/414,963, filed Oct. 31, 2016. |
| U.S. Appl. No. 62/485,578, filed Apr. 14, 2017. |
| U.S. Appl. No. 62/923,279, filed Oct. 18, 2019. |
| U.S. Appl. No. 62/926,767, filed Oct. 28, 2019. |
| U.S. Appl. No. 62/935,337, filed Nov. 14, 2019. |
| U.S. Appl. No. 62/967,158, filed Jan. 26, 2020. |
| U.S. Appl. No. 62/967,977, filed Jan. 30, 2020. |
| U.S. Appl. No. 62/991,754, filed Mar. 19, 2020. |
| U.S. Appl. No. 63/008,112, filed Apr. 10, 2020. |
| U.S. Appl. No. 63/094,646, filed Oct. 21, 2020. |
| U.S. Appl. No. 63/109,084, filed Nov. 3, 2020. |
| U.S. Appl. No. 63/133,892, filed Jan. 5, 2021. |
| U.S. Appl. No. 63/138,878, filed Jan. 19, 2021. |
| U.S. Appl. No. 63/150,640, filed Feb. 18, 2021. |
| U.S. Appl. No. 63/191,558, filed May 21, 2021. |
| U.S. Appl. No. 63/192,289, filed May 24, 2021. |
| U.S. Appl. No. 63/208,262, filed Jun. 8, 2021. |
| U.S. Appl. No. 63/230,897, filed Aug. 9, 2021. |
| U.S. Appl. No. 63/241,328, filed Sep. 7, 2021. |
| U.S. Appl. No. 63/299,208, filed Jan. 13, 2022. |
| U.S. Appl. No. 63/308,190, filed Feb. 9, 2022. |
| PureWick Corporation v. Sage Products, LLC Transcripts vol. 5, Apr. 1, 2022, 72 pages. |
| PureWick Corporation v. Sage Products, LLC Transcripts vol. 1, Mar. 28, 2022, 99 pages. |
| PureWick Corporation v. Sage Products, LLC Transcripts vol. 2, Mar. 29, 2022, 106 pages. |
| PureWick Corporation v. Sage Products, LLC Transcripts vol. 3, Mar. 30, 2022, 115 pages. |
| PureWick Corporation v. Sage Products, LLC Transcripts vol. 4, Mar. 31, 2022, 117 pages. |
| “AMXD Control Starter Kit”, Omni Medical Systems, Inc., 1 page. |
| “AMXDmax Advanced Mission Extender Device User & Maintenance Guide”, Omni Medical, Jan. 11, 2010, 10 pages. |
| “AMXDmax Development History 2002-2014”, Omni Medical Systems, Inc., 2 pages. |
| “Combat Force Multiplier in Flight Bladder Relief Cockpit Essential Equipment Brochure”, Omni Medical, 20 pages. |
| “GSA Price List”, Omni Medical, Apr. 2011, 2 pages. |
| “How is Polypropylene Fiber Made”, https:www.yarnsandfibers.com/textile-resources/synthetic-fibers/polypropylene-fiber/polypropylene-fiber-production-raw-materials/how-is-polypropylene-fiber-made/ last accessed 2020, Oct. 7, 2020, 3 pages. |
| “Letter to Mark Harvie of Omni Measurement Systems”, Department of Veterans Affairs, Nov. 1, 2007, 11 pages. |
| “Revised AMXDmax Advanced Mission Extender Device User & Maintenance Guide”, Omni Medical Systems, Oct. 8, 2019, 52 pages. |
| “Rising Warrior Insulated Gallon Jug Cover”, https://www.amazon.com/Rising-Warrior-Insulated-Sleeve, 2021, 2 pages. |
| “Urine Bag Cover-Catheter Bag Cover 2000 ml Volume—Medline Style-Multiple Sclerosis-Spine Injury—Suprapublic Catheter—Bladder Incontinence”, https://www.etsy.com/listing/1142934658/urine-bag-cover-caatheter-bag-cover-2000, 2022, 1 page. |
| “Vinyl Dust Cover, Janome #741811000, Janome, Sewing Parts Online”, https://www.sewingpartsonline.com/vinyl-dust-cover-janome-74181000, 2020, 2 pages. |
| Ali , “Sustainability Assessment: Seventh Generation Diapers versus gDiapers”, The University of Vermont, Dec. 6, 2011, pp. 1-31. |
| Autumn , et al., “Frictional adhesion: a new angle on gecko attachment”, The Journal of Experimental Biology, 2006, pp. 3569-3579. |
| Cañas , et al., “Effect of nano- and micro-roughness on adhesion of bioinspired micropatterned surfaces”, Acta Biomaterialia 8, 2012, pp. 282-288. |
| Chaudhary , et al., “Bioinspired dry adhesive: Poly(dimethylsiloxane) grafted with poly(2-ethylhexyl acrylate) brushes”, European Polymer Journal, 2015, pp. 432-440. |
| Dai , et al., “Non-sticky and Non-slippery Biomimetic Patterned Surfaces”, Journal of Bionic Engineering, Mar. 2020, pp. 326-334. |
| Espinoza-Ramirez , “Nanobiodiversity and Biomimetic Adhesives Development: From Nature to Production and Application”, Journal of Biomaterials and Nanobiotechnology, pp. 78-101, 2019. |
| Hwang , et al., “Multifunctional Smart Skin Adhesive Patches for Advanced Health Care”, Adv. Healthcare Mater, 2018, pp. 1-20. |
| Jagota , et al., “Adhesion, friction, and compliance of bio-mimetic and bio-inspired structured interfaces”, Materials Science and Engineering, 2011, pp. 253-292. |
| Jeong , et al., “A nontransferring dry adhesive with hierarchical polymer nanohairs”, PNAS, Apr. 7, 2009, pp. 5639-5644. |
| Jeong , et al., “Nanohairs and nanotubes: Efficient structural elements for gecko-inspired artificial dry adhesives”, Science Direct, 2009, pp. 335-346. |
| Karp , et al., “Dry solution to a sticky problem”, Nature., 2011, pp. 42-43. |
| Lee , et al., “Continuous Fabrication of Wide-Tip Microstructures for Bio-Inspired Dry Adhesives via Tip Inking Process”, Journal of Chemistry, Jan. 2, 2019, pp. 1-5. |
| Parness , et al., “A microfabricated wedge-shaped adhesive array displaying gecko-like dynamic adhesion, directionality”, J.R. Soc. Interface, 2009, pp. 1223-1232. |
| Pieper , et al., “An external urine-collection device for women: A clinical trial”, Journal of ER Nursing, vol. 20, No. 2, Mar./Apr. 1993, pp. 51-55. |
| Tsipenyuk , et al., “Use of biomimetic hexagonal surface texture in friction against lubricated skin”, Journal of the Royal Society—Interface, 2014, pp. 1-6. |
| Vinas , “A Solution for an Awkward—but Serious—Subject”, http://www.aero-news.net/index.cfm?do=main.textpost&id=69ae2bb1-838b-4098-a7b5-7flbb2505688 last accessed Feb. 8, 2021, 3 pages. |
| Advisory Action for U.S. Appl. No. 16/433,773 mailed Dec. 29, 2023. |
| Advisory Action for U.S. Appl. No. 16/449,039 mailed Jan. 25, 2024. |
| Advisory Action for U.S. Appl. No. 16/478,180 mailed Sep. 7, 2023. |
| Advisory Action for U.S. Appl. No. 16/904,868 mailed Jan. 2, 2024. |
| Advisory Action for U.S. Appl. No. 17/051,550 mailed Sep. 8, 2023. |
| Advisory Action for U.S. Appl. No. 17/051,585 mailed Oct. 17, 2023. |
| Advisory Action for U.S. Appl. No. 17/179,116 mailed Jan. 8, 2024. |
| Advisory Action for U.S. Appl. No. 17/444,792 mailed Aug. 25, 2023. |
| Advisory Action for U.S. Appl. No. 17/446,256 mailed Dec. 8, 2023. |
| Advisory Action for U.S. Appl. No. 17/448,811 mailed Nov. 15, 2023. |
| Advisory Action for U.S. Appl. No. 17/451,345 mailed Oct. 20, 2023. |
| Advisory Action for U.S. Appl. No. 17/451,354 mailed Jan. 30, 2024. |
| Advisory Action for U.S. Appl. No. 17/453,260 mailed Dec. 22, 2023. |
| Advisory Action for U.S. Appl. No. 17/646,771 mailed Feb. 29, 2024. |
| Advisory Action for U.S. Appl. No. 17/653,137 mailed Dec. 1, 2023. |
| Advisory Action for U.S. Appl. No. 17/655,464 mailed Dec. 13, 2023. |
| Advisory Action for U.S. Appl. No. 17/661,090 mailed Feb. 26, 2024. |
| Advisory Action for U.S. Appl. No. 17/663,330 mailed Feb. 27, 2024. |
| Advisory Action for U.S. Appl. No. 18/164,800 mailed Feb. 12, 2024. |
| Communication of Notice of Opposition of European Application No. 17807547.9 mailed Jan. 5, 2024. |
| Corrected Notice of Allowability for U.S. Appl. No. 16/369,676 mailed Dec. 7, 2023. |
| Corrected Notice of Allowability for U.S. Appl. No. 17/326,980 mailed Feb. 8, 2024. |
| Final Office Action for U.S. Appl. No. 16/369,676 mailed Aug. 31, 2023. |
| Final Office Action for U.S. Appl. No. 16/433,773 mailed Oct. 10, 2023. |
| Final Office Action for U.S. Appl. No. 16/449,039 mailed Nov. 21, 2023. |
| Final Office Action for U.S. Appl. No. 16/452,258 mailed Dec. 21, 2023. |
| Final Office Action for U.S. Appl. No. 16/478,180 mailed Feb. 28, 2024. |
| Final Office Action for U.S. Appl. No. 16/904,868 mailed Nov. 2, 2023. |
| Final Office Action for U.S. Appl. No. 17/051,399 mailed Jan. 8, 2024. |
| Final Office Action for U.S. Appl. No. 17/179,116 mailed Oct. 31, 2023. |
| Final Office Action for U.S. Appl. No. 17/446,256 mailed Sep. 19, 2023. |
| Final Office Action for U.S. Appl. No. 17/446,654 mailed Jan. 31, 2024. |
| Final Office Action for U.S. Appl. No. 17/450,864 mailed Dec. 28, 2023. |
| Final Office Action for U.S. Appl. No. 17/451,354 mailed Oct. 30, 2023. |
| Final Office Action for U.S. Appl. No. 17/453,260 mailed Oct. 5, 2023. |
| Final Office Action for U.S. Appl. No. 17/646,771 mailed Dec. 21, 2023. |
| Final Office Action for U.S. Appl. No. 17/653,137 mailed Sep. 21, 2023. |
| Final Office Action for U.S. Appl. No. 17/655,464 mailed Sep. 1, 2023. |
| Final Office Action for U.S. Appl. No. 17/661,090 mailed Dec. 11, 2023. |
| Final Office Action for U.S. Appl. No. 17/663,330 mailed Dec. 12, 2023. |
| Final Office Action for U.S. Appl. No. 17/664,487 mailed Jan. 4, 2024. |
| Final Office Action for U.S. Appl. No. 18/139,523 mailed Dec. 22, 2023. |
| Final Office Action for U.S. Appl. No. 18/140,751 mailed Jan. 17, 2024. |
| Final Office Action for U.S. Appl. No. 18/164,800 mailed Dec. 6, 2023. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/050909 mailed Jul. 24, 2023. |
| International Search Report and Written Opinion from International Application No. PCT/US2023/012696 mailed Jul. 6, 2023. |
| International Search Report and Written Opinion from International Application No. PCT/US2023/018474 mailed Sep. 11, 2023. |
| International Search Report and Written Opinion from International Application No. PCT/US2023/024805 mailed Dec. 14, 2023. |
| International Search Report and Written Opinion from International Application No. PCT/US2023/025192 mailed Feb. 7, 2024. |
| Issue Notification for U.S. Appl. No. 16/245,726 mailed Oct. 18, 2023. |
| Issue Notification for U.S. Appl. No. 17/051,554 mailed Mar. 6, 2024. |
| Issue Notification for U.S. Appl. No. 17/461,036 mailed Oct. 11, 2023. |
| Issue Notification for U.S. Appl. No. 17/663,046 mailed Dec. 20, 2023. |
| Issue Notification for U.S. Appl. No. 18/299,788 mailed Feb. 21, 2024. |
| Non-Final Office Action for U.S. Appl. No. 16/369,676 mailed Feb. 29, 2024. |
| Non-Final Office Action for U.S. Appl. No. 16/433,773 mailed Feb. 26, 2024. |
| Non-Final Office Action for U.S. Appl. No. 16/452,145 mailed Nov. 2, 2023. |
| Non-Final Office Action for U.S. Appl. No. 16/478,180 mailed Nov. 7, 2023. |
| Non-Final Office Action for U.S. Appl. No. 17/051,550 mailed Oct. 24, 2023. |
| Non-Final Office Action for U.S. Appl. No. 17/051,585 mailed Jan. 8, 2024. |
| Non-Final Office Action for U.S. Appl. No. 17/051,600 mailed Jan. 17, 2024. |
| Non-Final Office Action for U.S. Appl. No. 17/179,116 mailed Feb. 26, 2024. |
| Non-Final Office Action for U.S. Appl. No. 17/444,792 mailed Nov. 17, 2023. |
| Non-Final Office Action for U.S. Appl. No. 17/446,256 mailed Feb. 13, 2024. |
| Non-Final Office Action for U.S. Appl. No. 17/446,654 mailed Sep. 8, 2023. |
| Non-Final Office Action for U.S. Appl. No. 17/447,123 mailed Jan. 24, 2024. |
| Non-Final Office Action for U.S. Appl. No. 17/448,811 mailed Jan. 17, 2024. |
| Non-Final Office Action for U.S. Appl. No. 17/451,345 mailed Jan. 17, 2024. |
| Non-Final Office Action for U.S. Appl. No. 17/453,560 mailed Oct. 16, 2023. |
| Non-Final Office Action for U.S. Appl. No. 17/645,821 mailed Oct. 25, 2023. |
| Non-Final Office Action for U.S. Appl. No. 17/653,137 mailed Jan. 18, 2024. |
| Non-Final Office Action for U.S. Appl. No. 17/657,474 mailed Sep. 12, 2023. |
| Non-Final Office Action for U.S. Appl. No. 17/664,914 mailed Jan. 31, 2024. |
| Non-Final Office Action for U.S. Appl. No. 17/808,354 mailed Nov. 28, 2023. |
| Non-Final Office Action for U.S. Appl. No. 18/134,857 mailed Jan. 25, 2024. |
| Non-Final Office Action for U.S. Appl. No. 18/140,163 mailed Nov. 9, 2023. |
| Non-Final Office Action for U.S. Appl. No. 18/140,751 mailed Sep. 14, 2023. |
| Non-Final Office Action for U.S. Appl. No. 18/198,464 mailed Dec. 7, 2023. |
| Notice of Allowance for U.S. Appl. No. 16/369,676 mailed Nov. 14, 2023. |
| Notice of Allowance for U.S. Appl. No. 17/051,550 mailed Feb. 7, 2024. |
| Notice of Allowance for U.S. Appl. No. 17/051,554 mailed Oct. 18, 2023. |
| Notice of Allowance for U.S. Appl. No. 17/326,980 mailed Jan. 29, 2024. |
| Notice of Allowance for U.S. Appl. No. 17/453,560 mailed Jan. 31, 2024. |
| Notice of Allowance for U.S. Appl. No. 17/657,474 mailed Mar. 5, 2024. |
| Notice of Allowance for U.S. Appl. No. 17/662,700 mailed Mar. 6, 2024. |
| Notice of Allowance for U.S. Appl. No. 17/662,700 mailed Nov. 15, 2023. |
| Notice of Allowance for U.S. Appl. No. 18/299,788 mailed Nov. 6, 2023. |
| Restriction Requirement for U.S. Appl. No. 17/051,600 mailed Sep. 21, 2023. |
| Restriction Requirement for U.S. Appl. No. 18/134,857 mailed Oct. 23, 2023. |
| Submission in Opposition Proceedings for European Application No. 17807547.9 filed Jan. 10, 2024. |
| Supplemental Notice of Allowance for U.S. Appl. No. 17/051,550 mailed Feb. 21, 2024. |
| Supplemental Notice of Allowance for U.S. Appl. No. 17/051,554 mailed Feb. 14, 2024. |
| U.S. Appl. No. 17/451,719, filed Oct. 19, 2021. |
| U.S. Appl. No. 18/294,370, filed Feb. 1, 2024. |
| U.S. Appl. No. 18/294,403, filed Feb. 1, 2024. |
| U.S. Appl. No. 18/373,424, filed Sep. 27, 2023. |
| U.S. Appl. No. 18/376,274, filed Oct. 3, 2023. |
| U.S. Appl. No. 18/389,009, filed Nov. 13, 2023. |
| U.S. Appl. No. 18/415,080, filed Jan. 17, 2024. |
| U.S. Appl. No. 18/426,795, filed Jan. 30, 2024. |
| U.S. Appl. No. 18/548,152, filed Aug. 28, 2023. |
| U.S. Appl. No. 18/549,387, filed Sep. 7, 2023. |
| U.S. Appl. No. 18/549,658, filed Sep. 8, 2023. |
| U.S. Appl. No. 18/553,625, filed Oct. 2, 2023. |
| U.S. Appl. No. 18/556,945, filed Oct. 24, 2023. |
| U.S. Appl. No. 18/558,502, filed Nov. 1, 2023. |
| U.S. Appl. No. 18/562,626, filed Nov. 20, 2023. |
| U.S. Appl. No. 18/563,672, filed Nov. 22, 2023. |
| U.S. Appl. No. 18/569,711, filed Dec. 13, 2023. |
| U.S. Appl. No. 18/569,778, filed Dec. 13, 2023. |
| U.S. Appl. No. 18/584,002, filed Feb. 22, 2024. |
| U.S. Appl. No. 18/681,987, filed Feb. 7, 2024. |
| U.S. Appl. No. 18/682,006, filed Feb. 7, 2024. |
| U.S. Appl. No. 18/687,117, filed Feb. 27, 2024. |
| U.S. Appl. No. 18/688,023, filed Feb. 29, 2024. |
| U.S. Appl. No. 63/596,012, filed Nov. 3, 2023. |
| U.S. Appl. No. 63/608,553, filed Dec. 11, 2023. |
| Merriam-Webster Dictionary, “Embed Definition & Meaning”, https://www.merriam-webster.com/dictionary/embed last accessed Aug. 3, 2023, 2003. |
| Wikipedia Article, “Zylinder (Geometrie)”, https://de.wikipedia.org/w/index.php?title=Zylinder (Geometrie)&oldid=154862081, version of Jun. 1, 2016, 7 pages. |
| Advisory Action for U.S. Appl. No. 16/452,258 mailed Apr. 8, 2024. |
| Advisory Action for U.S. Appl. No. 16/478,180 mailed Jun. 7, 2024. |
| Advisory Action for U.S. Appl. No. 17/051,585 mailed Oct. 8, 2024. |
| Advisory Action for U.S. Appl. No. 17/444,792 mailed Jul. 8, 2024. |
| Advisory Action for U.S. Appl. No. 17/446,654 mailed Apr. 15, 2024. |
| Advisory Action for U.S. Appl. No. 17/450,864 mailed Mar. 21, 2024. |
| Advisory Action for U.S. Appl. No. 17/451,345 mailed Jul. 3, 2024. |
| Advisory Action for U.S. Appl. No. 17/645,821 mailed Jul. 2, 2024. |
| Advisory Action for U.S. Appl. No. 17/664,487 mailed Mar. 13, 2024. |
| Advisory Action for U.S. Appl. No. 17/808,354 mailed Jun. 12, 2024. |
| Advisory Action for U.S. Appl. No. 18/134,857 mailed Oct. 23, 2024. |
| Advisory Action for U.S. Appl. No. 18/139,523 mailed Apr. 24, 2024. |
| Advisory Action for U.S. Appl. No. 18/140,163 mailed Jun. 3, 2024. |
| Advisory Action for U.S. Appl. No. 18/140,751 mailed Apr. 24, 2024. |
| Corrected Notice of Allowability for U.S. Appl. No. 17/450,864 mailed Oct. 24, 2024. |
| Corrected Notice of Allowability for U.S. Appl. No. 17/657,474 mailed Mar. 13, 2024. |
| Corrected Notice of Allowability for U.S. Appl. No. 17/657,474 mailed May 14, 2024. |
| Corrected Notice of Allowability for U.S. Appl. No. 17/664,914 mailed Aug. 9, 2024. |
| Final Office Action for U.S. Appl. No. 16/433,773 mailed Sep. 9, 2024. |
| Final Office Action for U.S. Appl. No. 17/051,585 mailed Jul. 5, 2024. |
| Final Office Action for U.S. Appl. No. 17/051,600 mailed Jun. 27, 2024. |
| Final Office Action for U.S. Appl. No. 17/444,792 mailed Apr. 3, 2024. |
| Final Office Action for U.S. Appl. No. 17/446,256 mailed Aug. 7, 2024. |
| Final Office Action for U.S. Appl. No. 17/447,123 mailed May 14, 2024. |
| Final Office Action for U.S. Appl. No. 17/451,345 mailed Apr. 18, 2024. |
| Final Office Action for U.S. Appl. No. 17/597,673 mailed Oct. 22, 2024. |
| Final Office Action for U.S. Appl. No. 17/645,821 mailed Apr. 3, 2024. |
| Final Office Action for U.S. Appl. No. 17/653,137 mailed Aug. 7, 2024. |
| Final Office Action for U.S. Appl. No. 17/653,920 mailed Aug. 14, 2024. |
| Final Office Action for U.S. Appl. No. 17/808,354 mailed Apr. 10, 2024. |
| Final Office Action for U.S. Appl. No. 18/003,029 mailed Oct. 22, 2024. |
| Final Office Action for U.S. Appl. No. 18/134,857 mailed Jul. 25, 2024. |
| Final Office Action for U.S. Appl. No. 18/140,163 mailed Mar. 27, 2024. |
| Final Office Action for U.S. Appl. No. 18/164,800 mailed Oct. 22, 2024. |
| International Search Report and Written Opinion from International Application No. PCT/US2023/025939 mailed Feb. 7, 2024. |
| International Search Report and Written Opinion from International Application No. PCT/US2023/030365 mailed Mar. 13, 2024. |
| International Search Report and Written Opinion from International Application No. PCT/US2023/030373 mailed Mar. 13, 2024. |
| International Search Report and Written Opinion from International Application No. PCT/US2023/031433 mailed Mar. 4, 2024. |
| International Search Report and Written Opinion from International Application No. PCT/US2023/031740 mailed Mar. 4, 2024. |
| International Search Report and Written Opinion from International Application No. PCT/US2023/036238 mailed Jul. 22, 2024. |
| International Search Report and Written Opinion from International Application No. PCT/US2023/036868 mailed Jun. 5, 2024. |
| International Search Report and Written Opinion from International Application No. PCT/US2023/075507 mailed Jun. 13, 2024. |
| International Search Report and Written Opinion from International Application No. PCT/US2023/077168 mailed Jun. 24, 2024. |
| International Search Report and Written Opinion from International Application No. PCT/US2023/077208 mailed May 10, 2024. |
| International Search Report and Written Opinion from International Application No. PCT/US2023/080680 mailed Jul. 22, 2024. |
| International Search Report and Written Opinion from International Application No. PCT/US2023/085516 mailed Aug. 26, 2024. |
| Issue Notification for U.S. Appl. No. 16/369,676 mailed Oct. 2, 2024. |
| Issue Notification for U.S. Appl. No. 16/449,039 mailed Jun. 19, 2024. |
| Issue Notification for U.S. Appl. No. 16/452,145 mailed Oct. 23, 2024. |
| Issue Notification for U.S. Appl. No. 17/051,550 mailed Mar. 13, 2024. |
| Issue Notification for U.S. Appl. No. 17/326,980 mailed Jul. 10, 2024. |
| Issue Notification for U.S. Appl. No. 17/448,811 mailed Jul. 3, 2024. |
| Issue Notification for U.S. Appl. No. 17/453,260 mailed Jul. 10, 2024. |
| Issue Notification for U.S. Appl. No. 17/453,560 mailed Aug. 7, 2024. |
| Issue Notification for U.S. Appl. No. 17/657,474 mailed Jun. 19, 2024. |
| Issue Notification for U.S. Appl. No. 17/662,700 mailed Oct. 23, 2024. |
| Non-Final Office Action for U.S. Appl. No. 16/452,258 mailed Jun. 20, 2024. |
| Non-Final Office Action for U.S. Appl. No. 16/478,180 mailed Aug. 7, 2024. |
| Non-Final Office Action for U.S. Appl. No. 16/904,868 mailed Mar. 12, 2024. |
| Non-Final Office Action for U.S. Appl. No. 17/378,015 mailed Jul. 5, 2024. |
| Non-Final Office Action for U.S. Appl. No. 17/446,654 mailed Jun. 25, 2024. |
| Non-Final Office Action for U.S. Appl. No. 17/450,864 mailed May 29, 2024. |
| Non-Final Office Action for U.S. Appl. No. 17/451,345 mailed Jul. 25, 2024. |
| Non-Final Office Action for U.S. Appl. No. 17/451,354 mailed Apr. 4, 2024. |
| Non-Final Office Action for U.S. Appl. No. 17/595,747 mailed Jun. 7, 2024. |
| Non-Final Office Action for U.S. Appl. No. 17/597,408 mailed Aug. 15, 2024. |
| Non-Final Office Action for U.S. Appl. No. 17/597,673 mailed Mar. 20, 2024. |
| Non-Final Office Action for U.S. Appl. No. 17/614,173 mailed Sep. 24, 2024. |
| Non-Final Office Action for U.S. Appl. No. 17/628,411 mailed Sep. 23, 2024. |
| Non-Final Office Action for U.S. Appl. No. 17/645,821 mailed Sep. 6, 2024. |
| Non-Final Office Action for U.S. Appl. No. 17/646,771 mailed Apr. 24, 2024. |
| Non-Final Office Action for U.S. Appl. No. 17/653,314 mailed Aug. 29, 2024. |
| Non-Final Office Action for U.S. Appl. No. 17/653,920 mailed Mar. 15, 2024. |
| Non-Final Office Action for U.S. Appl. No. 17/655,464 mailed Mar. 26, 2024. |
| Non-Final Office Action for U.S. Appl. No. 17/661,090 mailed May 22, 2024. |
| Non-Final Office Action for U.S. Appl. No. 17/663,330 mailed Jul. 1, 2024. |
| Non-Final Office Action for U.S. Appl. No. 17/664,487 mailed Jun. 17, 2024. |
| Non-Final Office Action for U.S. Appl. No. 17/749,340 mailed Aug. 14, 2024. |
| Non-Final Office Action for U.S. Appl. No. 17/757,311 mailed Oct. 22, 2024. |
| Non-Final Office Action for U.S. Appl. No. 17/758,316 mailed Aug. 28, 2024. |
| Non-Final Office Action for U.S. Appl. No. 18/003,029 mailed Mar. 26, 2024. |
| Non-Final Office Action for U.S. Appl. No. 18/139,523 mailed Aug. 26, 2024. |
| Non-Final Office Action for U.S. Appl. No. 18/140,751 mailed Jun. 21, 2024. |
| Non-Final Office Action for U.S. Appl. No. 18/164,800 mailed Mar. 22, 2024. |
| Non-Final Office Action for U.S. Appl. No. 18/389,009 mailed May 24, 2024. |
| Non-Final Office Action for U.S. Appl. No. 18/426,795 mailed Aug. 9, 2024. |
| Non-Final Office Action for U.S. Appl. No. 18/451,080 mailed Jul. 30, 2024. |
| Non-Final Office Action for U.S. Appl. No. 18/584,002 mailed Sep. 19, 2024. |
| Notice of Allowance for U.S. Appl. No. 16/369,676 mailed Jun. 17, 2024. |
| Notice of Allowance for U.S. Appl. No. 16/449,039 mailed Mar. 28, 2024. |
| Notice of Allowance for U.S. Appl. No. 16/452,145 mailed Jul. 11, 2024. |
| Notice of Allowance for U.S. Appl. No. 16/904,868 mailed Sep. 29, 2024. |
| Notice of Allowance for U.S. Appl. No. 17/179,116 mailed Sep. 13, 2024. |
| Notice of Allowance for U.S. Appl. No. 17/326,980 mailed Apr. 5, 2024. |
| Notice of Allowance for U.S. Appl. No. 17/447,123 mailed Jul. 26, 2024. |
| Notice of Allowance for U.S. Appl. No. 17/448,811 mailed Jun. 14, 2024. |
| Notice of Allowance for U.S. Appl. No. 17/450,864 mailed Sep. 18, 2024. |
| Notice of Allowance for U.S. Appl. No. 17/453,260 mailed Apr. 8, 2024. |
| Notice of Allowance for U.S. Appl. No. 17/657,474 mailed May 2, 2024. |
| Notice of Allowance for U.S. Appl. No. 17/662,700 mailed Jun. 12, 2024. |
| Notice of Allowance for U.S. Appl. No. 17/664,914 mailed Jul. 26, 2024. |
| Notice of Allowance for U.S. Appl. No. 17/667,097 mailed Aug. 28, 2024. |
| Notice of Allowance for U.S. Appl. No. 18/140,163 mailed Aug. 21, 2024. |
| Notice of Allowance for U.S. Appl. No. 18/198,464 mailed Apr. 17, 2024. |
| Notice of Allowance for U.S. Appl. No. 18/198,464 mailed Jul. 30, 2024. |
| Notice of Allowance for U.S. Appl. No. 18/389,009 mailed Aug. 28, 2024. |
| Restriction Requirement for U.S. Appl. No. 17/527,769 mailed Jun. 17, 2024. |
| Restriction Requirement for U.S. Appl. No. 17/596,629 mailed Sep. 19, 2024. |
| Restriction Requirement for U.S. Appl. No. 17/625,941 mailed Aug. 7, 2024. |
| Restriction Requirement for U.S. Appl. No. 17/667,097 mailed Mar. 20, 2024. |
| Restriction Requirement for U.S. Appl. No. 17/756,201 mailed Oct. 4, 2024. |
| Restriction Requirement for U.S. Appl. No. 17/878,268 mailed Sep. 20, 2024. |
| U.S. Appl. No. 17/013,822, filed Sep. 7, 2020. |
| U.S. Appl. No. 17/444,792, filed Aug. 10, 2021. |
| U.S. Appl. No. 18/249,577, filed Oct. 19, 2021. |
| U.S. Appl. No. 18/610,523, filed Mar. 20, 2024. |
| U.S. Appl. No. 18/662,216, filed May 13, 2024. |
| U.S. Appl. No. 18/693,638, filed Mar. 20, 2024. |
| U.S. Appl. No. 18/694,090, filed Mar. 21, 2024. |
| U.S. Appl. No. 18/728,604, filed Jul. 12, 2024. |
| U.S. Appl. No. 18/757,964, filed Jun. 28, 2024. |
| U.S. Appl. No. 18/758,025, filed Jun. 28, 2024. |
| U.S. Appl. No. 18/828,559, filed Sep. 9, 2024. |
| U.S. Appl. No. 18/834,115 filed Jul. 29, 2024. |
| U.S. Appl. No. 18/834,176 filed Jul. 29, 2024. |
| U.S. Appl. No. 18/834,340, filed Jul. 30, 2024. |
| U.S. Appl. No. 18/835,068, filed Aug. 1, 2024. |
| U.S. Appl. No. 18/835,444, filed Aug. 2, 2024. |
| U.S. Appl. No. 18/836,204, filed Aug. 6, 2024. |
| U.S. Appl. No. 18/841,630, filed Aug. 26, 2024. |
| U.S. Appl. No. 18/851,197, filed Sep. 26, 2024. |
| U.S. Appl. No. 18/886,306, filed Sep. 16, 2024. |
| U.S. Appl. No. 18/903,592, filed Oct. 1, 2024. |
| U.S. Appl. No. 18/925,921, filed Oct. 24, 2024. |
| U.S. Appl. No. 18/930,014, filed Oct. 29, 2024. |
| U.S. Appl. No. 63/564,696 filed Mar. 13, 2024. |
| U.S. Appl. No. 63/561,893, filed Dec. 11, 2023. |
| U.S. Appl. No. 63/568,615, filed Mar. 22, 2024. |
| U.S. Appl. No. 63/683,428, filed Aug. 15, 2024. |
| U.S. Appl. No. 63/711,438, filed Oct. 24, 2024. |
| U.S. Appl. No. 63/711,445, filed Oct. 24, 2024. |
| “Dictionary.com, Abut Definition and Meaning”, Dictionary.com, https://www.dictionary.com/browse/abut, 2024, 1 page. |
| “Oblong”, Cambridge Dictionary, https://dictionary.cambridge.org/dictionary/english/oblong, 2024, 1 page. |
| Britannica, “Polyolefin”, Britannica Online Encyclopedia, T. Editors of Encyclopaedia, https://www.britannica.com/science/polyolefin, Jul. 26, 2012. |
| Martin, et al., “Chapter 5 Applications of Polyethylene Oxide (POLYOX) in Hydrophilic Matrices”, Hydrophilic Matrix Tablets for Oral Controlled Release, AAPS Advances in the Pharmaceutical Sciences vol. 16, 2014, pp. 123-141. |
| Wikipedia Article, “Decibel”, https://web.archive.org/web/2020041521917/https://en.wikipedia/org/wiki/Decibel last accessed Mar. 11, 2024, 21 pages. |
| Wikipedia Article, “Fiberglass”, https://web.archive.org.web/20200309194847/https://en.wikipedia.org/wiki/Fiberglass last accessed Mar. 11, 2024. |
| Number | Date | Country | |
|---|---|---|---|
| 20220117775 A1 | Apr 2022 | US |
| Number | Date | Country | |
|---|---|---|---|
| 63094608 | Oct 2020 | US |